

- Dubot, P., 400
 Duggin, G. G., S1:39
 Dunne, D., 86

 Ebeling, P. R., 515
 Ebihara, I., 32
 Ecdar, T., 461
 Eichhorn, J., 186
 Elseviers, M. M., S1:48
 Endoh, M., 14
 Eng, C., 329
 Erdem, Y., 454
 Erman, A., 220
 Ettinger, W. H., Jr., 72
 Evans, G. W., 72

 Falkenhain, M. E., 752
 Fan, X., 296
 Farragher, B., 553
 Fein, P., 924
 Fenves, A. Z., 832
 Ferguson, R. M., 752
 Ferrière, M., S3:67
 Finch, J., 589, 596
 Fine, A., 262
 Finkelstein, F. O., 86
 First, M. R., 466
 Fishbane, S., 257, 409
 Flanigan, M., 741
 Foley, R. N., 53
 Foppolo, M., 23
 Forte, L. R., 296
 Frangione, B., 676
 Friedman, E. A., 841, 943
 Friedman, S., 220
 Fukiyama, K., 541
 Fulton, J., 904
 Fung, H.-Y., 899

 Gabbai, F. B., 115
 Gagné, M., 105
 Gajaria, M. M., 132
 Gallego, M. J., 23
 Galli, G., 713
 Gallo, G., 676
 Ganesan, K., 270
 Gansevoort, R. T., 274
 Garcia, G. E., 115
 Gardner, K. D., Jr., 156, 624
 Garred, L. J., S3:67
 Gaston, R. S., 572
 Gaughan, W. J., 266
 Gelerenter, I., 220
 Gemperle, O., 668
 Ghiso, J., 676
 Gill, I. S., 867
 Gilmour, E. R., 350
 Ginsburg, C., 762
 Giorgini, A., 713

 Göbel, U., 186
 Godeau, P., 762
 Gokal, R., 553
 Gold, L., 676
 Golder, R., 918
 Goldie, S. J., 86
 Goldsmith, D. J. A., 278
 Golper, T. A., 428, S3:1
 Goodship, T. H. J., 350
 Goormastic, M., S3:81
 Gorban-Brennan, N., 86
 Grantham, J. J., 788
 Green, D. F., 292
 Greenberg, S., 387
 Greer, J. W., 235, S2:1
 Grieff, M., 589
 Grootendorst, A. F., S3:50
 Guillaumie, J., 400
 Gupta, B., 415
 Gupta, I., 132

 Haas, M., 365
 Hakamata, Y., 289
 Haller, H., 186
 Halperin, M. L., 1
 Halstenberg, W., S3:81
 Hamburger, R. J., 428
 Hamilton, R. W., 428
 Hammond, T. C., 115
 Hamra, F. K., 296
 Hänsch, G. M., 178
 Hansen-Schmidt, S., 451
 Hanss, B., 475
 Haqqie, S. S., 493
 Harford, A. M., 855
 Harland, R., 379
 Harnett, J. D., 53
 Harty, J., 553
 Hatcher, D., S2:1
 Held, P. J., S2:1
 Henderson, L. W., S3:105, 951
 Henrich, W. L., S1:1, S1:56
 Herzenberg, A. M., 128
 Hestin, D., 99
 Hiesse, C., 99
 Hildebrandt, F., 668
 Hill, S., 354
 Hirano, H., 420
 Hirth, R., S2:1
 Ho, K., 721
 Ho, S. K. N., 283
 Hod, M., 220
 Hoeben, K. H. N., S3:50
 Hoehn-Saric, E., 585
 Holley, J. L., 67
 Hollomby, D., 622
 Holstein-Rathlou, N.-H., 822
 Homel, P., 841

 Hoy, W., 339
 Hulbert-Shearon, T., S2:1
 Humar, A., 622
 Hwang, J.-C., 899

 Ifudu, O., 841
 Ikegawa, N., 878
 Imbasciati, E., 704
 Imberti, B., 23
 Iseki, K., 541
 Ishii, K., 289
 Islam, M., 610

 Jaber, B. L., S3:35
 Jacobs, J. M., 214
 Jaffe, N., 846
 Jagasia, M. H., 772
 James, S. H., 767
 Janin, G., 400
 Jena, M., 457
 Jerius, J. T., 867
 Jha, V., 137
 Jim, S., 339
 Johansen, M. J., 846
 Johnson, L. B., 585
 Johnson, R. W. G., 278
 Jones, C. A., S2:1
 Jones, E. R., 700
 Jones, N., 861
 Julian, B. A., 572

 Kalil, J., 92
 Kamper, A.-L., 822
 Kaplan, B., 220
 Kaplan, B. S., 804
 Kashem, A., 14
 Kaupke, C. J., 529
 Kawaguchi, Y., 420
 Keller, F., 451
 Kennedy, L., 772
 Kent, G. M., 53
 Kessler, M., 99
 Ketteler, M., 878
 Kettritz, R., 186
 Kharrat, M., S3:67
 Kher, V., 209
 Kierdorf, H. P., S3:90
 Kiernan-Troidle, L., 86
 Kimmel, P. L., 202
 Kinjo, K., 541
 Kirlin, L., 855
 Kita, T., 289
 Kjellstrand, C. M., 861
 Klahr, S., 787, 918
 Klassen, D. K., 585
 Kliger, A. S., 86
 Klotman, M. E., 475
 Klotman, P. E., 475
 Klouche, K., S3:67

- Knaus, J., 603
 Knelson, M. H., 379
 Kohli, H. S., 137
 Koide, H., 32
 Koide, M., 82
 Korbet, S. M., 47
 Koren, G., 132
 Kozłowski, L., S3:81
 Krapf, R., 668
 Kraus, M. A., S3:21
 Krieger, J. N., 195
 Krishna, V. S., 137
 Kronmal, R. A., 195
 Kubo, H., 420
 Kumar, A., 676
 Kumar, P., 209
 Kume, N., 289
 Kuo, P. C., 585
 Kurokawa, K., 420

 Lai, K. N., 721
 Lambrecht, L. J., 523
 Lampertico, P., 437
 Lazarus, J. M., 372
 Leblanc, M., S3:81
 Lee, J. C., S3:81
 Leray-Moragues, H., S3:67
 Levine, B., 270
 Levine, G. N., S2:1
 Lew, N., 741
 Leyssac, P. P., 822
 Li, M., 721
 Lien, J., 128
 Lien, Y.-H. H., 767
 Light, A., 339
 Lim, V., 529
 Lindschau, C., 186
 Lipkowitz, M. S., 475
 Lo, C. Y., 747
 Lo, J. C., 614
 Lo, W.-K., 549, 747
 Lowrie, E. G., 741
 Lu, C.-M. C., 767
 Luft, F. C., 186
 Lui, S. L., 747

 Maccario, M., 695
 Macias, W. L., S3:15, S3:21
 McMahon, J. T., 461
 Macres, M., 523
 Madden, T., 846
 Madore, F., 931
 Maesaka, J. K., 257, 409, 529
 Magil, A. B., 128
 Mahnensmith, R. L., 535
 Maini, A., 209
 Majka, T., 727
 Malberti, F., 704
 Mallick, N. P., 278

 Marcelli, D., 704
 Marsh, C. L., 561
 Marwah, D., 47
 Matsuo, M., 82
 Matsuo, T., 82
 Mattana, J., 893
 Matzke, G. R., S1:63
 Mayeux, D., 99
 Medina, R. A., 226
 Mege, J.-L., 395
 McGill, D., 339
 Mehta, R. L., S3:1, S3:2, S3:8, S3:74
 Mendonca, M. M., 115
 Mereghetti, M., 695
 Meyers, K. E. C., 804
 Michel, P., 400
 Micheletti, G., 23
 Mishkin, G. J., 202
 Mitch, W. E., 457
 Mitchell, H. C., 832
 Mittal, B. R., 209
 Mittman, N., 910, 937
 Molony, D. A., 846
 Monteiro, F., 92
 Monterrosa, A., 226
 Moore, L. C., 173
 Morcos, M., 178
 Moreno, L., S3:81
 Morigi, M., 23
 Moritz, M. J., 266
 Moroni, G., 695
 Morris, R. E., 159
 Mueller, B. A., S3:21
 Muirhead, N., 502
 Mulcahy, W., 832
 Murakami, M., 289
 Murray, D. C., 53
 Myles, J., 461

 Nadasdy, T., 618
 Najjar, D., 904
 Nakamura, T., 32
 Nakazawa, H., 14
 Nalesnik, M., 578
 Natke, E., 257
 Neumann, H. P. H., 329
 Neuweiler, J., 668
 Ng, W. K., 283
 Nicklin, P., 475
 Niederman, G., 676
 Nishime, K., 541
 Noble, N. A., 878
 Nomoto, Y., 14, 420
 Norris, K. C., 270

 Ochi, H., 289
 Ohtaka, M., 82
 Ojo, A. O., S2:1

 Olmer, M., 395
 Olyaei, A. J., 631
 Ootaka, T., 40, 685
 Ouimet, D., 105
 Ovadia, J., 220
 Owen, W. F., 931

 Packham, D. K., 515
 Paganini, E. P., S3:81
 Panzetta, G., 713
 Papadimitriou, J. C., 585
 Pardo, V., 292
 Parfrey, P. S., 53
 Pascasio, L., 713
 Paul, L. C., 441
 Paul, R. V., 610
 Pearson, B. C., 235
 Penner, B., 262
 Perazella, M. A., 535
 Pereira, B. J. G., S3:35
 Petrusevska, G., 888
 Pichette, V., 105
 Pietrzak, B., 578
 Pignatti, P. F., 759
 Piraino, B., 415
 Po, C., 904
 Ponticelli, C., 437, 695
 Poon, J. F.-M., 549
 Port, F. K., S2:1
 Porter, G. A., S1:30
 Porush, J. G., 387, 811
 Pouletty, P., 92
 Priester-Coary, A., 727
 Pronai, L., 14
 Prudhomme, L., 105
 Pugh, J. A., 226
 Purgus, R., 395

 Racusen, L., 618
 Radomski, J. S., 266
 Raja, R., 904
 Randhawa, P., 578
 Rappaport, J., 475
 Rauch, S., 811
 Ray, N. F., 235
 Reams, G., 603
 Regan, J., 92
 Remuzzi, A., 23
 Remuzzi, G., 23
 Rennke, H., 614
 Reutter, F. W., 668
 Ribeiro-Alves, M. A. V. F., 124
 Richard, C., 235
 Riesenberger, L. A., 732
 Rifle, G., 400
 Ring, E., S3:28
 Ritter, C. S., 589
 Ritz, E., 178
 Roberts, R. G., 350

- Rocco, M. V., 173, 250
 Roche, Z., 752
 Rödl, S., S3:28
 Roe, D. J., 855
 Roland, J., 178
 Ronco, C., S3:1, S3:2, S3:58,
 S3:100, S3:121
 Rossetti, S., 759
 Rostagno, A., 676
 Ruggian, J. C., 409
 Rumi, M. G., 437
 Rundback, J. H., 214

 Sabatini, S., S1:34
 Saika, S., 82
 St. Peter, W. L., 523
 Saito, K., 441
 Saito, T., 40, 685
 Sakai, H., 14, S3:81
 Sakai, S., 420
 Sakhuja, V., 137
 Salem, M. M., 737
 Sanders, C. E., 572
 Sanders, P. W., 775
 Sandooran, D., 278
 Sankaran, R., 893
 Santella, R. N., 140
 Sato, H., 685
 Scheel, P. J., Jr., 618
 Schreiber, M. J., 428
 Schrier, R. W., 315
 Schulman, G., 811
 Schultz, D. R., 292
 Schwab, S. J., 379
 Schweitzer, E. J., 585
 Sedmak, D. D., 752
 Seifter, J. L., 614
 Senn, J. S., 147
 Shanklin, N., 508
 Shapiro, S., 783
 Shapiro, W. B., 387
 Sharma, P. K., 137
 Sharpe, J., 622
 Sherrard, D. J., 195, 502
 Shihabi, Z. K., 173
 Shiohira, Y., 541
 Short, C. D., 278
 Sieberth, H. G., S3:90
 Silber, A. K., 732
 Silomon, J., 451
 Silver, S. M., 1
 Sima, D., 186
 Simon, A. H. R., 124
 Sindhi, R., 867
 Singh, J., 493
 Singh, P. J., 140
 Singhal, M. K., 209

 Singhal, P. C., 893
 Sklar, A. H., 732
 Slatopolsky, E., 589, 596
 Smith, R. D., 832
 Soffredini, R., 437
 Soma, J., 40, 685
 Speiser, D., 92
 Sreedhara, R., 910, 924, 937
 Stegman, M. H., 772
 Stehman-Breen, C., 502
 Stein, M. S., 515
 Sterns, R. H., 1
 Stoff, J. S., S1:56
 Strandgaard, S., 822
 Stratta, R. J., 867
 Strawderman, R. L., S2:1
 Strife, C. F., 428, 804
 Striker, G. E., 305
 Strom, T. B., 159
 Sud, K., 137
 Sudan, D., 867
 Suhocki, P. V., 379
 Suthanthiran, M., 159
 Suzuki, S., 82
 Szeto, C. C., 721

 Tanaka, M., 14, 289
 Tanawattanacharoen, S., 618
 Tapolyai, M., S3:81
 Tarantino, A., 437
 Taylor, R. J., 867
 Tazi, Z., 762
 Tbakhi, A., 461
 Tedeschi, P. J., S2:1
 Tell, G. S., 72
 Tenconi, R., 759
 Tetta, C., S3:121
 Thamer, M., 235
 Thompson, L., 195
 Thorning, D., 502
 Tobe, S. W., 147
 Tokuyama, K., 541
 Tomalis, E. A., 354
 Tomino, Y., 32
 Torres, C., 86
 Toto, R. D., 832
 Truong, L. D., 888
 Tubbs, R. R., 461
 Tung, R.-L., 700
 Turco, A. E., 759
 Turenne, M. N., S2:1
 Turgan, Ç., 454

 Uehara, H., 541
 Uematsu-Yanagita, M., 289
 Umana, W. O., 202
 Ungureanu, V.-D., 529
 Urizar, R. E., 493

 Valderrama, E., 893
 Van Leengoed, L. A. M. G., S3:50
 Van Saase, J. L. C. N., S3:50
 Van Wyck, D. B., 855
 Varghese, F., 888
 Vaziri, N. D., 274
 Venning, M., 553
 Vidal, R., 676
 Virot, J. S., 400

 Wagner, J. D., 893
 Wakatsuki, Y., 289
 Wall, S. M., 846
 Walser, M., 354
 Wang, A. Y. M., 721
 Wang, S.-R., 811
 Wark, J. D., 515
 Warrington, W., 339
 Wead, L. M., 115
 Weaver-Osterholtz, D., 603
 Webb, R. L., S2:1
 Weir, M. R., 585
 Wilcox, C. S., 334
 Wiltbank, T. B., 855
 Winchester, J. F., S1:20
 Winkelman, J. W., 372
 Wish, J., 529
 Witzleben, C., 804
 Wolfe, R. A., S2:1
 Wong, K. S., 721
 Woods, J. D., S2:1
 Wörner, I., 178
 Wortley, P., 195
 Wratten, M. L., S3:121
 Wu, Z., 603

 Yamamoto, S., 82
 Yamauchi, F., 14
 Yano, N., 14
 Yasavul, Ü., 454
 Yokode, M., 289
 Yoshihara, K., 541
 Yoshioka, H., 289
 Young, B. A., 561
 Young, E. W., S2:1
 Yu, A. W. Y., 721
 Yusa, A., 40

 Zager, P. G., 855
 Zäuner, I., 329
 Zawada, E. T., 140
 Zbar, B., 329
 Zhang, Q., S2:1
 Zhong, M., 589
 Zimmerman, B., 741
 Zobel, G., S3:28
 Zoja, C., 23

SUBJECT INDEX

Page references to supplements 1 (July 1996), 2 (September 1996), and 3 (November 1996) are preceded, respectively, by S1:, S2:, and S3:

- AAs, *see* Amino acids
- AAVs (adeno-associated viruses), gene delivery with, 479-480
- Ab(s), *see* Antibody(ies)
- Absolute proximal tubular reabsorption (APR), AA effects on, 115-118
- Absorption
 - antithymocyte and antilymphocyte globulin, 654
 - azathioprine, 632
 - colchicine, 655
 - CyA, 640-641
 - FK506, 648
 - MMF, 633
- Acceptance into ESRD therapy, analysis of, S2:156-157
- Access
 - to RT, USRDS 1996 ADR on, S2:18, S2:110-111
 - see also* Vascular access
- ACEIs, *see* Angiotensin-converting enzyme inhibitor(s)
- Acetaminophen (APAP), S1:3-19
 - acute nephrotoxicity due to, S1:4-5
 - in combination with aspirin, S1:30-33; *see also* Combination analgesic nephropathy
 - CRF and, *see* Chronic renal failure, APAP-induced reactive metabolites of, S1:3-4
 - see also* Nonrenal toxicity of APAP, ASA, and NSAIDs
- Acetate-based fluids in CRRT, S3:15-16
- Acetylsalicylic acid, *see* Aspirin
- Acid fibroblast growth factor (aFGF) in chronic renal rejection, 445
- Acidosis
 - in CRF, effects of correction of, on dietary protein intake in, 350-353
 - CRRT for, S3:125
 - HCO₃ in, *see* HCO₃ in acidosis
 - lactic, in MELAS syndrome, point mutations in mitochondrial tRNA genes and, 143
 - type IV tubular, and familial fibrillary GN with giant fibrillar deposits, 668-675
- Acknowledgment for use of USRDS data, S2:30
- Acronyms used in USRDS 1996 ADR, list of, S2:9-11
- ACTH (adrenocorticotrophic hormone) syndrome, ectopic, K in correction of metabolic alkalosis with, 610-613
- Activity level of ESRD patients on PD, HD, and with RT, race and, 73, 75, 77
- Acute illnesses, minor, with ESRD, care of, by nephrologists, 69
- Acute interstitial nephritis, NSAID-induced, S1:57, S1:59
- Acute massive gentamicin intoxication of ESRD patient on CAPD with peritonitis, 767-771
- Acute nephrotoxicity due to APAP, S1:4-5
- Acute rejection, renal graft, 572-584
 - effects of continued CsA therapy under NORD program on, 572-577
 - severe, EBV-associated PTLN compared with, using Banff schema, 578-584
- Acute renal failure (ARF), 451-460
 - contrast media, following intravenous urography in renally impaired patients, 454-456
 - CRRT for, 317-319; *see* Continuous renal replacement therapy
 - due to renal pseudolymphoma, Sjögren's syndrome with, 762-766
 - FSGS with, due to α -IFN therapy, 888-892
 - and HIT on HD, 83
 - with osmotic nephrosis due to high-dose sucrose-containing (but not glycine) Ig therapy in IgA nephropathy, 451-453
 - rapidly reversible, due to ureteral obstruction in pregnancy, 457-460
 - see also* Acute renal failure, analgesic-induced; Acute renal failure, management of
- Acute renal failure (ARF), analgesic-induced
 - aspirin, S1:27-28
 - combined analgesics, S1:40
 - NSAIDs, S1:57-58
- Acute renal failure (ARF), CRRT of, 317-319
 - CRRT role in future treatment of, S3:108-113
 - and of hepatic failure, S3:62-66
 - IHD versus, *see* Intermittent hemodialysis of ARF, CRRT versus
 - outcome of, *see* Outcome, ARF, with CRRT
 - see also* Continuous renal replacement therapy; Critically ill acute renal failure patients, CRRT of; Solute control in ARF with CRRT
- Acute renal failure (ARF), management of, 315-328
 - with ANPs, 319-320
 - and ARF due to acute tubular necrosis, factors affecting recovery of renal function with, 316
 - with Ca channel blockers, 320-322
 - with CRRT in, *see* Acute renal failure, CRRT of
 - with growth factors, 323-324
 - other factors related to, 324
 - role of biocompatible membranes in, 316-317
 - with vasoactive agents, 321-323
- Acute tubular necrosis (ATN), factors affecting recovery of renal function with, 316
- Acute tubulointerstitial nephritis and uveitis (TINU) syndrome with ANCA, 124-127
- Adeno-associated viruses (AAVs), gene delivery with, 479-480
- Adenoviral vectors, gene delivery with, 479
- Adhesion molecules, *see* Intercellular adhesion molecule-1; Intercellular adhesion molecule-3; Vascular adhesion molecule-1
- Adjustment
 - standard population for, in USRDS 1996 ADR, S2:14, S2:152
 - standardization rates for, analysis of, S2:157-158
- Adjuvant immunosuppressive therapy, 168

- Admissions, *see* Hospitalization
- ADPKD, *see* Autosomal dominant polycystic kidney disease
- ADR (Annual Data Report) of USRDS, *see* United States Renal Data System, 1993 ADR of; United States Renal Data System, 1995 ADR of; United States Renal Data System, 1996 ADR of
- α (alpha)-Adrenergic agonist(s)
midodrine as, 132-136
see also specific α -agonists
- Adrenocorticotrophic hormone (ACTH) syndrome, ectopic, K in correction of metabolic alkalosis with, 610-613
- Adult Navajo Indians with NIDDM, renal function in, 339-349
- Advance directives (Living Wills), as substitute decision making on withdrawal of dialysis, 151-152
- Adverse effects
of antithymocyte and antilymphocyte globulin, 655
of azathioprine, 633
of corticosteroids, 639-640
of CsA, 644; *see also* Cyclosporine nephrotoxicity
of cyclophosphamide, chlorambucil, and melphalan, 636
of FK506, 651
of MMF, 635
of OKT3, 653-653
of omega-fatty acids, 657
see also Analgesic nephropathy; Intoxication; Intravenous iron dextran for anemic ESRD patients on HD, adverse effects of; Nephrotoxicity; Nonrenal toxicity of APAP, ASA, and NSAIDs and *specific drugs*
- AECAs (antiendothelial cell antibodies), disease activity and, in Wegener's granulomatosis, 186-194
- AED (atheroembolic disease), renal, nephrotic-range proteinuria in, 493-501
- aFGF (acidic fibroblast growth factor) in chronic renal rejection, 445
- African Americans, *see* Race and ethnicity
- Age
of AN patients, S1:52
of ARF patients, *see* Age of ARF patients, CRRT and of chronic renal disease patients with and without hypertension and, 816
of CRF patients with acidosis, 350; *see also* Age of ESRD patients, USRDS 1996 ADR on; Age of ESRD patients on HD and/or CAPD; Age of ESRD patients on PD
of familial fibrillary GN patients, 670, 671
of FSGS-like IgA nephropathy patients, 368
of HD patients, *see* Age of HD and/or CAPD patients
of HIVAN patients, 204
and HTN in pregnancy, 222
of methotrexate patients, 849
of MODS with septic shock patients, S3:53, S3:54
of MPGN type I patients, 687
of nephrotic patients, 355
of percutaneous renal biopsy patients, complications and, 48, 49
of PKT recipients, 870
of pregnant patients with ureteral obstruction, 459
of renal AED patients, 494
renal function and, in Navajo Indians, 341-343
of renovascular fibromuscular disease patients, 335, 336
of RT recipients, *see* Age of RT recipients
of RVH patients, 215, 216
- Age of ARF patients, CRRT and dialysis dose and outcome of ARF, S3:83, S3:84
of pediatric patients, S3:29
- Age of ESRD patients, USRDS 1996 ADR on, S2:15
modality utilization by, S2:53-55
mortality by, S2:81-82, S2:95, S2:96
registered in USRDS, S2:40, S2:42-43
remaining years of life by, S2:89-90
of treated ESRD patients, S2:37
- Age of ESRD patients on HD and/or CAPD
anemia and, *see* Age of ESRD patients on HD and/or CAPD, anemia and
Candida peritonitis and, 551
and dialysis-refractory hypertension, 258
and glycated albumin accumulation, 64
race, survival and, 75, 77, 228, 230-232
with SEP, 422-423
with TBP, 748
see also Age of ESRD patients on long-term HD and/or CAPD
- Age of ESRD patients on HD and/or CAPD, anemia and of diabetic ESRD patients, race and survival and, 228, 230, 231
and impact of anemia on ESRD, 55, 56
and intravenous FeD for anemia, 530
see also Age of ESRD patients on HD and/or CAPD, rHuEPO for anemia and
- Age of ESRD patients on HD and/or CAPD, rHuEPO for anemia and
- ACEI effects on rHuEPO and, 537
insurance status and rHuEPO therapy, 239, 242, 243, 245
- Age of ESRD patients on long-term HD and/or CAPD, 919
cardiovascular disease and, 932
PTH level and, 928
prealbumin level and, 938, 939, 941
spontaneous tendon ruptures and, 863
for up to 30 years, 911, 913
- Age of ESRD patients on PD
and care received prior to starting maintenance HD, 842
on CPD with fungal peritonitis, 87
and impact of anemia on ESRD, 55, 56
race, survival and, 75, 77
- Age of HD and/or CAPD patients
fatigue and, 733
and HD access complications, 251, 253
HIT on HD and, 84
mortality risk and, 742, 744
and protective effects of cool HD dialysate, 264
see also Age of ESRD patients on HD and/or CAPD
- Age of RT recipients
bone loss and, 110, 111
in continued CsA therapy NORD program, 573
with ESRD, race and survival and, 75, 77
HCV RNA detection and, 438
or pancreas-renal transplant recipients, CyA-associated TMA/HUS and, 564
and recurrent IgA nephropathy following transplantation, 102
- Aggregation size, minimum, in USRDS 1996 ADR, S2:153

- Aging, mtDNA mutations associated with, 143
 Agreement for USRDS data release, S2:32-33
 Air embolism due to CRRT, S3:101
 AL-amyloidosis, systemic, twenty-one year survival with, 278-282
 Alanine aminotransferase (ALT), and HCV in native and transplanted kidneys, 755
 Albumin
 in HD patients, *see* Albumin in HD and/or CAPD patients
 in systemic AL-amyloidosis, 279
 urinary excretion of, in chronic progressive nephropathy, 828; *see also* Albuminuria
 Albumin in ESRD patients on HD and/or CAPD
 accumulation of glycates, 62-66
 and ACEI effects on rHuEPO therapy of ESRD, 538
 hypertension and, 738
 see also Albumin in ESRD patients on long-term HD and/or CAPD; Serum albumin in ESRD
 Albumin in ESRD patients on long-term HD and/or CAPD with bone disease, 920
 with cardiovascular disease, 935
 prealbumin values and ESRD survival, 937-942
 predictive value of, for patients on HD for up to 30 years, 910-917
 PTH and, 928
 Albumin in HD and/or CAPD patients
 with atherosclerotic lesions in carotid vessels, 715
 and protective effects of cool HD dialysate, 264
 and spontaneous tendon ruptures, 863
 see also Albumin in ESRD patients on HD and/or CAPD
 Albuminuria
 renal function and, in Navajo Indians, 339-349
 see also Microalbuminuria; Proteinuria
 Albuterol, effects of insulin and, on plasma K concentration in ESRD patients on HD, HCO₃ effects compared with, 508-514
 Alcoholism in ESRD patients on PD, HD, and with RT, race and survival and, 75, 77
 Aldosterone, serum, in metabolic alkalosis with ectopic ACTH syndrome, 611
 Alkaline phosphatase (ALP)
 in idiopathic GN, 755
 in long-term HD patients, *see* Alkaline phosphatase in ESRD patients on long-term HD and/or CAPD
 serum, and bone loss as long-term effect of RT, 107
 Alkaline phosphatase (ALP) in ESRD patients on long-term HD and/or CAPD
 bone disease and, 920
 and spontaneous tendon ruptures, 863
 Alkalosis, metabolic, in ectopic ACTH syndrome, K in correction of, 610-613
 Allergic reactions to bioincompatible membranes in CRRT, S3:102
 ALP (alkaline phosphatase), serum, and bone loss as long-term effect of RT, 107
 Alpha-adrenergic agonists, *see* α -Adrenergic agonist(s)
 Alpha (α)-globulin, *see entries beginning with acronym:* IgA
 1-Alpha (α)-hydroxylase, and renal calcitriol synthesis, 589-595
 Alpha-interferon therapy (α -IFN), FSGS with ARF due to, 888-892
 ALT (alanine aminotransferase), and HCV in native and transplanted kidneys, 755
 Alternative treatment modalities for ESRD, Medicare expenditures for, USRDS 1996 ADR on, S2:19, S2:135-140
 Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis
 Amenorrhea, secondary, as risk factor for osteopenia, 515-522
 Amino acids (AAs)
 All effects on GFR and NO response to, 115-123
 in fibrillary GN, 678-680
 very low-protein diet supplemented with, nephrosis management with, 354-364
 see also specific amino acids
 Amyloidosis
 in long-term HD patients, bone disease and, 920-921
 renal, extracapillary GN and, 695-699
 systemic AL-, twenty-one year survival with, 278-282
 AN, *see* Analgesic nephropathy
 Analgesic abuse
 of combined analgesics, epidemiology of, S1:53-55
 etiology of, S1:39-40
 Analgesic nephropathy (AN)
 aspirin-induced, S1:20; *see also* Aspirin
 commentary on, 783-785
 introduction to, S1:1-2
 see also Acetaminophen; Combination analgesic nephropathy; Nonsteroidal anti-inflammatory drugs, renal effect(s) of; Renal papillary necrosis, analgesic-induced
 Analytical methods used in USRDS 1996 ADR, S2:13, S2:14, S2:20, S2:152-165
 for annual death rate, S2:158-161
 for cost effectiveness, S2:163-164
 for data, *see* Data, USRDS
 for Death Notification Form, S2:152, S2:155-156
 differences in, between 1995 ADR and, S2:152-153
 for graft survival, S2:162-163
 for hospitalization, S2:152, S2:158-161
 for incidence of treated ESRD, S2:13, S2:154
 for lost to follow-up status, S2:14, S2:152, S2:155
 for Medicare claims data, S2:154-155, S2:163
 for patient survival, S2:161-162
 for race code, S2:14, S2:152-153, S2:157
 for treatment modalities, S2:163
 ANCAs, *see* Antineutrophil cytoplasmic antibodies
 Anemia
 of nephrotic syndrome, rHuEPO for, 274-277
 see also Anemia of ESRD in HD patients
 Anemia of ESRD in HD patients
 impact of, on cardiomyopathy, cardiac disease, and mortality, 53-61
 iron dextran for, *see* Intravenous iron dextran for anemic ESRD patients on HD
 rHuEPO for, *see* Recombinant human erythropoietin for anemia of ESRD patients on HD
 Angiography, digital subtraction, of RVH, CRS compared with, 211
 Angioplasty, percutaneous transluminal renal, for HTN and azotemia, percutaneous renal artery stent placement compared with, 214-220
 Angiotensin I (AI), enalaprilat and ramiprilat effects on urinary bladder response to, 603-609

- Angiotensin II (AII)
effects of, on GFR and NO response to AAs, 115-123
plasma, *see* Plasma angiotensin II
- Angiotensin-converting enzyme inhibitor(s) (ACEIs)
effects of, on tubular function in chronic progressive nephropathy, 822-831
for ESRD patients on HD, effects of, on rHuEPO, 535-540
see also specific angiotensin-converting enzyme inhibitors; for example: Captopril
- Anion, *see* Anion gap; Dialysate anion; Replacement fluid/dialysate anion in CRRT
- Anion gap in familial fibrillary GN, 671
- Annual Data Report of USRDS, *see* United States Renal Data System, 1993 ADR of; United States Renal Data System, 1995 ADR of; United States Renal Data System, 1996 ADR of
- Annual death rate, ESRD patient, USRDS 1996 ADR on, S2:158-161
- Annual Facility Survey, *see* Facilities for ESRD care, USRDS 1996 ADR on
- Anoxia in analgesic-induced RPN, S1:34-38
- ANPs, *see* Atrial natriuretic peptides
- Antiallograft response
immunobiology of, 159-161
see also Renal graft loss; Renal graft rejection
- Antibody(ies) (Abs)
anti-HLA class I, ELISA of, pretransplantation assessment of rejection risk with, 92-98
antilymphocytic, immunopharmacology of, 652, 655
antineutrophil cytoplasmic, *see* Antineutrophil cytoplasmic antibodies
anti-T cell and other, directed at cell-surface proteins in clinical immunosuppressive regimen, 167-168
to HCV in renal transplant recipients, detection of, by third-generation assays, 437-440
monoclonal, *see* Monoclonal antibody(ies), as immunosuppressants; Monoclonal antibody(ies) in sepsis
PF4-heparin complex, in diagnosis of HIT in HD patients, 82-85
polyclonal, *see* Polyclonal antibodies
in vasculitis, *see* Vasculitis, Abs in
- Antibody(ies) (Abs) in sepsis, S3:40-42
monoclonal, *see* Monoclonal antibody(ies) in sepsis
neutralizing, against IL-1 receptors, S3:43
against O-polysaccharide chain, S3:40
polyclonal, against lipid A and R-core, S3:41
- Anticoagulants on CRRT, S3:8-14
for ARF, S3:92
circuit and, S3:9
citrate, S3:18-19
clinical experience with, S3:11-12
for hepatic failure and ARF, S3:64-65
monitoring, S3:12-13
- Anticoagulation, *see* Anticoagulants on CRRT; Heparin
- Antiendothelial cell antibodies (AECAs), disease activity and, in Wegener's granulomatosis, 186-194
- Antifactor Xa, effects of low-dose LMW heparin on, 721-726
- Anti-HLA class I antibodies (Abs), pretransplantation assessment of rejection risk with ELISA of, 92-98
- Antihypertensives
effects of ACEIs and, in chronic progressive nephropathy, 824-826
for hypertension in chronic renal disease, 814-815
for hypertensive ESRD patients on HD, survival and, 737-740
see also specific antihypertensives
- Anti-inflammatory drugs, *see* Nonsteroidal anti-inflammatory drugs, renal effect(s) of
- Antilymphocyte globulin, immunopharmacology of, 654-655
- Antilymphocytic antibodies (Abs), immunopharmacology of, 652, 655
- Antineutrophil cytoplasmic antibodies (ANCAs)
TINU syndrome with, 124-127
in vasculitis, 178-185
- Antiretroviral (ARTV) therapy, captopril and, in HIVAN, 202-208
- Antisense oligodeoxynucleotides (ODNs), molecular therapy with, 482-484
- Anti-T cell antibodies (Abs) directed at cell-surface proteins in clinical immunosuppressive regimen, 167-168
- Antithymocyte globulin, immunopharmacology of, 654-655
- AI (angiotensin I), enalaprilat and ramiprilat effects on urinary bladder response to, 603-609
- Aortoarteritis, RVH due to, 209-213
- APAP, *see* Acetaminophen
- APR (absolute proximal tubular reabsorption), AA effects on, 115-118
- ARF, *see* Acute renal failure
- Arginase, L-arginine metabolized to urea and L-ornithine by, 878-887
- D-Arginine, salt-sensitive hypertension and, 778
- L-Arginine
in immune-mediated GN, 878-887
in salt-sensitive hypertension, 775-782
- L-Arginine:NO pathway in salt-sensitive hypertension, 776-779
- Arterial blood pressure, *see* Blood pressure
- Arterial HCO₃ (bicarbonate) in metabolic alkalosis with ectopic ACTH syndrome, 611
- Arterial pH in metabolic alkalosis with ectopic ACTH syndrome, 611
- Arterial puncture with CRRT of ARF, S3:93
- Arterialized pH in acidosis of CRF patients, 351
- Arteriovenous (AV) circuit in CRRT, defined, S3:6
- Arteriovenous (AV) fistulas in HD, inpatient and outpatient care of, 250-256
- Arteriovenous hemodiafiltration, *see* Continuous arteriovenous hemodiafiltration
- Arteriovenous hemodialysis, *see* Continuous arteriovenous hemodialysis
- ARTV (antiretroviral) therapy, captopril and, in HIVAN, 202-208
- ASA (acetylsalicylic acid), *see* Aspirin
- Ascites
HD patients with, hemodynamic effects of PVSs in, 387-394
tense, secondary to decompensated liver cirrhosis in ESRD, UF for, 899-903
- Aspartate aminotransferase (AST), and HCV in native and transplanted kidneys, 755

- Aspirin (acetylsalicylic acid; ASA), S1:20-33
 ARF induced by, S1: 27-28
 in combination with APAP, S1:30-33 *see* Combination analgesic nephropathy
 CRF induced by, S1:24-27
 therapeutic uses of, *see* Aspirin, therapeutic uses of, in renal diseases
see also Nonrenal toxicity of APAP, ASA, and NSAIDs
 Aspirin (acetylsalicylic acid; ASA), therapeutic uses of, in renal diseases, S1:20-23
 isradipin, pentoxifylline, and aspirin for CyA-associated TMA/HUS in renal and renal-pancreas transplantation, 561-571
 AST (aspartate aminotransferase), and HCV in native and transplanted kidneys, 755
 Atheroembolic disease (AED), renal, nephrotic-range proteinuria in, 493-501
 Atherosclerotic lesions in carotid vessels of HD patients, echo color Doppler imaging, 713-720
 ATN (acute tubular necrosis), factors affecting recovery of renal function with, 316
 Atrial natriuretic peptides (ANPs)
 in ARF management, 319-320
 in dialysis-refractory hypertension in ESRD patients, 257-261
 AII, *see* Angiotensin II
 Australian experience with combination AN, *see* Combination analgesic nephropathy
 Autosomal dominant polycystic kidney disease (ADPKD), 788-803
 etiology of, 788-791
 linked to PKD3 gene, 759-761
 mechanisms of fluid accumulation in, 794-799
 modification of progression of, 799-800
 pathogenesis of, 791-794
 AV, *see* entries beginning with term: Arteriovenous
 Availability of anticoagulants, S3:11-12
 Azathioprine (AZA; Imuran)
 cellular and molecular mechanisms of action of, 163
 immunopharmacology of, 631-633
 Azotemia
 RVH and, percutaneous renal artery stent placement for, 214-220
 TBW effects on control of, S3:22
 see also specific renal replacement therapies
 B cells, CsA effects on, 643
 Backfiltration control system in CRRT, defined, S3:6
 Bacteria, *see* Infections; Sepsis, CRRT and *and* entries beginning with terms: Bacterial, Microbial
 Bacterial enzymes in intestinal dialysis, 947-948
 Banff schema, 578-584
 EBV-associated PTLD compared with severe acute rejection using, 578-584
 significance of Banff borderline biopsy, 585-588
 BCAAs (branched-chain amino acids), AII effects on GFR and NO response to, 115-123
 Beer drinking, as risk factor for urolithiasis, 195-201
 Behavioral risk factors, dietary and, for urolithiasis, implications of, for prevention, 195-201
 Bence-Jones protein, and twenty-one year survival with systemic AL-amyloidosis, 279
 Berger's disease, *see* IgA nephropathy
 11-Beta (β)-hydroxysteroid dehydrogenase in metabolic alkalosis with ectopic ACTH syndrome, 610-613
 Bicarbonate, *see* HCO_3
 Bilateral renal artery stenosis, RVH due to, 209-213
 Bilirubin
 dialysis dose and, and ARF outcome, S3:83
 total, in CyA-associated TMA/HUS, 564, 565
 Biochemistry
 of combined analgesic nephrotoxicity, S1:44-45
 see also Laboratory data
 Biocompatible membranes in ARF management, 316-317
 Bioincompatible membranes in CRRT of ARF, S3: 91-92, S3:102
 and hepatic failure, S3:63-64
 Biological actions of ET, S3:37
 Biomedical Scientific Advisory Committee (B-SAC), S2:6
 Biopsy, *see* Renal biopsy
 Birth weight of infants born to five-year posttransplant CsA-treated RT recipients, 267
 Black Americans, *see* Race and ethnicity
 Bladder, urinary, ramipril and enalapril effects on response of, to angiotensin I, 603-609
 Bleeding, as CRRT complication, S3:101-102
 Bleeding time (BT) of percutaneous renal biopsy patients, 48, 49
 Blood, peripheral, increased MMP-9 mRNA expression in monocytes of, in IgA nephropathy patients, 32-39
 Blood-brain barrier, urea diffusion across, postdialytic disequilibrium syndrome and, 2-3
 Blood flow
 CRRT, *see* Blood flow in CRRT
 renal, redistribution of, RPN and, S1:34-38
 Blood flow in CRRT
 during CAVH of pediatric ARF patients, S3:31
 reduced, S3:100-101
 Blood HCO_3 (bicarbonate) in familial fibrillary GN with giant fibrillar deposits, 671
 Blood pH, HCO_3 effects on, in hyperkalemic ESRD patients on HD, 511
 Blood pressure (BP)
 AA effects on, 118
 of CRF patients, 842
 of diabetic ESRD patients, race, survival and, 228, 230
 or HD patients, *see* Blood pressure of HD patients
 initial, and survival on chronic dialysis, 542, 543
 of pediatric ARF patients on CRRT, S3:29
 in percutaneous renal biopsy patients, 48, 49
 ramipril effects on protein excretion and, in normotensive nondiabetic patients with proteinuria, 832-840
 in systemic AL-amyloidosis patients, 279
 see also Hypertension; Hypotension
 Blood pressure (BP) of HD patients
 with ascites, effects of PVSs on, 389, 391, 393
 fatigue and, 734
 Blood purification, inadequate, with CRRT, S3:103
 Blood transfusions for anemia of ESRD, 537
 Blood urea
 in acidosis of CRF patients, 351

- clearance of, with IHD versus CRRT, S3:23
see Azotemia
- Blood urea nitrogen, *see* BUN
- BMD, *see* Bone mineral density
- Body iron (Fe), total, IV iron dextran effects on, 858
- Body mass index of chronic renal disease patients with and without hypertension and, 816, 818
- Body temperature, *see* Hypothermia
- Body water, total, effects of, on azotemia control, S3:22
- Body weight
 of ARF patients, pediatric, CRRT and, S3:29
 of chronic renal disease patients with and without hypertension and, 816
 of HD patients with ascites, PVS effects on, 389, 391, 393
 initial, and survival on chronic dialysis, 542, 543
 intradialytic, of HD patients, fatigue and, 734
 midodrine effects on, 133
 of neonates born five years after RT to CsA-treated mothers, 267
 of PKT recipients, 870
 predialysis, of CRF patients, 842
 of RT recipients, bone loss and, 111
 of systemic AL-amyloidosis patients, 279
- Bone(s)
 steroid effects on, 639-640
see also Bone disease; Bone loss; Bone mineral density
and entries beginning with element: Osteo-
- Bone disease in ESRD patients on long-term HD, 918-923
- Bone loss, as long-term effect of RT, 105-113
- Bone mineral density (BMD)
 long-term effects of RT on, 105-113
 in osteopenia, densitometry of, in HD and PD patients, 515-522
- Borderline biopsy, Banff, significance of, 585-588
- BP, *see* Blood pressure
- Brain, *see entries beginning with terms: Brain, Cerebral*
- Brain osmolality, and "idiogenic osmole hypothesis" of postdialytic disequilibrium syndrome, 8-11
- Brain-to-plasma urea concentrations, postdialytic disequilibrium syndrome and, 2-8
- Brain water, effects of urea-containing dialytic bath on, 6
- Branched-chain amino acids (BCAAs), AII effects on GFR and NO response to, 115-123
- Brequinar sodium, cellular and molecular mechanisms of action of, 166
- B-SAC (Biomedical Scientific Advisory Committee), USRDS, S2:6
- BT (bleeding time) of percutaneous renal biopsy patients, 48, 49
- BUN (blood urea nitrogen)
 and atherosclerotic lesions in carotid vessels of HD patients, 715
 with CRRT of ARF, S3:22
 dialysis dose and, and ARF outcome, S3:93
 initial, and survival on chronic dialysis, 542, 543
 in metabolic alkalosis with ectopic ACTH syndrome, 611
 in renal AED patients, 494
 and spontaneous tendon ruptures on CAPD, 863
see also Azotemia
- Bypass, venovenous, CVVHDF with, S3:5
- C, *see* Complement
- Ca (calcium)
 bone loss as long-term effect of RT and, 111
 CyA-associated TMA/HUS effects on, 564, 565
 in insulin-dependent diabetic patients on HD with proximal calciphylaxis, 410
 in restless legs syndrome with ESRD, 374
 set point for, and long-term effects of IV calcitriol on secondary hyperparathyroidism, 704-712
see also Ca in long-term HD and/or CAPD patients
- Ca (calcium) channel blockers in ARF management, 320-322
- Ca (calcium) in long-term HD and/or CAPD patients
 PTH and, 928
 and spontaneous tendon ruptures, 863
 total Ca in patients with bone disease, 920
- Cadaveric renal transplantation (RT)
 de novo LCDD in, 461-465
see also Cadaveric renal transplantation, USRDS 1996
- ADR on: Renal transplantation
- Cadaveric renal transplantation (RT), USRDS 1996 ADR on
 graft loss with, S2:106-108
 graft survival with, S2:106
 patient survival with, S2:162
- Caffeine, *see* Combination analgesic nephropathy
- Calcification, periarticular, in long-term HD patients, 921
- Calcineurin, CyA and, 642
- Calciphylaxis, proximal, in HD patients with IDDM, 409-414
- Calcitriol [1,25-(OH)₂D₃]
 long-term effects of IV, on secondary hyperparathyroidism, 704-712
 serum, and parathyroid hyperplasia, 601
 synthesis of, and serum P response to dietary P restriction, GH or insulin effects on, 589-595
- Calcium, *see* Ca
- Calculi (urolithiasis), dietary and behavioral risk factors for, implications of, for prevention, 195-201
- Candida peritonitis (CP) on CAPD, oral nystatin in prevention of, 549-552
- CAPD, *see* Continuous ambulatory peritoneal dialysis
- Capillary electrophoresis using nonradioactive iothexol in GFR measurement, 173-177
- Captopril, and renal survival in HIVAN, 202-208
- Captopril renal scintigraphy (CRS) in RVH diagnosis, 209-213
- Carbon dioxide, *see* Total CO₂
- Cardiac disease, impact of anemia on cardiomyopathy, mortality and, in ESRD patients on HD, 53-61
- Cardiac function, effects of slow isolated UF for CHF on, S3:70
- Cardiomyopathy
 impact of anemia on cardiac disease, mortality and, in ESRD patients on HD, 53-61
 in MIMAC, point mutations in mitochondrial tRNA genes and, 143
- Cardiovascular disease
 in long-term ESKD survivors, 931-936
see also specific conditions
- Cardiovascular system
 analgesics effects on, S1:68
 CRRT effects on, S3:124-125

- dysfunctional, and inflammatory mediators in sepsis, S3:40
see also Congestive heart failure; Heart transplantation *entries beginning with terms*: Myocardial, Renovascular, Vascular and element: Card-
- Carotid vessels of HD patients, evidence of atherosclerotic lesions in, with echo color Doppler imaging, 713-720
- Cartilage, steroid effects on, 639-640
- Case Mix Adequacy Study (CMAS), USRDS, S2:28-29
- Case Mix Severity Study, USRDS, S2:28
- Catabolic rate, normalized protein, and effects of small solute clearance on dietary protein intake by CAPD patients, 553-560
- Catabolism, and nutrition in ARF, CRRT and, S3:109
- Catheters
- CAPD, *see* Exit site infections, catheter, on CAPD, peritonitis due to; Tunnel infections
 - CPD, FP therapy with and without removal of, 88-89
 - silastic cuffed, thrombolytic and mechanical correction of malfunctioning, 379-386
- Caveats on release of USRDS data, S2:31-33
- CAVH, *see* Continuous arteriovenous hemofiltration
- CAVHD, *see* Continuous arteriovenous hemodialysis
- CAVHDF, *see* Continuous arteriovenous hemodiafiltration
- CC (Coordinating Center) of the University of Michigan, S2:5-6
- CCPD (continuous cycling peritoneal dialysis), USRDS 1996 ADR on, *see* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1996 ADR on
- CD-ROM, USRDS 1996 ADR on, S2:27-30
- CMAS on, S2:29
 - core SAFs on, S2:27-30
 - file media and formats of, S2:29-30
- CD-ROM drive needed to use USRDS SAFs, S2:30
- Cell proliferation
- smooth muscle, aspirin effects on, S1:20-23
 - tubular wall, ADPKD and, 791-792
- Cell-surface proteins, anti-T cell and other Abs directed at, in clinical immunosuppressive regimen, 167-168
- Cell-surface tumor necrosis factor receptor (sTNFR) neutralizing TNF in sepsis, S3:43
- Cellular injury, and analgesic-induced RPN, S1:34-38
- Cellular mechanisms of immunosuppressants, *see* Immunosuppressants, cellular and molecular mechanisms of
- Cellulose triacetate (CT) membranes, high-flux, modulating TGF- β monocyte production in long-term HD, 395-399
- Census population base of USRDS 1996 ADR, S2:156-157
- Central nervous system
- effects of analgesics on, S1:65-66
 - see also* Neuropathy and *entries beginning with term*: Brain
- Cerebral cortex, urea removal from, postdialytic disequilibrium syndrome and, 7-8
- Cerebral edema, *see* Disequilibrium syndrome, postdialytic
- C4R (complement receptor 4), glomerular immune cell infiltration and activation in IgA nephropathy mediated by leukocyte function-associated antigen-1 α , ICAM-1 and, 40-46
- cGMP (cyclic guanosine monophosphate)
- in salt-sensitive hypertension, 777, 779
 - uroguanylin effects on, *see* Uroguanylin
- Chemotherapy with methotrexate, renal failure with, 846-854
- Cheyenne Bottoms Salt Lake model of fluid accumulation in ADPKD, 795-796
- CHF, *see* Congestive heart failure
- Chlorambucil, immunopharmacology of, 635-636
- Chloride (Cl), serum, in metabolic alkalosis with ectopic ACTH syndrome, 611
- Cholesterol, *see* Cholesterol in ESRD patients on long-term HD and/or CAPD; Cholesterolemia; Total cholesterol
- Cholesterol in ESRD patients on long-term HD and/or CAPD
- PTH and, 928
 - survival and, 938-941
 - for up to 30 years, predictive value of, 910-917
- Cholesterolemia, and atherosclerotic lesions in carotid vessels of HD patients, 715
- Chromatography, high-performance liquid, capillary electrophoresis and, in GFR measurement, compared, 173-177
- Chronic dialysis
- impact of initial laboratory data on survival with, 541-548
 - nephrologists as primary care providers for ESRD patients on, 67-72
 - peritoneal, fungal peritonitis on, 86-91
 - see also* Chronic hemodialysis for ESRD; Continuous ambulatory peritoneal dialysis
- Chronic hemodialysis (HD) for ESRD
- differences in HCO₃ assays and magnitude of metabolic acidosis in patients on, 700-703
 - IV FeD for anemic patients on, 855-860
- Chronic progressive external ophthalmoplegia (CPEO), 143
- Chronic rejection, renal transplant, GF mRNA in, 441-450
- Chronic renal diseases
- prevalence of hypertension in, diet modification effects on, 811-821
 - progressive, ACEI effects on, 822-831
 - see also specific conditions*
- Chronic renal failure (CRF)
- effects of acidosis correction on protein intake in, 350-353
 - HD for, *see* Chronic renal failure, HD for
 - L-lysine-associated Fanconi's syndrome with tubulointerstitial nephritis and, 614-617
 - P effects on development of parathyroid hyperplasia and secondary hyperparathyroidism in, 596-602
 - see also* Chronic renal failure, analgesic-induced; End-stage renal disease
- Chronic renal failure (CRF), analgesic-induced
- APAP, *see* Chronic renal failure, APAP-induced
 - aspirin, S1:24-27
 - combined analgesics, S1:40
 - NSAIDs, S1:59-60
- Chronic renal failure (CRF), APAP-induced, S1:5, S1:7-19
- case control studies since 1986, S1:8-10
 - effects of APAP used alone and in combination, compared, S1:10-11
 - outcome of, S1:14-19
 - phenacetin and, S1:10-12
 - reports on, S1:12
- Chronic renal failure (CRF), HD for
- and HIT on HD, 83
 - hospitalization of patients with, to start maintenance HD, 841-845

- see also* Hemodialysis for ESRD
- Chronic renal insufficiency, capillary electrophoresis using nonradioactive iohexol to measure GFR in, 173-177
- Chronic renal resection, GF mRNA in, 441-450
- Circuit in CRRT
- for anticoagulants, S3:9
 - AV and VV, defined, S3:6
 - clotting of, S3:100-101
- Cirrhosis, decompensated liver, tense ascites secondary to, in ESRD, UF for, 899-903
- Citrate anticoagulation on CRRT, S3:18-19
- Cl (chloride)
- in familial fibrillary GN, 671
 - secretion of, in ADPKD, 796-798
 - serum, in metabolic alkalosis with ectopic ACTH syndrome, 611
 - see also* NaCl
- Claims, Medicare, *see* Medicare claims, USRDS 1996 ADR on
- Clinical complications
- of CRRT, S3:101-102
 - of renal effects of NSAIDs, S1:57-58
- Clinical course
- of familial fibrillary GN patients, 670-672
 - see also* Progression of renal disease
- Clinical cyclosporine (CsA; CyA) nephrotoxicity, 644-646
- Clinical experiences, *see* Clinical uses
- Clinical factors in withdrawal of dialysis, 148
- Clinical features and presentation
- of analgesic abuse, S1:39-40
 - of combination AN, S1:40
 - of FK506 nephrotoxicity, 651
 - of FSGS-like IgA nephropathy and of FSGS, 358
 - of long-term HD patients, 918-920
 - of MPGN type I, 687
 - of TBP, 749
 - see also specific conditions*
- Clinical immunosuppressive regimens, 167-168
- Clinical significance of elastase antibodies and antineutrophil cytoplasmic antibodies in Wegener's granulomatosis, 183-184
- Clinical studies of pheochromocytoma-associated syndromes, 329
- Clinical uses
- of anticoagulants in CRRT, S3:11-12
 - of antithymocyte and antilymphocyte globulin, 655
 - of azathioprine, 633
 - of colchicine, 656
 - of corticosteroids, 640
 - of CsA, 647
 - of cyclophosphamide, chlorambucil, and melphalan, 636
 - of FK506, 651-652
 - of MMF, 635
 - of new CRRT technology, S3:123-125
 - of OKT3, 654
 - of omega-fatty acids, 657
- Clinical variables in MODS with septic shock, CRRT effects on, S3:52
- Clinically effective intestinal dialysis, 945-946
- Clotting
- circuit, in CRRT, S3:100-101; *see also* Anticoagulants on CRRT
 - see also* entries beginning with element: Thromb-
- CMAS (Case Mix Adequacy Study), USRDS, S2:28-29
- CO₂, *see* Total CO₂
- CoA (coenzyme A) reductase inhibitors, HMG-, immunopharmacology of, 657
- Codeine, *see* Combination analgesic nephropathy
- Coenzyme A (CoA) reductase inhibitors, HMG-, immunopharmacology of, 657
- Colchicine, immunopharmacology of, 655-656
- Colic, renal, due to combined analgesics, clinical features of, S1:40
- Collagen, L-arginine metabolism in immune-mediated GN and synthesis of, 878-887
- Collagen vascular diseases, ANCA in, 183
- Color Doppler imaging, echo, of carotid vessels of HD patients, evidence of atherosclerotic lesions with, 713-720
- Combination analgesic nephropathy (AN), S1:10-11, S1:39-55
- biochemistry of toxicity, S1:44-45
 - clinical features of, S1:40
 - combination aspirin-APAP-induced nephropathy, experimental data on, S1:30-33
 - effects of APAP alone and in combination, S1:10-11
 - and etiology of analgesic abuse, S1:39-40
 - European experience with, S1:48-55
 - intrarenal distribution of analgesics and, S1:42-44
 - renal excretion of analgesics and, S1:41-42
- Committees, USRDS, S2:6-7, S2:22-23
- Comorbid conditions
- and HIT on HD, 83
 - maternal, and outcome of five-year posttransplant pregnancy in CsA-treated patients, 267
 - see also* Morbidity due to ESRD, USRDS 1996 ADR on and specific conditions
- Compartmentalization of PGs, as NSAID effect, S1:56-57
- Complement (C)
- activation of, and recovery of renal function with HD for ARF, 316
 - discordant findings between histopathology and profiles of, in MPGN type III, 804-810
 - see also* Hypocomplementemia
- Complement 3b1 receptor (C3b1R), role of, in C4R-, leukocyte function-associated antigen-1 α -, and ICAM-1-mediated glomerular immune cell infiltration and activation in IgA nephropathy, 40-46
- Complement 4 receptor (C4R), leukocyte function-associated antigen-1 α , and ICAM-1 mediating glomerular immune cell infiltration and activation in IgA nephropathy, 40-46
- Complications, *see* Adverse effects; Complications of CRRT specific conditions and therapeutic modalities
- Complications of CRRT, S3:100-104
- of prophylactic CRRT, S3:117-118
- Compression, extrinsic, renal graft salvage with renal vein occlusion secondary to, 622-623
- Computers needed for USRDS SAF use, S2:30
- Congestive heart failure (CHF)
- in ESRD, impact of anemia on, 55-57
 - slow isolated UF for, S3:67-73
- Consumer Price Index (CPI), changes in Medicare payments for ESRD and changes in (1991-1993), S2:134

- Contacts, USRDS, S2:24
- Continuous ambulatory peritoneal dialysis (CAPD)
for ESRD, *see* Continuous ambulatory peritoneal dialysis for ESRD
small solute clearance effects on dietary protein intake in patients on, S53-560
see also Peritonitis on CAPD
- Continuous ambulatory peritoneal dialysis (CAPD) for ESRD
long-term, spontaneous tendon ruptures on, 861-866
video-assisted talc pleurodesis of pleural effusion secondary to, 772-774
see also Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1996 ADR on; Long-term hemodialysis and/or continuous ambulatory peritoneal dialysis for ESRD
- Continuous ambulatory peritoneal dialysis (CAPD) for ESRD, USRDS 1996 ADR on
annual death and hospitalization rate of patients on, S2:160
prescription of, S2:55-56
see also United States Renal Data System, 1996 ADR of
- Continuous arteriovenous hemodiafiltration (CAVHDF)
defined, S3:3-4
of pediatric ARF patients, S3:28-34
see also Continuous renal replacement therapy
- Continuous arteriovenous hemodialysis (CAVHD)
defined, S3:4-5
see also Continuous renal replacement therapy
- Continuous arteriovenous hemofiltration (CAVH)
defined, S3:3
pediatric ARF patients on, S3:28-34
see also Continuous renal replacement therapy
- Continuous cycling peritoneal dialysis for ESRD, *see* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1996 ADR on
- Continuous renal replacement therapy (CRRT)
defined, S3:3
dietary management of critically ill ARF patients on, S3:58-61
introduction to, S3:1
major developments in, S3:105-107
nomenclature for, S3:2-7
slow isolated ultrafiltration for CHF, S3:67-76
see also Acute renal failure, CRRT of; Anticoagulants on CRRT; Complications of CRRT; Dialysis modalities for ARF, outcome and; Inflammatory mediators in sepsis; Multiorgan dysfunction syndrome; Multiple organ failure, CRRT in; Renal function, CRRT and; Replacement fluid/dialysate anion in CRRT
- Continuous ultrafiltration (UF), slow, defined, S3:3
- Continuous venovenous hemodiafiltration (CVVHDF)
defined, S3:4
with ECMO or venovenous bypass, S3:5
of pediatric ARF patients, S3:28-34
see also Continuous renal replacement therapy
- Continuous venovenous hemodialysis (CVVHD)
defined, S3:4-5
see also Continuous renal replacement therapy
- Continuous venovenous hemofiltration (CVVH)
defined, S3:3
pediatric ARF patients on, S3:28-34
see also Continuous renal replacement therapy
- Contrast media acute renal failure (ARF) following intravenous urography in renally impaired patients, 454-456
- Convection in CRRT, defined, S3:6
- Cool dialysate, HD, protective effects of, dependent on predialysis body temperature, 262-265
- Coordinating Center (CC) of the University of Michigan, S2:5-6
- Copper,zinc superoxide dismutase, *see* Cu,Zn-SOD
- Core Standard Analysis Files (SAFs) on CD-ROM, S2:27-30
- Corticosteroids and glucocorticoids
cellular and molecular mechanisms of action of, 162-163
in IgA nephropathy therapy, 42, 45
immunopharmacology of, 636-640
in RT, osteoporosis and, 105-114
for spontaneous tendon ruptures on long-term HD and/or CAPD, 861-866
see also specific corticosteroids
- Cortisol, serum and urinary, in metabolic alkalosis with ectopic ACTH syndrome, 611
- Cost
adverse effects and, of intravenous push and/or infusion
FeD in ESRD patients on HD, 523-528
of continued CsA therapy, noncompliance and, 572-577
of ESRD care, *see* Cost and cost-effectiveness of ESRD care, USRDS 1996 ADR on
of USRDS SAFs, S2:30
- Cost and cost-effectiveness of ESRD care, USRDS 1996 ADR on
analysis of, S2:163-164
see also Medicare expenditures for ESRD, USRDS 1996 ADR on
- Costimulatory signals in antiallograft response, 161
- Course, *see* Clinical course
- CP (*Candida* peritonitis) on CAPD, oral nystatin in prevention of, 549-552
- CPD (chronic peritoneal dialysis), FP on, 86-91
- CPEO (chronic progressive external ophthalmoplegia), 143
- CPI (Consumer Price Index), changes in Medicare payments for ESRD and changes in (1991-1993), S2:134
- C-reactive protein in Wegener's granulomatosis, 188
- Creatinine (Cr) and creatinine (Cr) clearance
and atherosclerotic lesions in carotid vessels of HD patients, 715
in azotemia, 218
and continued CsA therapy effects of RT, 573
in CyA-associated TMA/HUS, 562, 564, 565, 567
in ESRD, *see* Creatinine and creatinine clearance in ESRD
in familial fibrillary GN with giant fibrillar deposits, 671
following TBP therapy, 750
in HIVAN patients, 204
in nephrosis, 354
in percutaneous renal biopsy patients, complications and, 48, 49
in renal AED patients, 494
renal function and, in Navajo Indians, 343
in renovascular fibromuscular disease, 335
serum, *see* Serum creatinine
in systemic AL-amyloidosis, 279
- Creatinine (Cr) and creatinine (Cr) clearance in ESRD
in diabetic ESRD patients, race, survival and, 228, 230

- see also* Creatinine and creatinine clearance in ESRD patients on long-term HD and/or CAPD
- Creatinine (Cr) and creatinine (Cr) clearance in ESRD patients on long-term HD and/or CAPD
- cardiovascular disease and, 935
- methotrexate and, 849
- PTH and, 928
- spontaneous tendon ruptures and, 863
- survival and, 939-941
- for up to 30 years, predictive value of, 910-917
- Crescentic nodular glomerulosclerosis (GS) secondary to truncated IgA heavy chain deposition disease, 283-288
- CRF, *see* Chronic renal failure
- Critically ill acute renal failure (ARF) patients, CRRT of
- dietary management and, S3:58-61
- of pediatric patients, S3:28-34
- CRRT, *see* Continuous renal replacement therapy
- CRS (captopril renal scintigraphy) in RVH diagnosis, 209-213
- Cryoprotein in fibrillary GN, 668-675
- CsA, *see* Cyclosporine
- CT (cellulose triacetate) membranes, high-flux, modulating TGF- β monocyte production in long-term HD, 395-399
- C3bIR (complement 3b receptor), role of, in C4R-, leukocyte function-associated antigen-1 α -, and ICAM-1-mediated glomerular immune cell infiltration and activation in IgA nephropathy, 40-46
- Cuffed catheters, silastic, HD, thrombolytic and mechanical correction of malfunctioning, 379-386
- Cu,Zn-SOD (copper,zinc superoxide dismutase), 16-18
- localization of, 17-18
- CVVH, *see* Continuous venovenous hemofiltration
- CVVHD, *see* Continuous venovenous hemodialysis
- CVVHDF, *see* Continuous venovenous hemodiafiltration
- CyA, *see* Cyclosporine
- Cyclic guanosine monophosphate, *see* cGMP
- Cycling peritoneal dialysis, continuous, USRDS 1996 ADR on, *see* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1996 ADR on
- Cyclophosphamide, immunopharmacology of, 635-636
- Cyclosporine (CsA; CyA)
- cellular and molecular mechanisms of, *see* Cyclosporine, cellular and molecular mechanisms of
- effects of, on leukocyte adhesion to vascular endothelium under physiological flow conditions, 23-31
- see also* Cyclosporine, immunopharmacology of; Cyclosporine nephrotoxicity; Cyclosporine in RT
- Cyclosporine (CsA; CyA), cellular and molecular mechanisms of, 161-163
- cellular mechanisms of CsA nephrotoxicity, 644
- Cyclosporine (CsA; CyA), immunopharmacology of, 161, 640-648
- absorption of, 640-641
- adverse effects of, 644; *see also* Cyclosporine nephrotoxicity
- clinical uses of, 647
- and CsA effects on B cells and mesangial cells, 643
- and CsA effects on renin-angiotensin system, 643-644
- and CsA interactions with vasculature, 644
- distribution, metabolism, and excretion of, 641
- drug interactions with CsA, *see* Drug interactions with CsA
- mechanisms of action of, 641-643
- Neoral formulation of CsA and, 647-648
- new CsA analogs and, 648
- Cyclosporine (CsA; CyA) nephrotoxicity, 644-647
- cellular mechanisms of, 644
- clinical, 644-646
- pathogenesis of, 646-647
- recurrent, in heart transplantation, 466-468
- Cyclosporine (CsA; CyA) in RT, 561-577
- aspirin interaction with, S1:20-23
- benefit of continued, through indigent drug program, 572-577
- cellular and molecular mechanisms, *see* Cyclosporine, cellular and molecular mechanisms of
- immunopharmacology of, *see* Cyclosporine, immunopharmacology of
- outcome of five-year posttransplant pregnancy in CsA-treated patients, 266-269
- recurrent IgA nephropathy following, 99-104
- and in renal-pancreas transplantation, TMA/HUS associated with, 561-571
- Cyst, *see* Autosomal dominant polycystic kidney disease
- Cytokines
- immunosuppressant effects on, 159, 161-163, 168
- see also* specific cytokines
- Cytoplasmic antibodies, *see* Antineutrophil cytoplasmic antibodies
- Data, USRDS
- acknowledgment for use of, S2:30
- agreement for release of, S2:32-33
- changes in data system, S2:13
- delays in receiving, S2:153
- on ESRD treatment modality analyses, S2:49
- on Medicare claims, S2:154-155, S2:163
- new, S2:13, S2:153-154
- policy on release of, for investigator initiated research, S2:30-32
- see also* United States Renal Data System
- Data Request Review Committee (DRRC), USRDS, S2:7, S2:22-23
- Database, USRDS, S2:23-24
- see also* Data, USRDS
- Death, *see* Mortality
- Death Notification Form, new, S2:152, S2:155-156
- Decompensated liver cirrhosis, tense ascites secondary to, in ESRD, UF for, 899-903
- Deflazacort, 640
- Degenerative conditions, mtDNA mutations associated with, 143
- De-glymidodrine, as active metabolite of midodrine, 132-136
- Dehydroepiandrosterone, serum, in metabolic alkalosis with ectopic ACTH syndrome, 611
- Delays, USRDS 1996 ADR on
- in eligibility to Medicare, S2:35, S2:153
- in receiving data, S2:153
- Deletions, insertions and, in mitochondrial genome, 143
- Delivery of CRRT in ARF, factors influencing, S3:21-22
- Demographic characteristics, *see* Patient characteristics

- De novo light-chain deposition disease (LCDD) in cadaveric RT, 461-465
- Densitometry of BMD in HD and PD patients, 515-522
- Deoxyribonucleic acid, *see* Mitochondrial DNA mutations
- 15-Deoxyspergualin (DSG), cellular and molecular mechanisms of action of, 166
- Department of Veterans Affairs (DVA) report on ESRD care facilities, S2:144-145
- Dermatologic effects of analgesics, S1:65
- Development of pediatric ESRD patients, study of, S2:28
- Dexamethasone, effects of, in salt-sensitive hypertension, 779
- Diabetes mellitus (DM)
- prepregnancy, and outcome of five-year posttransplant pregnancy in CsA-treated patients, 267
 - type 2, renal function and, in adult Navajo Indians, 339-349
 - see also* Diabetic end-stage renal disease; Diabetic nephropathy
- Diabetic end-stage renal disease (ESRD)
- anemia in, *see* Diabetic end-stage renal disease, anemia in
 - and fungal peritonitis on CPD, 87
 - glycated albumin accumulation in, 62-66
 - HD for, *see* Diabetic end-stage renal disease, HD for
 - hypertensive, 738, 739
 - management of, by nephrologists, 69
 - mortality with, USRDS 1996 ADR on, S2:95, S2:96
 - of PKT recipients, 870
 - see also* Diabetic nephropathy
- Diabetic end-stage renal disease (ESRD), anemia in
- impact of anemia, 55-57
 - see also* Diabetic end-stage renal disease, anemia in, rHuEPO therapy of
- Diabetic end-stage renal disease (ESRD), anemia in, rHuEPO therapy of, 43
- and ACEI effects on rHuEPO, 537
- Diabetic end-stage renal disease (ESRD), HD for
- and HD access complications, 251, 253
 - race and survival with, 74, 75, 77, 226-234
 - safety of intravenous FeD in, 530
 - type 1 diabetes, proximal calciphylaxis in HD patients with, 409-414
- Diabetic end-stage renal disease (ESRD), long-term HD and/or CAPD for
- prealbumin level and, 939, 940
 - race, survival and, on PD and with RT, 74, 75, 77
 - as risk factor for cardiovascular disease, 934
 - as risk factor for peritonitis on long-term CAPD, 428-436
 - for up to 30 years, 911
- Diabetic nephropathy
- and *Candida* peritonitis on CAPD, 551
 - and HIT on HD, 83, 84
 - and mortality risk on HD, 742, 744
 - and protective effects of cool dialysate in HD patients, 264
 - RT in patients with, benefits of continued CsA therapy in, 573
 - in RVH patients, 215
 - therapeutic uses of aspirin in, S1:20-23
 - see also* Diabetic end-stage renal disease
- Diagnosis and detection
- HCV RNA, with third-generation assays, in renal transplant recipients, 437-440
 - of HIT in HD, role of PF4-heparin complex Ab in, 82-85
 - RVH, with CRS, 209-213
 - see also* specific conditions and specific diagnostic techniques
- Dialysate(s)
- in CRRT, defined, S3:6
 - see also* Dialysate, HD, for ESRD
- Dialysate, HD, for ESRD
- protective effects of cool, dependent on predialysis body temperature, 262-265
 - 21st century, 954
 - USRDS 1996 ADR on, S2:68-69
- Dialysate anion, *see* Replacement fluid/dialysate anion in CRRT
- Dialysis, *see* Chronic dialysis; Continuous ambulatory peritoneal dialysis; Dialysate(s); Dialysis membranes; Dialysis Morbidity and Mortality Study, USRDS 1996 ADR on; Dialysis-refractory hypertension; Dialytic bath; Dialyzers; Discontinuation of dialysis by ESRD patients; Dose, dialysis, CRRT and; Hemodialysis; Peritoneal dialysis; Withdrawal of dialysis, ethical issues related to and entries beginning with terms: Dialysis modalities, Intradialytic
- Dialysis membranes
- biocompatible, in ARF management, 316-317
 - in HD, *see* Dialysis membranes in HD for ESRD; High-flux hemodialysis membranes
 - see also* Dialysis membranes in CRRT
- Dialysis membranes in CRRT
- anticoagulant therapy and, S3:9-10
 - of ARF, S3:108-113
 - see also* Bioincompatible membranes in CRRT of ARF
- Dialysis membranes in HD for ESRD
- 21st-century, 953-954
 - USRDS 1996 ADR on, S2:65
- Dialysis modalities for ARF, outcome and, S3:74-89
- CRRT, S3:74-80
 - in ICU, dialysis dose and, S3:81-89
- Dialysis modalities for ESRD, USRDS 1996 ADR on
- comparison of internal, S2:146-147
 - patient survival with, S2:162
 - see also* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1996 ADR on; Hemodialysis for ESRD, USRDS 1996 ADR on; Peritoneal dialysis for ESRD, USRDS 1996 ADR on
- Dialysis Morbidity and Mortality Study (DMMS), USRDS 1996 ADR on, S2:13-14, S2:16-17, S2:58-78
- see also* Hemodialysis for ESRD in DMMS, USRDS 1996 ADR on
- Dialysis-refractory hypertension in ESRD, role of volume overload in, 257-261
- Dialytic bath, urea-containing, effects of, on brain water, 6
- Dialyzers used in HD of ESRD, USRDS 1996 ADR on, S2:65-68
- Diarrhea, induced, as therapy of irreversible ESRD, 946
- Diastolic blood pressure, *see* Blood pressure
- Diclofenac, *see* Nonrenal toxicity of APAP, ASA, and NSAIDs
- Dietary management
- of critically ill ARF patients on CRRT, S3:58-61
 - of hypertension in chronic renal diseases, 811-821

- in urolithiasis prevention, 195-201
 - see also* Dietary P restriction; Dietary protein intake
- Dietary P (phosphorus) restriction, synthesis of renal calcitriol and serum P response to, GH or insulin effects on, 589-595
- Dietary protein intake (DPI), 350-364
 - in CRF, effects of acidosis correction on, 350-353
 - small solute clearance effects on, in CAPD patients, 553-560
 - supplemented, very low-, nephrosis management with, 354-364
- Dietary risk factors, behavioral and, for urolithiasis, implications of, for prevention, 195-201
- Diffusion in CRRT, defined, S3:5-6
- Digital subtraction angiography of RVH, CRS compared with, 211
- Dilatation, left ventricular, in ESRD, impact of anemia on, 57
- Diltiazem, immunopharmacology of, 657
- Direct patient care, ESRD, Medicare expenditures for, USRDS 1996 ADR on, S2:130-135
 - changes over time in resource cost per patient, S2:133-134 and errata for 1992 estimate of total federal spending for ESRD in 1995 ADR, S2:134
 - limitations of research on, S2:134-135
 - MSP and, S2:131-133
 - by source of claim, S2:130
- Disconnection of CRRT line, S3:101
- Discontinuation of dialysis by ESRD patients
 - as cause of mortality, USRDS 1996 ADR, S2:99-101
 - premature, with restless legs syndrome, 373-376
- Discovery of uroguanylin, 297-298
- Discussing benefits and limits of dialysis, withdrawal of dialysis and, 150-151
- Disequilibrium syndrome (cerebral edema), postdialytic, 1-13
 - additional mechanisms of, 11
 - appendix on, 11-12
 - "idiogenic osmole hypothesis" of, 2, 6-11
 - "reverse urea hypothesis" of, 2-6
- Disk storage for USRDS SAF use, S2:30
- Distribution
 - of azathioprine, 634
 - of corticosteroids, 637
 - of CsA, 641
 - of FK506, 648
- DM, *see* Diabetes mellitus
- DMMS, *see* Dialysis Morbidity and Mortality Study, USRDS 1996 ADR on
- DNA, *see* Mitochondrial DNA mutations
- Documentation with SAFs, S2:30
- Dominant polycystic disease, *see* Autosomal dominant polycystic kidney disease
- Dopamine in ARF management, 321-323
- Doppler imaging, echo color, of carotid vessels of HD patients, evidence of atherosclerotic lesions and, 713-720
- Dose
 - dialysis, *see* Dose, dialysis, CRRT and
 - HD, USRDS 1996 ADR on, S2:59-62, S2:64-65
 - low-, of LMW heparin in HD, 721-726
 - osmotic nephrosis due to high-dose sucrose-containing Ig therapy of IgA nephropathy, 451-453
 - rHuEPO, ACEI effects on, 535-540
 - see also* Dose, analgesic
- Dose, analgesic
 - effects of high-dose ASA, S1:25-26
 - usual, S1:65
- Dose, dialysis, CRRT and
 - for ARF patients in ICU, S3:81-89
 - for pediatric ARF patients, outcome and, S3:24-25
- DPI, *see* Dietary protein intake
- Drinking beer, as risk factor for urolithiasis, 195-201
- DRRC (Data Request Review Committee), USRDS, S2:7, S2:22-23
- Drug(s), *see specific drugs and entries beginning with element: Pharmacology*
- Drug abuse, *see* Substance abuse
- Drug history, and combination AN, S1:40
- Drug interactions
 - with CsA, *see* Drug interactions with CsA
 - with steroids, 639
- Drug interactions with CsA, 644
 - with aspirin, S1:20-23
- Duration of dialysis, *see* Time on dialysis
- DSG (15-deoxyspergualin), cellular and molecular mechanisms of action of, 166
- DVA (Department of Veterans Affairs) report on ESRD care facilities, S2:144-145
- Early readmissions to hospital after PKT, 867-875
- EBV (Epstein-Barr virus)-associated posttransplant lymphoproliferative disease (PTLD), severe acute rejection compared with, using Banff schema, 578-584
- EC (Executive Committee), USRDS, S2:6, S2:22
- ECG (electrocardiogram) in systemic AL-amyloidosis, 279
- Echo color Doppler imaging of carotid vessels of HD patients, evidence of atherosclerotic lesions with, 713-720
- ECM (extracellular matrix) in ADPKD, 793-794
- ECMO (extracorporeal membrane oxygenation), CVVHDF with, S3:5
- Economic Scientific Advisory Committee (E-SAC), USRDS, S2:6-7
- Ectopic adrenocorticotrophic hormone (ACTH) syndrome, K in correction of metabolic alkalosis with, 610-613
- Edema
 - cerebral, *see* Disequilibrium syndrome, postdialytic
 - in CHF, effects of slow isolated UF on, S3:67-73
- Education
 - of diabetic ESRD patients, race, survival and, 228-232
 - and risk factors for urolithiasis, 197, 198
- Effusion, pleural, secondary to CAPD of ESRD, video-assisted talc pleurodesis of, 772-774
- EGF (epidermal growth factor) in ARF management, 323
- Elastase (EL) antibodies (Abs) in vasculitis, 178-185
- Electrocardiogram (ECG), in systemic AL-amyloidosis, 279
- Electrolytes, *see* Fluid and electrolytes in CRRT and specific electrolytes
- Electron microscopy
 - of ARF with osmotic nephrosis, 452
 - of fibrillary GN, *see* Electron microscopy of fibrillary GN

- of HCDD, 129-130
- of idiopathic GN, HCV status and, 755
- see also specific conditions*
- Electron microscopy of fibrillary GN, 678
- of familial fibrillary GN, 673
- Electrophoresis, capillary, using nonradioactive iothexol in GFR measurement, 173-177
- Eligibility, *see* Patient eligibility, USRDS 1996 ADR on
- Elimination
 - antithymocyte and antilymphocyte globulin, 654
 - azathioprine, 632
 - colchicine, 655
- ELISA (enzyme-linked immunosorbent assay)
 - of anti-HLA class I antibodies in pretransplantation assessment of rejection risk, 92-98
 - HCV RNA detection with, in renal transplant recipients, 437-440
- Embolism, air, due to CRRT, S3:101
- Enalapril, effects of, on chronic progressive nephropathy, 822-831
- Enalaprilat, effects of, on urinary bladder response to angiotensin I, 603-609
- Encapsulating peritonitis, sclerosing, on CAPD, 420-427
- Encephalopathy in MELAS syndrome, point mutations in mitochondrial tRNA genes and, 143
- Endocrine neoplasia type 2, multiple, monogenetic hypertension and, 329-332
- Endothelial cells, Abs against, in WG, disease activity and, 186-194
- Endothelium, vascular, CyA effects on leukocyte adhesion to, under physiological flow conditions, 23-31
- Endotoxin, *see* Lipopolysaccharide
- End-stage renal disease (ESRD)
 - CAPD for, video-assisted talc pleurodesis of pleural effusion secondary to, 772-774; *see also* Peritoneal dialysis for ESRD
 - chronic dialysis for, impact of initial laboratory data on survival with, 541-548; *see also* Hemodialysis for ESRD, race and survival with
 - diabetic, *see* Diabetic end-stage renal disease
 - due to CsA therapy in transplant recipients, 466-468
 - with HIVAN, 204
 - nephrologists as primary care providers for patients with, 67-72
 - parathyromatosis with secondary hyperparathyroidism in, 502-507
 - pediatric, *see* Pediatric end-stage renal disease, USRDS 1996 ADR on
 - tense ascites secondary to decompensated liver cirrhosis in, UF for, 899-903
 - see also* Chronic renal failure; Discontinuation of dialysis by ESRD patients; Hemodialysis for ESRD; Hypertension in ESRD; Primary renal disease in ESRD; United States Renal Data System
- Enrollment parathyroid hormone (PTH), and survival with long-term HD and/or PD for ESRD, 924-930
- Entry criteria for PKT, 869
- Enzyme(s)
 - bacterial, in intestinal dialysis, 947-948
 - see also specific enzymes*
- Enzyme-linked immunosorbent assay, *see* ELISA
- Epidemiology
 - of APAP-induced CRF, S1:14-19
 - of combination AN, S1:50-55
 - see also* Incidence; Prevalence and specific conditions
- Epidermal growth factor (EGF) in ARF management, 323
- Epilepsy with ragged-red fibers, myoclonic, point mutations in mitochondrial tRNA genes and, 142
- EPO, *see* Recombinant human erythropoietin for anemia
- Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease (PTLD), severe acute rejection compared with, using Banff schema, 578-584
- Equipment
 - HD, in 21st century, 952-952
 - needed to use USRDS SAFs, S2:30
 - PD, in 21st century, 955-956
- Errata for 1992 estimate of total federal spending for ESRD in 1995 ADR, S2:134
- Erythrocyte sedimentation rate (ESR)
 - in renal AED patients, 494
 - in systemic AL-amyloidosis, 279
 - in Wegener's granulomatosis, 188
- Erythropoietin, *see* Recombinant human erythropoietin for anemia
- E-SAC (Economic Scientific Advisory Committee), USRDS, S2:6-7
- ESR, *see* Erythrocyte sedimentation rate
- ESRD, *see* End-stage renal disease
- Estimate of 1992 total federal spending for ESRD in USRDS 1995 ADR, errata in, S2:134
- ET (endotoxin), *see* Lipopolysaccharide
- Ethical issues, *see* Withdrawal of dialysis, ethical issues related to
- Etiology
 - of ADPKD, 788-791
 - of analgesic abuse, S1:39-40
 - of dialysis-refractory hypertension in ESRD, 258
 - of HD access complications, 252, 254
 - see also* Primary renal disease and specific conditions
- European experience with combination AN, S1:48-55
- Exclusion
 - criteria of, for PKT, 869
 - from ESRD therapy, intestinal dialysis and, 943; *see also* Intestinal dialysis, as substitute therapy in ESRD
- Excretion, CsA, 641
- Executive Committee (EC), USRDS, S2:6, S2:22
- Exit site infections, catheter, on CAPD, peritonitis due to, 415-419
- risk factors for peritonitis on long-term CAPD, 428-436
- Expected remaining years of life of ESRD patients, USRDS 1996 ADR on, S2:89-90, S2:162
- Expenditures, *see* Cost
- External ophthalmoplegia, chronic progressive, 143
- Extracapillary glomerulonephritis (GN), renal amyloidosis and, 695-699
- Extracellular matrix (ECM) in ADPKD, 793-794
- Extracorporeal anticoagulation for CRRT of hepatic and acute renal failure, S3:64-65
- Extracorporeal membrane oxygenation (ECMO), CVVHDF with, S3:5
- Extracorporeal therapies, *see* Continuous renal replacement therapy

- Extreme posthemodialysis (HD) urea rebound, Smye method in screening for, 727-736
- Extrinsic compression, renal graft salvage with renal vein occlusion secondary to, 622-623
- Facilities for ESRD care, USRDS 1996 ADR on, S2:19-20, S2:141-145
DVA report on facilities, S2:144-145
number and location of, S2:141
number of treatments administered by, S2:142-143
and SHR by profit status and type of, S2:123-125
and SHR by size of, S2:122-123
types of, S2:141-142
- Facility-specific Standardized Mortality Ratio (SMR), USRDS 1996 ADR on, S2:90-91
- Familial fibrillary glomerulonephritis (GN) with giant fibrillar deposits, 668-675
- Family history of urolithiasis, 197, 198
- Fanconi's syndrome, TIN and, associated with L-lysine ingestion, 614-617
- Fatigue, posthemodialysis, 732-736
- ω (omega)-Fatty acids (fish oils), immunopharmacology of, 656-657
- Fe, *see* Iron, IV iron dextran effects on; Iron in ESRD
- FeD, *see* Intravenous iron dextran for anemic ESRD patients on HD
- Federal spending, *see* Total federal spending for ESRD
- Femoral bone mineral density (BMD), long-term effect of RT on, 107-108
- Ferritin, rHuEPO effects on, 402
- FGF-1 (fibroblast growth factor-1), transcription of, in chronic renal rejection, 441-450
- FGS (focal glomerulosclerosis) in HIVAN, renal survival with captopril therapy of, 202-208
- Fibrillar serum Ig (immunoglobulin)-fibronectin complexes, fibrillary GN related to, 676-684
- Fibrillary deposits, giant, fibrillary GN with, 668-675
- Fibrillary glomerulonephritis (GN), 668-684
with giant fibrillar deposits, 668-675
related to fibrillar serum Ig-fibronectin complexes, 676-684
- Fibroblast growth factor-1 (FGF-1), transcription of, in chronic renal rejection, 441-450
- Fibromuscular disease, renovascular, predictors of cure of hypertension in, 334-338
- Fibronectin, *see* Fibrillary glomerulonephritis
- Fibrosis, and L-arginine metabolism in immune-mediated GN, 878-887
- "Fifteen Month Rule", S2:153-154
- Files, USRDS SAF, media and formats of, on CD-ROM, S2:29-30
- Filter efficiency in CRRT, loss of, S3:101
- First renal transplantation (RT), cadaveric and living-related, survival with, S2:162
- First service date, errors in, S2:153
- Fish oils (omega-fatty acids), immunopharmacology of, 656-657
- Fistulas, *see* Arteriovenous fistulas in HD
- Five-year posttransplant pregnancy in CsA-treated patients, 266-269
- FK506 (tacrolimus)
in CyA-associated TMA/HUS in renal and renal-pancreas transplantation, 563-571
immunopharmacology of, 161, 648-652
- Flow conditions, physiological, CyA effects on leukocyte adhesion to vascular endothelium under, 23-31
- Fluid(s)
accumulation of, in ADPKD, mechanisms of, 794-799
turnover of, with future CRRT technology, S3:124; *see also* Fluid and electrolytes in CRRT; Replacement fluid/dialysate anion in CRRT
see also Water
- Fluid and electrolytes in CRRT
avoiding rapid shift in, S3:91
errors in balance of, S3:101
see also specific electrolytes
- Focal segmental glomerulosclerosis (FSGS)
with ARF due to α -IFN therapy, 888-892
in HIVAN, renal survival with captopril therapy of, 201-208
IgA nephropathy histology resembling that of, 365-371
- Folate, rHuEPO and
and ACEI effects on rHuEPO therapy of ESRD, 538
effects of, on serum folate, 402
- Follow-up
lost to follow-up status, USRDS 1996 ADR on, S2:14, S2:152, S2:155
of RVH patients, 218
- Formats, USRDS SAF CD-ROM file, S2:29-30
- FP (fungal peritonitis) on CPD, 86-91
- Fractional proximal tubular reabsorption (FR), AA effects on, 115-118
- Fractures, vertebral, as long-term effects of RT, 110
- Free radical formation, and analgesic-induced RPN, S1:34-38
- FSGS, *see* Focal segmental glomerulosclerosis
- Fungal peritonitis (FP) on CPD, 86-91
- Futility, medical, defined, withdrawal of dialysis and, 148
- Future technology for CRRT, S3:121-129
beyond CRRT and toward renal protection, S3:125-127
new directions and clinical applications of, S3:123-125
- Gamma (γ)-globulin, *see entries beginning with acronym: IgG*
- Gamma (γ)-glutamyltransferase (GGT), and HCV in native and transplanted kidneys, 755
- Gastrointestinal effects of analgesics, S1:66-67
- Gender, *see* Sex
- Gene(s)
IL-2 gene model of CyA mechanisms of action, 642-643
PKD3, ADPKD linked to, but not to PKD1 and PKD2, 759-761
steroid induction of, 638
VHL, germline mutation of, monogenetic hypertension and, 329-332
see also Gene delivery; Gene expression, steroid effects on; Gene replacement therapy
- Gene delivery, 477-482
with AAVs, 479-480
with adenoviral vectors, 479
with kidney-specific promoters, 482
nonviral systems of, 480-482

- with retroviral vectors, 478-479
- Gene expression, steroid effects on
 - nontranscriptional effects of, 639
 - nuclear transcriptional factors of, 638
- Gene replacement therapy, 476
 - see also* Gene delivery
- Genetic heterogeneity of ADPKD, 759-761
- Genotype-phenotype correlations in Von-Hippel disease and MEN 2A, 332
- Gentamicin intoxication, acute massive, of ESRD patient on CAPD with peritonitis, 767-771
- Geography in USRDS 1996 ADR, S2:156
- Germline mutation of *RET* proto-oncogene and *VHL* gene associated with pheochromocytoma, 329-332
- GF(s), *see* Growth factor(s)
- GFR, *see* Glomerular filtration rate
- GGT (γ -glutamyltransferase), and HCV in native and transplanted kidneys, 755
- GH (growth hormone), effects of insulin or, on synthesis of renal calcitriol and serum P response to dietary P restriction, 589-595
- Giant fibrillar deposits, familial GN with, 668-675
- Globulin
 - antilymphocyte and antithymocyte, immunopharmacology of, 654-655
 - see also* entries beginning with acronym: Ig
- Glomerular filtration rate (GFR)
 - capillary electrophoresis using nonradioactive iohexol in measurement of, 173-177
 - in chronic progressive nephropathy, ACEI effects on, 822-824, 826, 828
 - in chronic renal disease patients with and without hypertension and, 816, 818
 - in nephrosis, 354-364
 - response of, to AAs, AII effects on NO and, 115-123
 - in salt-sensitive hypertension, dexamethasone effects on, 779
- Glomerular immune cells, leukocyte function-associated antigen-1 α , C4R, and ICAM-1 mediating infiltration and activation of, in IgA nephropathy, 40-46
- Glomerulonephritis (GN)
 - extracapillary, renal amyloidosis and, 695-699
 - fibrillary, *see* Fibrillary glomerulonephritis
 - idiopathic, prevalence of HCV in native and transplanted kidneys in, 752-758
 - immune-mediated, L-arginine in, 878-887
 - membranoproliferative, *see* Membranoproliferative glomerulonephritis type I; Membranoproliferative glomerulonephritis type III
 - mesangial proliferative, superoxide dismutase activity in, 14-22
 - therapeutic uses of aspirin in, S1:20-23
 - see also* Primary renal disease and specific types of glomerulonephritis
- Glomerulosclerosis, *see* Focal segmental glomerulosclerosis; Nodular glomerulosclerosis, HCDD and
- Glucocorticoids, *see* Corticosteroids and glucocorticoids
- Glucose
 - in ESRD, *see* Glucose in ESRD
 - following TBP therapy, 750
 - serum, in metabolic alkalosis with ectopic ACTH syndrome, 611
- Glucose in ESRD
 - and glycated albumin accumulation in ESRD, 64
 - race and survival and, in diabetic ESRD, 228, 230, 231
- γ (gamma)-Glutamyltransferase (GGT), and HCV in native and transplanted kidneys, 755
- Glycated albumin, accumulation of, in ESRD patients on HD, 62-66
- Glycine-containing Ig (immunoglobulin) therapy, high-dose, in IgA nephropathy, 451-453
- Glycohemoglobin in PKT recipients, 870
- GMP (guanosine monophosphate), cyclic, *see* cGMP
- GN, *see* Glomerulonephritis
- Graft, *see* Graft survival; Polytetrafluoroethylene graft; Rejection, graft; Renal transplantation and entries beginning with terms: Renal graft
- Graft survival
 - PKT, 871
 - see also* Renal graft survival, USRDS 1996 ADR on
- Granulomatosis, *see* Wegener's granulomatosis
- Great Salt Lake model of fluid accumulation in ADPKD, 795
- Gross hematuria in FSGS-like IgA nephropathy, 368
- Growth and development of pediatric ESRD patients, USRDS 1996 ADR on, study of, S2:28
- Growth factor(s) (GFs)
 - in ARF management, 323-324
 - mRNA of, in chronic renal rejection, 441-450
 - see also* specific growth factors
- Growth hormone (GH), effects of insulin or, on synthesis of renal calcitriol and serum P response to dietary P restriction, 589-595
- GS (glomerulosclerosis), *see* Focal segmental glomerulosclerosis; Nodular glomerulosclerosis, HCDD and
- Guanosine monophosphate, *see* cGMP
- Guanylate cyclase, *see* Uroguanylin
- Guanylin, 298-299
 - natriuretic activity of, 299
 - tissues producing, 298-299
- Habitual use of APAP, renal disease and, S1:12
- Hb (hemoglobin)
 - in ESRD, *see* Hb in ESRD
 - in HD patients, *see* Hb in HD and/or CAPD patients
 - IV iron dextran effects on, 858
 - in percutaneous renal biopsy patients, complications and, 48, 49
- Hb (hemoglobin) in ESRD
 - in diabetic ESRD, race, survival and, 228, 230, 231
 - impact of anemia on level of, 55-57
 - with restless legs syndrome, 374
 - rHuEPO effects on, 402-403
- Hb (hemoglobin) in HD and/or CAPD patients
 - with ESRD, rHuEPO effects on, 402-403
 - protective effects of cool dialysate on, 264
 - and spontaneous tendon ruptures, 863
- HCDD, *see* Heavy chain deposition disease
- HCFA (Health Care Financing Administration), S2:5
- HCO₃ (bicarbonate)
 - in acidosis, *see* HCO₃ in acidosis
 - arterial, in metabolic alkalosis with ectopic ACTH syndrome, 611

- blood, in familial fibrillary GN with giant fibrillar deposits, 671
- of CyA-associated TMA/HUS effects on, 564
- effects of, on plasma K in ESRD patients on HD, insulin and albuterol effects compared with, 508-514
- HCO₃-based fluids in CRRT, S3:16-17
- and spontaneous tendon ruptures on long-term HD and/or CAPD, 863
- HCO₃ (bicarbonate) in acidosis
 - of CRF patients, 351
 - differences in assays of, and magnitude of metabolic acidosis in ESRD patients on HD, 700-703
- HCT, *see* Hematocrit
- HCV, *see* Hepatitis C virus
- HD, *see* Hemodialysis
- HDF (hemodiafiltration), *see* Continuous arteriovenous hemodiafiltration; Continuous venovenous hemodiafiltration
- HDL (high-density lipoprotein) in nephrosis, 354
- Health Care Financing Administration (HCFA), S2:5
- Heart, *see* Congestive heart failure *entries beginning with term: Myocardial and element: Card-*
- Heart transplantation, recurrent CsA nephropathy in recipients of, 466-468
- Heavy chain deposition disease (HCDD)
 - IgG₁, monoclonal nonamyloid, 128-131
 - nodular GS and, *see* Nodular glomerulosclerosis, HCDD and
- Height
 - of long-term HD patients, 919
 - and survival on chronic dialysis, 542, 543
- Hematocrit (HCT)
 - effects of CyA-associated TMA/HUS on, 564
 - initial, and survival on chronic dialysis, 542, 543
 - midodrine effects on, 133
 - see also* Hematocrit of ESRD patients on HD
- Hematocrit of ESRD patients on HD
 - mortality risk and, 741-746
 - predictive value, for patients on HD for up to 30 years, 910-917
 - see also* Hematocrit of ESRD patients on HD, rHuEPO and
- Hematocrit of ESRD patients on HD, rHuEPO and
 - and ACEI effects on rHuEPO, 538
 - with restless legs syndrome, 374
 - rHuEPO effects on, 235-249, 402
- Hematologic effects of analgesics, S1:65
- Hematuria
 - as complication of percutaneous renal biopsy, 47-52
 - renal function and, in Navajo Indians, 343
 - see also* Macroscopic hematuria; Microscopic hematuria
- Hemodiafiltration, *see* Continuous arteriovenous hemodiafiltration; Continuous venovenous hemodiafiltration
- Hemodialysis (HD)
 - continuous arteriovenous, *see* Continuous arteriovenous hemodialysis
 - continuous venovenous, *see* Continuous venovenous hemodialysis
 - for CRF, *see* Chronic renal failure, HD for
 - evidence of atherosclerotic lesions in carotid vessels of patients on, with echo color Doppler imaging, 713-720
 - hemodynamic effects of PVSs in HD patients with ascites, 387-394
 - HIT and, 82-85
 - intermittent, *see* Intermittent hemodialysis of ARF, CRRT versus
 - long-term, *see* Long-term hemodialysis
 - low-dose LMW heparin in, 721-726
 - prevalence of, and risk factors for osteopenia in, 515-522
 - protective effects of cool HD dialysate dependent on pre-HD body temperature, 262-265; *see also* Dialysate, HD, for ESRD
 - proximal calciphylaxis in IDDM patients on, 409-414
 - spontaneous tendon ruptures on, 861-866
 - vascular access for, *see* Arteriovenous fistulas in HD; Silastic cuffed catheters
 - see also* Hemodialysis for ESRD and *entries beginning with term: Posthemodialysis*
- Hemodialysis (HD) for ESRD
 - chronic, *see* Chronic hemodialysis for ESRD
 - for diabetic ESRD, *see* Diabetic end-stage renal disease, HD for
 - dialysis-refractory hypertension and, 257-261
 - glycated albumin accumulation in, 62-66
 - HCO₃ effects on plasma K in patients on, insulin and albuterol effects compared with, 508-514
 - hypertension and survival on, 737-740; *see also* Hemodialysis for ESRD, race and survival with
 - inpatient and outpatient care of HD vascular access complications, 250-256
 - mortality and, *see* Mortality of HD patients
 - in 21st century, 951-957
 - see also* Anemia of ESRD in HD patients; of; Hemodialysis for ESRD, USRDS 1996 ADR on; Intravenous iron dextran for anemic ESRD patients on HD; Long-term hemodialysis and/or continuous ambulatory peritoneal dialysis for ESRD
- Hemodialysis (HD) for ESRD, race and survival with
 - compared with survival on PD and with RT, 72-81
 - with diabetic ESRD, 226-234
- Hemodialysis (HD) for ESRD, USRDS 1996 ADR on, S2:49
 - prescription of, S2:55
 - see also* Hemodialysis for ESRD in DMMS, USRDS 1996 ADR on
- Hemodialysis (HD) for ESRD in DMMS, USRDS 1996 ADR on, S2:59-78
 - on causes of death, S2:97-99
 - on dialysates used, S2:68-69
 - on dialyzers used in, S2:65-68
 - on EPO therapy, *see* Recombinant human erythropoietin for anemia of ESRD patients on HD, USRDS 1996 ADR on
 - on HD dose, S2:59-62, S2:64-65
 - on membranes used, S2:65
 - on number of weekly sessions, S2:64
 - on prescription of, S2:55-56
 - on time spent on, S2:63
 - on vascular access for, S2:69-73
 - on water treatment for, S2:68
- Hemodynamics
 - effects of PVSs on, in HD patients with ascites, 387-394
 - renal, effects of ramipril on, 836, 837

- see also Blood flow; Blood pressure; Hemodynamics, CRRT effects on
- Hemodynamics, CRRT effects on, S3:91
- in sepsis, S3:125
- Hemofiltration (HF)
- citrate anticoagulated, S3:18-19
- continuous arteriovenous and continuous venovenous, see Continuous arteriovenous hemofiltration; Continuous venovenous hemofiltration
- Hemoglobin, see entries beginning with acronym: Hb
- Hemolytic uremic syndrome (HUS), CyA-associated TMA/, in renal and renal-pancreas transplantation, 561-571
- Hemoperfusion for massive acute gentamicin intoxication, 767-771
- Hemorrhages, pulmonary, and WG followed by sarcoidosis, 893-898
- Henoch-Schönlein purpura (HSP), recurrence of, following RT with CyA immunosuppression, 99-104
- Heparin
- low-dose LMW, on HD, 721-726
- as risk factor for osteopenia, 515-522
- thrombocytopenia induced by, in HD patients, 82-85
- Hepatic failure, ARF and, CRRT of, S3:62-66
- Hepatitis C virus (HCV)
- prevalence of, in idiopathic GN in native and transplanted kidneys, 752-758
- in RT, see Renal transplantation, HCV in
- Hepatocyte growth factor (HGF) in ARF management, 324
- Hereditary optic neuropathy, Leber's, point mutations in mitochondrial genes and, 142
- Heterogeneity, genetic, of ADPKD, 759-761
- HF, see Hemofiltration
- HGF (hepatocyte growth factor) in ARF management, 324
- High-density lipoprotein (HDL) in nephrosis, 354
- High-dose aspirin (ASA), effects of, S1:25-26
- High-dose sucrose-containing (but not glycine) Ig (immunoglobulin) therapy in IgA nephropathy, osmotic nephrosis due to, 451-453
- High-flux hemodialysis (HD) membranes
- cellulose triacetate, membranes modulating TGF- β monocyte production in long-term HD, 395-399
- methotrexate clearance with, 846-854
- High-performance liquid chromatography (HPLC), capillary electrophoresis and, in GFR measurement, compared, 173-177
- High-volume continuous venovenous hemofiltration (HV-CVVH) in MODS with septic shock, S3:53-55
- Histology
- IgA nephropathy, resembling that of FSGS, 365-371
- of MPGN type I, 687, 689
- see also Histopathology; Renal biopsy
- Histopathology
- of chronic renal rejection, 441-450
- of EBV-associated PTLN, severe acute rejection compared with, using Banff schema, 578-584
- of familial fibrillary GN, 673
- in MPGN type III, discordant findings between complement profiles and, 804-810
- HIT (heparin-induced thrombocytopenia) in HD patients, 82-85
- HIV (human immunodeficiency virus) infection, SLE with, 292-295
- HIVAN, see Human immunodeficiency virus-associated nephropathy
- HLA (human leukocyte antigen) matching in RT, USRDS 1996 ADR on, S2:108
- HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase inhibitors, immunopharmacology of, 657
- Holt's syndrome, point mutations in mitochondrial genes and, 142
- Homeostasis, water and NaCl, see Uroguanylin
- Hospital Standard Analysis File (SAF) on CD-ROM, S2:29
- Hospitalization
- of CRF patients to start maintenance HD, 841-845
- early readmissions after PKT, 867-875
- see also Hospitalization for ESRD, USRDS 1996 ADR on
- Hospitalization for ESRD, USRDS 1996 ADR on, S2:18-19, S2:114-126
- analysis of, S2:152, S2:158-160
- crude rates of, based on total admissions, S2:116-119
- and SHR, see Standard Hospitalization Ratio, USRDS 1996 ADR on
- trends in, S2:115-120
- Host mediators, inflammatory, in sepsis, S3:36-40
- HPLC (high-performance liquid chromatography), capillary electrophoresis and, in GFR measurement, compared, 173-177
- HSP (Henoch-Schönlein purpura), recurrence of, following RT with CyA immunosuppression, 99-104
- HTN, see Hypertension
- Human immunodeficiency virus-associated nephropathy (HIVAN)
- captopril and antiretroviral therapy of, renal survival and, 202-208
- renal failure due to, prednisone for, 618-621
- Human immunodeficiency virus (HIV) infection, SLE with, 292-295
- Human leukocyte antigen (HLA) matching in RT, USRDS 1996 ADR on, S2:108
- HUS (hemolytic uremic syndrome), CsA-associated TMA/, in renal and renal-pancreas transplantation, 561-571
- HV-CVVH (high-volume continuous venovenous hemofiltration) in MODS with septic shock, S3:53-55
- 1 α (alpha)-Hydroxylase, and renal calcitriol synthesis, 589-595
- Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, immunopharmacology of, 657
- 11- β (beta) Hydroxysteroid dehydrogenase in metabolic alkalosis with ectopic ACTH syndrome, 610-613
- Hyperkalemia in ESRD patients on HD, HCO₃, albuterol, and insulin effects on, compared, 508-514
- Hyperlipidemia, as risk factor for cardiovascular disease in ESRD patients on long-term HD, 934
- Hyperparathyroidism, see Hyperparathyroidism in long-term HD and/or CAPD for ESRD; Secondary hyperparathyroidism
- Hyperparathyroidism in long-term HD and/or CAPD for ESRD
- and bone disease, 918-923
- spontaneous tendon ruptures and, 861-866
- Hyperplasia, parathyroid, P effects on development of secondary hyperparathyroidism and, in CRF, 596-602
- Hypertension (HTN)

- due to combined analgesics, clinical features of, S1:40
in ESRD, *see* Hypertension in ESRD
in familial fibrillary GN with giant fibrillar deposits, 671
in FSGS-like IgA nephropathy, 368
in HIVAN, 204
monogenetic, pheochromocytoma and, 329-333
predictors of cure of, in renovascular fibromuscular disease, 334-338
in pregnancy, *see* Pregnancy, hypertension in
prevalence of, in chronic renal diseases, diet modification and, 811-821
and renal function in Navajo Indians, 339-349
renovascular, *see* Renovascular hypertension
salt-sensitive, 775-782
- Hypertension in ESRD
in HD patients, survival and, 737-740
role of volume overload in dialysis-refractory, 257-261
see also Hypertension in ESRD, anemia and
- Hypertension in ESRD, anemia and
hypertension due to rHuEPO, 403
and impact of anemia, 55, 56
rHuEPO therapy of anemia and, 243
- Hyperthyroid-related hypokalemia and hypophosphatemia, thyrotoxic periodic paralysis associated with, 270-273
- Hypertrophy, *see* Left ventricular hypertrophy
- Hypobicarbonatemia, and metabolic acidosis in ESRD patients on chronic HD, 700-703
- Hypocomplementemia
in idiopathic GN, 753
in MPGN type I, 687
- Hypokalemia
in ectopic ACTH syndrome, K in correction of, 610-613
hyperthyroid-related hypophosphatemia and, thyrotoxic periodic paralysis associated with, 270-273
- Hypophosphatemia, hyperthyroid-related hypokalemia and, thyrotoxic periodic paralysis associated with, 270-273
- Hypotension
midodrine for recurrent, efficacy and pharmacokinetics of, 132-136
systemic, in HD patients, protective effects of cool dialysate on, 262-265
- Hypotensive episodes on HD for ARF, recovery of renal function and, 316
- Hypothermia
due to in CRRT, S3:102-103
protective effects of cool HD dialysate in patients with, 262-265
- Ibuprofen, *see* Nonsteroidal anti-inflammatory drugs, renal effect(s) of
- ICAM, *see* Intercellular adhesion molecule-1; Intercellular adhesion molecule-3
- ICU (intensive care unit), *see* Critically ill acute renal failure patients, CRRT of
- IDDM (insulin-dependent diabetes mellitus), proximal calciphylaxis in HD patients with, 409-414
- "Idiogenic osmole hypothesis" of postdialytic disequilibrium, syndrome, 2, 6-11
- Idiopathic glomerulonephritis (GN), prevalence of HCV in native and transplanted kidneys in, 752-758
- α -IFN (α -interferon) therapy, FSGS with ARF due to, 888-892
- Ig (immunoglobulin)-fibronectin complexes, fibrillar, fibrillary GN related to, 676-684
- Ig (immunoglobulin) isotopes, ELISA in pretransplantation detection of anti-HLA class I, to assess rejection risk, 93-95
- Ig (immunoglobulin) therapy, high-dose sucrose-containing, of IgA nephropathy, osmotic nephrosis and, 451-453
- IgA (immunoglobulin A; α -globulin)
ELISA in pretransplantation detection of anti-HLA class I, to assess rejection risk, 93-95
and twenty-one year survival with systemic AL-amyloidosis, 279
- IgA (immunoglobulin A; α -globulin) heavy chain deposition disease (HCCD), truncated, crescentic nodular GS secondary to, 283-288
- IgA (immunoglobulin A; α -globulin) nephropathy (Berger's disease)
glomerular immune cell infiltration and activation mediated by leukocyte function-associated antigen-1 α , C4R, and ICAM-1 in, 40-46
histologically resembling FSGS, 365-371
increased MMP-9 mRNA expression in peripheral blood monocytes of patients with, 32-39
osmotic nephrosis in, due to sucrose-containing Ig therapy, 451-453
recurrent, following RT with CyA immunosuppression, 99-104
superoxide dismutase activity in mesangial proliferative GN and, 14-22
- IGF (insulin-like growth factor) in ARF management, 323-324
- IGF-I (insulin-like growth factor-I), effects of, on synthesis of renal calcitriol and serum P response to dietary P restriction, 589-595
- IgG (immunoglobulin G; γ -globulin)
detection of anti-HLA class I, with ELISA in pretransplantation assessment of rejection risk, 92-98
and twenty-one year survival with systemic AL-amyloidosis, 279
urinary excretion of, ramipril effects on, 837
- IgG₃ (immunoglobulin G₃; γ -globulin₃) heavy chain deposition disease (HCDD), monoclonal nonamyloid, 128-131
- IgM (immunoglobulin M)
detection of anti-HLA class I, with ELISA in pretransplantation assessment of rejection risk, 93-95
in systemic AL-amyloidosis, 279
- IHD, *see* Intermittent hemodialysis of ARF, CRRT versus
- IL-1, *see* entries beginning with term: Interleukin-1
- IL-2 (interleukin-2) gene model of CyA mechanisms of action of, 642-643
- IL-6, *see* Interleukin-6
- IL-8 (interleukin-8), clearance of, in MODS with septic shock, S3:50, S3:55
- IL-10 (interleukin-10), clearance of, in MODS with septic shock, S3:50, S3:55
- Immune cells, glomerular, leukocyte function-associated antigen-1 α , C4R, and ICAM-1 mediating infiltration and activation of, in IgA nephropathy, 40-46

- Immune complexes in fibrillary GN, 668-675
 Immune-mediated glomerulonephritis (GN), L-arginine in, 878-887
 Immunobiology of antiallograft response, 159-161
 Immunoblot assays, recombinant, in HCV RNA detection in renal transplant recipients with, 437-440
 Immunoelectron microscopy of fibrillary GN, 678
 Immunofluorescence microscopy
 of HCDD, 129
 of idiopathic GN, HCV status and, 755
 of renal AED with nephrotic-range proteinuria, 495
 see also Immunofluorescence microscopy of fibrillary GN and specific conditions
 Immunofluorescence microscopy of fibrillary GN, 677-678
 of familial fibrillary GN, 673
 Immunoglobulin, *see entries beginning with acronym*: Ig
 Immunohistology of ARF with osmotic nephrosis, 452
 Immunologic injury in analgesic-induced RPN, S1:34-38
 Immunopharmacology of immunosuppressant(s), 631-657
 of antilymphocytic antibodies, 652, 655
 of antithymocyte globulin and antilymphocyte globulin, 654-655
 of azathioprine, 631-633
 of colchicine, 655-656
 of CyA, *see* Cyclosporine, immunopharmacology of
 of cyclophosphamide, chlorambucil, and melphalan, 635-636
 of fish oils, 656-657
 of FK506, 161, 648-652
 of glucocorticoids, 636-640
 of ketoconazole, HMG-CoA reductase inhibitors, and diltiazem, 657
 of mycophenolate mofetil, 633-635
 of OKT3, 652-655
 of rapamycin, 652
 Immunosorbent assays, enzyme-linked, in HCV RNA detection in renal transplant recipients, 437-440
 Immunosuppressants, cellular and molecular mechanisms of, 159-177
 of azathioprine, 163
 clinical immunosuppressive regimens, 167-168
 of corticosteroids, 162-163
 of CsA, *see* Cyclosporine, cellular and molecular mechanisms of
 and immunobiology of antiallograft response, 159-161
 and immunopharmacology of, *see* Immunopharmacology of immunosuppressant(s)
 of mizoribine, 15-deoxyspergualin, brequinar sodium, and leflunomide, 166
 of mycophenolate mofetil, 165-166
 of rapamycin, 163-165
 Immunosuppression
 and intramedullary plasmacytoma in RT recipients, 904-906
 see also Immunosuppressants, cellular and molecular mechanisms of and specific immunosuppressants
 IMPDH (inosine monophosphate dehydrogenase) inhibitor, *see* Mycophenolate mofetil
 Imuran, *see* Azathioprine
 Inadequate blood purification with CRRT, S3:103
 Incidence
 of ASA-induced RPN, S1:31
 on nonrenal toxicities of analgesics, S1:64
 see also Incidence (and prevalence) of ESRD, USRDS 1996 ADR on; Incidence (and prevalence) of treated ESRD, USRDS 1996 ADR on; Prevalence and specific conditions
 Incidence (and prevalence) of ESRD, USRDS 1996 ADR on, S2:13-15
 see also Incidence (and prevalence) of treated ESRD, USRDS 1996 ADR on
 Incidence (and prevalence) of treated ESRD, USRDS 1996 ADR on, S2:34-47
 analysis of, S:13, S2:156-157
 characteristics of patients registered in USRDS, S2:40-47
 international, S2:146, S2:147
 Medicare ESRD program and, *see* Medicare end-stage renal disease program, USRDR 1996 ADR on
 number of patients treated, S2:35-40
 slight undercount of 1993, S2:36, S2:152, S2:154
 Inclusion criteria for PKT, 869
 Indigent program, NORD, benefits of continued CyA therapy in RT under, 572-577
 Induced diarrhea, as therapy of irreversible ESRD, 946
 Infections
 catheter, *see* Exit site infections, catheter, on CAPD, peritonitis due to; Tunnel infections
 as CRRT complication, S3:102; *see also* Sepsis, CRRT and
 and CyA-associated TMA/HUS in renal and renal-pancreas transplantation, 566
 urinary tract, due to combined analgesics, clinical features of, S1:40
 see also specific conditions
 Inflammatory mediators
 in ARF, CRRT and elimination of, S3:92
 see also Inflammatory mediators in sepsis
 Inflammatory mediators in sepsis, S3:35-49
 cardiovascular dysfunction and, S3:40
 introduction to, S3:35-36
 microbial and host mediators, S3:36-40
 therapeutic strategies for, S3:37, S3:40-44
 Inflammatory response, mechanisms of steroid inhibition of, 639-640
 Informed choice, withdrawal of dialysis based, 148-150
 Infusion iron dextran (FeD), intravenous, in ESRD patients on HD, cost and adverse effects of intravenous push and, compared, 523-528
 Inherited myopathy and cardiomyopathy, maternally, point mutations in mitochondrial tRNA genes and, 143
 Injury
 immunologic and cellular, and analgesic-induced RPN, S1:34-38
 renal tissue, *see* Renal tissue injury
 Inosine monophosphate dehydrogenase inhibitor, *see* Mycophenolate mofetil
 Inpatient care of HD access complications, 250-256
 Insertions, deletions and, in mitochondrial genome, 143
 Insulin
 effects of albuterol and, on plasma K in ESRD patients on HD, HCO₃, effects compared with, 508-514
 effects of GH or, on synthesis of renal calcitriol and serum P response to dietary P restriction, 589-595

- Insulin-dependent diabetes mellitus (IDDM; type 1 insulin-dependent diabetes mellitus), proximal calciphylaxis in HD patients with, 409-414
- Insulin-like growth factor (IGF) in ARF management, 323-324
- Insulin-like growth factor-I (IGF-I), effects of, on synthesis of renal calcitriol and serum P response to dietary P restriction, 589-595
- Insurance status
effects of, on rHuEPO therapy of anemia of ESRD, 235-249
withdrawal from CsA therapy, race and, 572-577
see also Medicaid coverage and entries beginning with term: Medicare
- Integrins, leukocyte, ICAM-1, ICAM-3 and, in leukocyte accumulation in MPGN type I, 685-694
- Intensive care unit, *see* Critically ill acute renal failure patients, CRRT of
- Intent-to-treat model, USRDS 1996 ADR on, S2:163-164
- Intercellular adhesion molecule-1 (ICAM-1)
glomerular immune cell infiltration and activation in IgA nephropathy mediated by leukocyte function-associated antigen-1 α C4R and, 40-46
in leukocyte accumulation in MPGN type I, 685-694
role of, in CyA-induced adhesion of leukocytes to vascular endothelium under, 23-31
- Intercellular adhesion molecule-3 (ICAM-3), and leukocyte integrins in leukocyte accumulation in, MPGN type I, 685-694
- Interdialytic weight gain by HD patients with ascites, PVS effects on, 389, 391, 393
- α -Interferon therapy (alpha-IFN), FSGS with ARF due to, 888-892
- Interleukin-1 (IL-1) converting enzyme inhibitor in sepsis, S3:43
- Interleukin-1 (IL-1) in sepsis, S3:37-40
clearance of, in MODS with shock, S3:50
therapeutic strategies against, S3:43
- Interleukin-1 (IL-1) receptor, soluble, in sepsis, neutralizing Abs against, S3:43
- Interleukin-2 (IL-2) gene model of CyA mechanisms of action of, 642-643
- Interleukin-6 (IL-6)
clearance of, in MODS with septic shock, S3:50, S3:55
high-flux CT and PAN membranes modulating monocyte production of, in long-term HD, 395-399
- Interleukin-8 (IL-8), clearance of, in MODS with septic shock, S3:50, S3:55
- Interleukin-10 (IL-10), clearance of, in MODS with septic shock, S3:50, S3:55
- Intermittent hemodialysis (IHD) of ARF, CRRT versus, S3:90-96
outcome with, S3:74-80
of pediatric ART, RRT versus, *see* Intermittent hemodialysis of pediatric ARF, CRRT versus
- Intermittent hemodialysis (IHD) of pediatric ARF, CRRT versus, S3:22-25
outcome and CRRT dose, S3:24-25
- Internal dialysis modalities for ESRD, compared, USRDS 1996 ADR on, S2:146-147
- International renal replacement therapy (RRT) modality(ies) for ESRD, compared, USRDS 1996 ADR on, S2:20, S2:146-151
incidence and prevalence, S2:146, S2:147
patient survival, S2:148-151
RT as, S2:147-148
types of, S2:146-147
- Internet World Wide Web, USRDS on, S2:25
- Interstitial nephritis, *see* Acute tubulointerstitial nephritis and uveitis; Tubulointerstitial nephritis
- Intestinal dialysis, as substitute therapy in ESRD, 943-950
bacterial enzymes in, 947-948
clinically effective, 945-946
exclusion from effective ESRD therapy and, 943
and induced diarrhea as therapy of irreversible ESRD, 946
and oral sorbents in renal insufficiency, 946-947
preliminary trials with, 944-945
- Intestinal natriuretic peptide, *see* Uroguanylin
- Intoxication
acute massive gentamicin, of ESRD patient on CAPD with peritonitis, 767-771
see also Adverse effects
- Intradialytic hypotension, midodrine for recurrent, efficacy and pharmacokinetics of, 132-136
- Intradialytic weight of HD patients, fatigue and, 734
- Intramedullary plasmacytoma (IPCT) in RT recipients, immunosuppression and, 904-906
- Intrarenal distribution of analgesics, S1:42-44
- Intravenous (IV) calcitriol [1,25(OH) $_2$ D $_3$], long-term effects of, on secondary hyperparathyroidism, 704-712
- Intravenous (IV) iron dextran (FeD) for anemic ESRD patients on HD, 537
on chronic HD, 855-860
see also Intravenous iron dextran for anemic ESRD patients on HD, adverse effects of
- Intravenous (IV) iron dextran (FeD) for anemic ESRD patients on HD, adverse effects of, 523-534
cost and adverse effects of intravenous push and intravenous infusion FeD, compared, 523-528
types of adverse effects of, 529-534
- Intravenous (IV) recombinant human erythropoietin (rHuEPO) to anemic ESRD patients on ESRD, 400-408
- Intravenous (IV) urography in renally impaired patients, ARF due to, 454-456
- Investigator initiated research, policy on USRDS data release for, S2:30-32
- Iohexol, nonradioactive, capillary electrophoresis using, in GFR measurement, 173-177
- Ions
NSAIDs and interruption in tubular transport of, S1:59
see also specific ions
- Iothalamate in HPLC to measure GFR, 173-177
- IPCT (intramedullary plasmacytoma) in RT recipients, immunosuppression and, 904-906
- Iron (Fe), IV iron dextran effects on
in anemic ESRD patients, 855-860
on total body Fe, 858
- Iron dextran, *see* Intravenous iron dextran for anemic ESRD patients on HD
- Iron (Fe) in ESRD
with restless legs syndrome, 374

- serum, rHuEPO effects on, 402
- Isolated ultrafiltration (UF), slow, for CHF, S3:67-76
- Isotopes, Ig, ELISA pretransplantation detection of anti-HLA class I to assess rejection risk, 93-95
- Israpidine for CyA-associated TMA/HUS in renal and renal-pancreas transplantation, 561-571
- IV (intravenous) calcitriol [1,25(OH)₂D₃], long-term effects of, on secondary hyperparathyroidism, 704-712
- IV (intravenous) iron dextran, *see* Intravenous iron dextran for anemic ESRD patients on HD
- IV (intravenous) recombinant human erythropoietin (rHuEPO) for anemic ESRD patients on ESRD, 400-408
- IV (intravenous) urography in renally impaired patients, ARF due to, 454-456
- Justice issues in withdrawal of dialysis, 149-150, 152
- K (potassium)
- NSAID-induced retention of, S1:57
- plasma, *see* Plasma K
- serum, *see* Serum K
- urinary excretion of, *see* Urinary excretion, K
- see also* Hyperkalemia; Hypokalemia
- Karnofsky activity score, modified, for white and African American ESRD patients on PD, HD, and with RT, 73
- Kearns-Sayre syndrome, mtDNA deletions and, 143
- Ketoconazole, immunopharmacology of, 657
- Ketodeoxyoctonate, *see* R-core in sepsis
- Ketoprofen, *see* Nonsteroidal anti-inflammatory drugs, renal effect(s) of
- Kidney(s)
- native, prevalence of HCV in transplant and, in idiopathic GN, 752-758
- preservation of, for RT, aspirin in, S1:20-23
- supply of, for transplantation, USRDS 1996 ADR on, S2:108-110
- see also* entries beginning with term: Renal and elements: Nephro-, Reno-
- Kidney-specific promoters, gene delivery with, 482
- Kt/V
- effects of increasing, on protein intake by CAPD patients, 553-560
- in HD, *see* Kt/V in HD
- Kt/V in HD
- and atherosclerotic lesions in carotid vessels of HD patients, 715
- effects of IHD versus CRRT on, S3:23
- in ESRD patients, 64
- and extreme posthemodialysis urea rebound, 729, 730
- fatigue and, 734
- low-dose LMW heparin effects on, 723
- Laboratory data
- on CyA-associated TMA/HUS, 565
- impact of initial, on ESRD chronic dialysis patient survival, 541-548
- on long-term HD patients with bone disease, 920
- see also* specific laboratory data
- Lactate-based fluids in CRRT, S3:17-18
- Lactate dehydrogenase (LDH), effects of CyA-associated TMA/HUS on, 564, 565
- Lactate load in CRRT of ARF, S3:93-94
- Lactic acidosis in MELAS syndrome, point mutations in mitochondrial tRNA genes and, 143
- Lake Tahoe model of fluid accumulation in ADPKD, 795
- LCDD (light-chain deposition disease), de novo, in cadaveric RT, 461-465
- LDH (lactate dehydrogenase), effects of CyA-associated TMA/HUS on, 564, 565
- LDL (low-density lipoprotein) in nephrosis, 354
- Leber's hereditary optic neuropathy, point mutations in mitochondrial genes and, 142
- Leflunomide, cellular and molecular mechanisms of, 166
- Left ventricular dilatation in ESRD, impact of anemia on, 57
- Left ventricular hypertrophy (LVH)
- in ESRD, impact of anemia on, 57
- and hypertension in chronic renal disease, 814
- Length of dialysis, *see* Time on dialysis
- Leukocyte(s)
- adhesion of, to vascular endothelium under physiological flow conditions, CyA effects on, 23-31
- rHuEPO administration and, 402
- role of leukocyte integrins, ICAM-1, and ICAM-3 in accumulation of, in MPGN type I, 685-694
- Leukocyte function-associated antigen-1 α (LFA1 α), glomerular immune cell infiltration and activation in IgA nephropathy mediated by C4R, ICAM-1 and, 40-46
- Light chain(s), urinary, and twenty-one year survival with systemic AL-amyloidosis, 279
- Light-chain deposition disease (LCDD), de novo, in cadaveric RT, 461-465
- Light microscopy
- of ARF with osmotic nephrosis, 452
- of fibrillary GN, *see* Light microscopy of fibrillary GN of HCDD, 129
- of renal AED with nephrotic-range proteinuria, 495
- see also* specific conditions
- Light microscopy of fibrillary GN, 677
- of familial fibrillary GN, 673
- Line disconnection, CRRT, S3:101
- Lipid A in sepsis, Abs against, S3:36-37
- monoclonal antibodies, S3:41-42
- polyclonal antibodies, S3:41
- Lipodystrophy, partial, MPGN type III and, 804-810
- Lipopolysaccharide (LPS; endotoxin), S3:36-38
- removal of, with CRRT, S3:127
- Liquid chromatography, high-performance, capillary electrophoresis and, in GFR measurement, compared, 173-177
- Lithium, ACEI effects on clearance of, in chronic progressive nephropathy, 822-831
- Liver cirrhosis, decompensated, tense ascites secondary to, in ESRD, UF for, 899-903
- Liver transplantation, CRRT as bridge to, S3:65
- Living related renal transplantation (RT), USRDS 1996 ADR on
- graft survival with, S2:106
- patient survival with, S2:162

- Living Wills (advance directives), and substitute decision making, 151-152
- LMW (low molecular weight) heparin, low-dose, in HD, 721-726
- Location, number and, of ESRD care facilities, S2:141
- Long-term bone loss with RT, 105-113
- Long-term continuous ambulatory peritoneal dialysis (CAPD), risk factors for peritonitis on, 428-436
- Long-term hemodialysis (HD)
- high-flux CT and PAN membranes modulating TGF- β monocyte production in, 395-399
 - see also* Long-term hemodialysis and/or continuous ambulatory peritoneal dialysis for ESRD
- Long-term hemodialysis (HD) and/or continuous ambulatory peritoneal dialysis (CAPD) for ESRD
- bone disease in, 918-923
 - enrollment PTH and survival with, 924-930
 - overview of, 907-909
 - see also* Intestinal dialysis, as substitute therapy in ESRD; Long-term survival of ESRD patients on long-term HD and/or CAPD
- Long-term outcome
- of IV calcitriol therapy of secondary hyperparathyroidism, 704-712
 - optimal therapy and, of TBP in ESRD patients on CAPD, 747-751
 - see also* Long-term survival of ESRD patients
- Long-term survival of ESRD patients
- on HD, *see* Long-term survival of ESRD patients on long-term HD and/or CAPD
 - with restless legs syndrome, 375
 - USRDS 1996 ADR on, S2:85-86
- Long-term survival of ESRD patients on long-term HD and/or CAPD
- cardiovascular disease and, 931-936
 - enrollment PTH and, 924-930
 - prealbumin values and, 937-942
 - predictive value of albumin, cholesterol, creatinine, and hematocrit and, 910-917
- Lost to follow-up status, analysis of, in USRDS 1996 ADR, S2:14, S2:152, S2:155
- Low-density lipoprotein (LDL) in nephrosis, 354
- Low-dose low molecular weight (LMW) heparin in HD, 721-726
- Low-fat diet in prevention of urolithiasis, 195-201
- Low molecular weight (LMW) heparin, low-dose, in HD, 721-726
- Low-protein diet, supplemented very, nephrosis management with, 354-364
- LPS, *see* Lipopolysaccharide
- Lumbar bone mineral density (BMD), long-term effect of RT on, 107-108, 110
- Lupus erythematosus, systemic, with HIV infection, 292-295
- LVH, *see* Left ventricular hypertrophy
- Lymphoproliferative disease, EBV-associated posttransplant, severe acute rejection compared with, using Banff schema, 578-584
- L-Lysine, Fanconi's syndrome and tubulointerstitial nephritis associated with, 614-617
- Macrophage-1 (Mac-1)-positive cells in leukocyte accumulation in MPGN type I, 685-694
- Macroscopic hematuria due to combination analgesics, clinical features of, S1:40
- Magnesium (Mg), serum, in metabolic alkalosis with ectopic ACTH syndrome, 611
- Maintenance hemodialysis (HD), CRF patients starting, without prior care by nephrologist, 841-845
- Malnutrition in ESRD patients on HD for up to 30 years, 910-917
- Manganese superoxide dismutase (Mn-SOD) proteins in kidney, 16-17
- Marrow-pancreas syndrome, Pearson's, deletions in mtDNA and, 143
- Massive gentamicin intoxication, acute, of ESRD patient on CAPD with peritonitis, 767-771
- Maternal comorbid factors, and outcome of five-year post-transplant pregnancy in CsA-treated patients, 267
- Maternally inherited myopathy and cardiomyopathy (MI-MAC), point mutations in mitochondrial tRNA genes and, 143
- MCP (membrane cofactor protein), role of, in C4R-, leukocyte function-associated antigen-1 α -, and ICAM-1-mediated glomerular immune cell infiltration and activation in IgA nephropathy, 40-46
- Mechanical correction of malfunctioning silastic cuffed HD catheters, 379-386
- Mechanisms of action
- of antithymocyte and antilymphocyte globulin, 654-655
 - of azathioprine, 632-633
 - of colchicine, 656
 - of corticosteroids, 638-640
 - of CsA, 641-643
 - of cyclophosphamide, chlorambucil, and melphalan, 636
 - of FK506, 649, 651
 - of MMF, 634-635
 - of OKT3, 653
 - of omega-fatty acids, 656-657
 - of uroguanylin, 300-301
 - see also* Immunosuppressants, cellular and molecular mechanisms of
- Mediators of renal diseases, inhibition of, with molecular therapy, 476-477
- Medicaid coverage, effects of, on rHuEPO for anemia of ESRD, 235-249
- Medical futility, defined, withdrawal of dialysis and, 148
- Medicare claims, USRDS 1996 ADR on
- analysis of, S2:154-155, S2:163
 - by source of claims, S2:130
 - see also* Medicare expenditures for ESRD, USRDS 1996 ADR on
- Medicare Claims Data Standard Analysis File (SAF), S2:39
- Medicare end-stage renal disease (ESRD) program
- loss of coverage under, and withdrawal from CsA therapy by RT recipients, race and, 572
 - and reimbursement for FeD, 527
 - and rHuEPO for anemia of ESRD, 235-249
 - see also* Medicare end-stage renal disease program, USRDS 1996 ADR on
- Medicare end-stage renal disease (ESRD) program, USRDS 1996 ADR on, S2:34
- eligibility to, S2:35, S2:153
 - number of patients in, S2:38-39

- patients in, by ESRD networks, S2:46
see also Medicare expenditures for ESRD, USRDS 1996 ADR on
- Medicare expenditures for ESRD, USRDS 1996 ADR on, S2:127-140
 for alternative treatment modalities, S2:19, S2:135-140
 cost effectiveness of, S2:163-164
 for direct patient care, *see* Direct patient care, ESRD, Medicare expenditures for, USRDS 1996 ADR on
see also Medicare claims, USRDS 1996 ADR on
- Medicare Secondary Payers (MSPs), Medicare expenditures for direct ESRD patient care and, USRDS 1996 ADR on, S2:131-133
- MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes), point mutations in mitochondrial tRNA genes and, 143
- Melphalan, immunopharmacology of, 635-636
- Membrane(s), *see* Dialysis membranes
- Membrane cofactor protein (MCP), role of, in C4R-, leukocyte function-associated antigen-1 α -, and ICAM-1-mediated glomerular immune cell infiltration and activation in IgA nephropathy, 40-46
- Membranoproliferative glomerulonephritis (MPGN) type I, ICAM-1, ICAM-3, and leukocyte integrins in leukocyte accumulation in, 685-694
- Membranoproliferative glomerulonephritis (MPGN) type III, discordant findings between complement profiles and histopathology of, 804-810
- MEN 2 (multiple endocrine neoplasia type 2), monogenetic hypertension and, 329-332
- MERRF syndrome (myoclonic epilepsy with ragged-red fibers), point mutations in mitochondrial tRNA genes and, 142
- Mesangial cells, CsA effects on, 643
- Mesangial proliferative glomerulonephritis (GN), superoxide dismutase activity in, 14-22
- Messenger ribonucleic acid, *see* mRNA expression
- Metabolic acidosis in ESRD patients on chronic HD, differences in HCO₃ assays and magnitude of, 700-703
- Metabolic alkalosis in ectopic ACTH syndrome, K in correction of, 610-613
- Metabolism
 azathioprine, 632
 CsA, 641
 FK506, 648
 MMF, 634-635
see also entries beginning with term: Metabolic
- Metabolite(s)
 de-glymidodrine as active midodrine, 132-136
 reactive APAP, S1:3-4
- Metalloproteinase-9 (MMP-9) mRNA (messenger ribonucleic acid), increased expression of, in peripheral blood monocytes of IgA nephropathy patients, 32-39
- Methodology, USRDS, *see* Analytical methods used in USRDS 1996 ADR
- Methotrexate, clearance of, using high-flux HD membranes, 846-854
- Mexican-Americans, *see* Race and ethnicity
- Mg (magnesium), serum, in metabolic alkalosis with ectopic ACTH syndrome, 611
- Microalbuminuria
 physiological, glycated albumin accumulation in ESRD as evidence of, 62-66
 as predictor of hypertension in pregnancy, 220-225
- Microangiopathy, CyA-associated TMA/HUS in renal and renal-pancreas transplantation, 561-571
- Microbial mediators, inflammatory, in sepsis, S3:36-40
- Microbial ST peptides, natriuretic activity of, 299
- Microencapsulation to preserve bacterial enzyme activity in intestinal dialysis, 947-948
- Microscopic hematuria
 due to combination analgesics, clinical features of, S1:40
 in FSGS-like IgA nephropathy, 368
- Microscopic polyarteritis during PMR remission, renal biopsy of, 289-291
- Microscopy, *see* Electron microscopy; Immunoelectron microscopy; Immunofluorescence microscopy; Light microscopy
- Midodrine for recurrent intradialytic hypotension, efficacy and pharmacokinetics of, 132-136
- MIMAC (maternally inherited myopathy and cardiomyopathy), point mutations in mitochondrial tRNA genes and, 143
- Minimal change glomerulopathy, NSAIDs and, S1:59
- Minimum aggregation size in USRDS 1996 ADR, S2:153
- Minor acute illnesses with ESRD, care of, by nephrologists, 69
- Minorities, *see* Race and ethnicity
- Mitochondrial diseases, and mtDNA mutations, 142-143
- Mitochondrial DNA (deoxyribonucleic acid; mtDNA) mutations, 140-148
 directions in research on, 144-145
 mitochondrial diseases and, 142-143
 molecular biology of mitochondrial genome and, 140-141
 reasons for high rate of, 141-142
 renal diseases and, 143-144
- Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like (MELAS) episodes syndrome, point mutations in mitochondrial tRNA genes and, 143
- Mizoribine, cellular and molecular mechanisms of action of, 166
- MMF, *see* Mycophenolate mofetil
- MMP-9 (metalloproteinase-9) mRNA (messenger ribonucleic acid), increased expression of, in peripheral blood monocytes of IgA nephropathy, 32-39
- Mn-SOD (manganese superoxide dismutase) in kidney, 16-17
- MoAbs, *see* Monoclonal antibody(ies), as immunosuppressants
- Modified Karnofsky activity score for white and African American ESRD patients on PD, HD, and with RT, 73
- MODS, *see* Multiorgan dysfunction syndrome
- Molecular biology of mitochondrial genome, 140-141
- Molecular mechanisms of immunosuppressants, *see* Immunosuppressants, cellular and molecular mechanisms of
- Molecular therapy of renal diseases, 475-492
 animals models for, 477
 gene replacement therapy and, 476; *see also* Gene delivery summary on, 486-487
 targeting diseases for, 476-477
 therapeutic modalities for, 482-486

- Monitoring of anticoagulant therapy in CRRT, S3:12-13
- Monoclonal antibody(ies) (MoAbs), as immunosuppressants
cellular and molecular mechanisms of, 167-168
OKT3 as, immunopharmacology of, 652-655
- Monoclonal antibody(ies) (MoAbs) in sepsis
against lipid A, S3:41-42
against TNF, S3:43
- Monoclonal nomamyloid IgG₃ (immunoglobulin G₃) heavy
chain deposition disease (HCDD), 128-131
- Monocytes
peripheral blood, increased MMP-9 mRNA expression in,
in IgA nephropathy, 32-39
TGF- β production of, in long-term HD, high-flux CT and
PAN membranes modulating, 395-399
- Monogenetic hypertension, pheochromocytoma and, 329-333
- Mononeuritis multiplex, renal biopsy of, 289-291
- Monophosphate, *see* cGMP
- Morbidity
in CRF patients starting maintenance HD without prior
care by nephrologist, 841-845
following PKT, early readmissions and, 867-875
see also Morbidity due to ESRD, USRDS 1996 ADR on
and specific conditions
- Morbidity due to ESRD, USRDS 1996 ADR on, S2:13-14
in DMMS, S2:14
study of, S2:29
- Mortality
with CRRT, *see* Mortality with CRRT of ARF
due to peritonitis on CPD, 89
of HD patients, *see* Mortality of HD patients
see also Mortality of ESRD patients; Outcome
- Mortality with CRRT of ARF, S3:74-80
with CRRT versus IHD, S3:90-96
- Mortality of ESRD patients
on chronic dialysis, impact of initial laboratory data on,
542, 544, 545
see also Mortality of ESRD patients, USRDS 1996 ADR
on; Mortality of ESRD patients on HD
- Mortality of ESRD patients, cause(s) of, USRDS 1996 ADR
on, S2:14, S2:17-18, S2:81-82, S2:93-102
analysis of, S2:93-94, S2:152
cause specific rates of, S2:94-97
of HD and/or PD patients, S2:97-99
among pediatric patients, S2:101
with RT, S2:99
withdrawal from dialysis as, S2:99-101
- Mortality of ESRD patients, USRDS 1996 ADR on, S2:13,
S2:17, S2:29
and DMMS, *see* Dialysis Morbidity and Mortality Study,
USRDS 1996 ADR on
and expected remaining years of life, S2:89-90, S2:162
rates of, S2:86-89, S2:158-161
SMR and, *see* Standardized Mortality Ratio, USRDS 1996
ADR on
of treated patients, S2:79-85
see also Mortality of ESRD patients, cause(s) of, USRDS
1996 ADR on
- Mortality of ESRD patients on HD
hypertension and, 737-740
impact of anemia on cardiomyopathy and cardiac disease
on, 53-61
- USRDS 1996 ADR on, S2:97-99
see also specific conditions
- Mortality of HD patients
laboratory values and risk of, 741-746
see also Mortality of ESRD patients on HD
- MPGN, *see* entries beginning with terms: Membranoprolifer-
ative glomerulonephritis
- mRNA (messenger ribonucleic acid) expression
Cu,Zn-SOD and Mn-SOD, 16-17
GF, in chronic renal rejection, 441-450
increased MMP-9, in peripheral blood monocytes of IgA
nephropathy patients, 32-39
- MSPs (Medicare Secondary Payers), Medicare expenditures
for direct ESRD patient care and, USRDS 1996 ADR
on, S2:131-133
- mtDNA, *see* Mitochondrial DNA mutations
- Multiorgan dysfunction syndrome (MODS)
with ARF, CRRT versus IHD for, S3:90-96
see also Multiorgan dysfunction syndrome, septic shock
and, CRRT for
- Multiorgan dysfunction syndrome (MODS), septic shock and,
CRRT for, S3:50-57
effects of, on clinical variables, S3:52
in experimental shock, S3:52-53
future developments in CRRT and, S3:56
HV-CVVH effects on, S3:53-54
outcome and, S3:51-52
rationale for CRRT, S3:50-51
- Multiple endocrine neoplasia type 2 (MEN 2), monogenetic
hypertension in, 329-332
- Multiple organ failure, CRRT in, S3:97-99
outcome of, S3:74-80
see also Multiorgan dysfunction syndrome
- Mutation(s)
germline, of *RET* proto-oncogene and *VHL* gene associated
with pheochromocytoma, 329-332
see also Mitochondrial DNA mutations
- Mycophenolate mofetil (MMF; RS-61443)
cellular and molecular mechanisms of, 165-166
immunopharmacology of, 633-635
- Myocardial uroguanylin, role of, 300
- Myoclonic epilepsy with ragged-red fibers (MERRF) syn-
drome, point mutations in mitochondrial tRNA genes
and, 142
- Myopathy
in MIMAC, point mutations in mitochondrial tRNA genes
and, 143
see also Cardiomyopathy
- N (nitrogen), *see* Azotemia; BUN; Serum urea nitrogen
- Na (sodium)
in familial fibrillary GN with giant fibrillar deposits, 671
NSAID-induced retention of, S1:57
serum, *see* Serum Na
urinary excretion of, *see* Urinary excretion, Na
- NaCl (table salt; sodium chloride)
homeostasis of, *see* Uroguanylin
and salt-sensitive hypertension, 775-782
- Naproxen, *see* Nonsteroidal anti-inflammatory drugs, renal
effect(s) of

- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), S2:5
- National Organization for Rare Disorders (NORD) program, benefits of continued CsA therapy of RT under, 572-577
- Native Americans, renal function and NIDDM in adult Navajo Indians, 339-349
- Native kidneys, prevalence of HCV in transplant and, in idiopathic GN, 752-758
- Natriuretic hormone, *see* Uroguanylin
- Natriuretic peptides
CRRT with, in future treatment of ARF, S3:111-112
see also Atrial natriuretic peptides; Uroguanylin
- Navajo Indians, adult, renal function and NIDDM in, 339-349
- NBCAAs (non-branched-chain amino acids), AII effects on GFR and NO response to, 115-123
- Necrosis, *see* Renal papillary necrosis, analgesic-induced
- Necrotizing vasculitis, systemic, ANCA in, 183
- Negotiating withdrawal of dialysis, 151-152
- Neoral formulation of CsA, 647-648
- Nephritis, *see* Acute interstitial nephritis; Glomerulonephritis; Tubulointerstitial nephritis
- Nephritogenic factor in MPGN type III, 804-810
- Nephrologists
CRF patients starting maintenance HD without prior care by, 841-845
as primary care providers for ESRD patients on chronic dialysis, 67-72
- Nephrosclerosis, hypertensive, as consequence and contributing factor in hypertension, 779
- Nephrosis
due to high-dose sucrose-containing (but not glycine) Ig therapy in IgA nephropathy, 451-453
supplemented, very low-protein diet in management of, 354-364
- Nephrotic-range proteinuria
in FSGS-like IgA nephropathy, 368
in renal AED, 493-501
- Nephrotic syndrome (NS)
and familial fibrillary GN with giant fibrillar deposits, 668-675
FSGS and, due to α -IFN therapy, 888-892
rHuEPO for anemia of, 274-277
- Nephrotoxicity
acute APAP-associated, S1:4-5
of cyclosporine, *see* Cyclosporine nephrotoxicity of FK506, 651
see also specific nephrotoxic agents
- Networks, ESRD, USRDS 1996 ADR on analysis of, S2:152
ESRD patients in Medicare program by, S2:46
and their states, S2:7-8, S2:14, S2:152
- Neuropathy, Leber's hereditary optic, point mutations in mitochondrial genes and, 142
- Neutralizing antibodies (Abs) to IL-1 receptor in sepsis, S3:43
- New data, in USRDS 1996 ADR, S2:13, S2:153-154
- New products of USRDS, S2:21
- NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), S2:5
- NIDDM (non-insulin-dependent diabetes mellitus), renal function and, in adult Navajo Indians, 339-349
- Nitric oxide (NO)
response of, to AAs, AII effects on, 115-123
in salt-sensitive hypertension, 775-782
- Nitric oxide (NO):L-arginine pathways in salt-sensitive hypertension, 776-779
- Nitric oxide (NO) synthase in salt-sensitive hypertension, 775-782
- Nitrogen, *see* Azotemia; BUN; Serum urea nitrogen
- NO, *see* Nitric oxide; Nitric oxide:L-arginine pathways; Nitric oxide synthase
- Nodular glomerulosclerosis (GS), HCDD and, 128-131
crescentic nodular GS secondary to truncated IgA HCDD, 283-288
- Nomenclature for CRRT, S3:2-7
- Nonamyloid IgG₃ (immunoglobulin G₃) heavy chain deposition disease (HCDD), monoclonal, 128-131
- Non-branched-chain amino acids (NACAAs), AII effects on GFR and NO response to, 115-123
- Noncompliance, cost of continued CsA therapy of RT as reason for, race and, 572-577
- Nondiabetic patients with proteinuria, normotensive, ramipril effects on protein excretion and BP in, 832-840
- Non-insulin-dependent diabetes mellitus (NIDDM), renal function and, in adult Navajo Indians, 339-349
- Non-Medicare end-stage renal disease (ESRD) patients, number of treated, S2:38-40
- Nonnarcotic analgesics, *see* Analgesic nephropathy
- Nonoliguric acute renal failure (ARF), oliguric versus, CRRT and, S3:108-109
- Nonradioactive iohexol, capillary electrophoresis using, in GFR measurement, 173-177
- Nonrenal toxicity of APAP, ASA, and NSAIDs, S1:63-70
cardiovascular effects, S1:68
central nervous effects, S1:65-66
dermatologic and hematologic effects, S1:65
gastrointestinal effects, S1:66-68
- Nonsteroidal anti-inflammatory drugs (NSAIDs), renal effect(s) of, S1:56-62
acute interstitial nephritis as, S1:57, S1:59
ARF as, S1:57-58
clinical consequences of, S1:57-58
CRF as, S1:59-60
interruption of tubular ion and water transport as, S1:59
minimal change glomerulopathy as, S1:59
on PG synthesis and compartmentalization, S1:56-57
see also Nonrenal toxicity of APAP, ASA, and NSAIDs
- Nontranscriptional effects of steroids, 639
- Nonviral systems of gene delivery, 480-482
- NORD (National Organization for Rare Disorders) program, benefits of continued CsA therapy of RT under, 572-577
- Normal renal function, patients with, prophylactic use of CRRT in, S3:114-120
- Normalized protein catabolic rate (nPCR)
effects of IHD versus CRRT on, S2:23
and effects of small solute clearance on dietary protein intake by CAPD patients, 553-560
- Normotensive nondiabetic patients with proteinuria, ramipril effects on protein excretion and BP in, 832-840

- nPCR, *see* Normalized protein catabolic rate
- NS, *see* Nephrotic syndrome
- NSAIDs, *see* Nonsteroidal anti-inflammatory drugs, renal effect(s) of
- Nuclear transcriptional factors of steroids, 638
- Number of ESRD care facilities, USRDS 1996 ADR on, S2:141
- Nutrients
- loss of, with CRRT, S3:103
 - see also specific nutrients*
- Nutrition
- in ARF, catabolism and, CRRT and, S3:109
 - see also* Malnutrition; Nutrients and entries beginning with term: Dietary
- Nystatin, oral, in prevention of *Candida* peritonitis on CAPD, 549-552
- O_2^- (superoxide) dismutase activity in IgA nephropathy and mesangial proliferative GN, 14-22
- Obstruction, ureteral, in pregnancy, rapidly reversible ARF due to, 457-460
- Occlusion, renal vein, secondary to extrinsic compression, renal graft salvage with, 622-623
- ODNs (oligodeoxynucleotides), antisense, molecular therapy with, 482-484
- 1,25-(OH) $_2$ D $_3$, *see* Calcitriol
- OKT3, immunopharmacology of, 652-655
- Oligodeoxynucleotides (ODNs), antisense, molecular therapy with, 482-484
- Oliguric acute renal failure (ARF), nonoliguric versus, CRRT and, S3:108-109
- Omega (ω)-fatty acids (fish oils), immunopharmacology of, 656-657
- Oncogene, germline mutation of *RET* proto-oncogene associated with pheochromocytoma, 329-332
- Ophthalmoplegia, chronic progressive external, 143
- O-polysaccharide chain in sepsis, S3:36
- antibodies against, S3:40
- Optic neuropathy, Leber's hereditary, point mutations in mitochondrial genes and, 142
- Oral nystatin in prevention of *Candida* peritonitis on CAPD, 549-552
- Oral sorbents in renal insufficiency, intestinal dialysis and, 946-947
- Organic acids, as "idiogenic osmoles", postdialytic disequilibrium syndrome and, 9-11
- Organic osmolyte-dependent fluid accumulation in ADPKD, 798
- L-Ornithine, L-arginine metabolized to, by arginase, 878-887
- Osmolality, brain, "idiogenic osmole hypothesis" of postdialytic disequilibrium syndrome and, 8-11
- Osmolytes, organic, fluid accumulation in ADPKD dependent on, 798
- Osmotic nephrosis due to high-dose sucrose-containing (but not glycine) Ig therapy of IgA nephropathy, 451-453
- Osteitis in long-term HD for ESRD, 918-923
- Osteomalacia in long-term HD for ESRD, 918-923
- Osteopenia
- in HD and PD patients, risk factors for, and prevalence of, 515-522
 - as long-term effect of RT, 105-113
- Osteoporosis, spinal, as long-term effect of RT, 105-113
- OTC (over-the-counter) analgesics, *see* Analgesic nephropathy
- Ototoxicity due to acute massive gentamicin intoxication, 767-771
- Outcome
- of APAP-induced CRF, S1:14-19
 - of ARF, *see* Outcome, ARF
 - of CRRT, *see* Outcome, CRRT
 - of ESRD, *see* Outcome, ESRD
 - of five-year posttransplant pregnancy in CsA-treated patients, 266-269
 - of fungal peritonitis on CPD, 88-89
 - long-term, *see* Long-term outcome
 - PKT, 871
 - predictors of hypertension, in renovascular fibromuscular disease, 334-338
 - of renal AED with nephrotic-range proteinuria, 494
 - RT, *see* Outcome, RT
 - of SEP, 422-423
 - of sepsis, ET levels and, S3:37-38
 - see also* Graft survival; Mortality; Patient survival; Rejection, graft and specific conditions
- Outcome, ARF, 317-319
- see also* Dialysis modalities for ARF, outcome and; Outcome, ARF, with CRRT; Patient survival with ARF
- Outcome, ARF, with CRRT
- with dialysis for ARF, S3:74-80
 - dialysis dose and, S3:83
 - solute control and CRRT dose and, S3:24-25
 - see also* Mortality with CRRT of ARF
- Outcome, CRRT
- with different anticoagulation regimens, S3:11-12
 - of MODS with septic shock, S3:51-52
 - and slow isolated UF for CHF, S3:69-70
 - see also* Mortality with CRRT of ARF; Outcome, ARF, with CRRT; Patient survival on CRRT
- Outcome, ESRD
- impact of anemia on, 55-57
 - see also* Mortality of ESRD patients; Patient survival with ESRD
- Outcome, RT
- long-term bone loss as, 105-113
 - with renal vein occlusion secondary to extrinsic compression, 622-623
 - USRDS 1996 ADR on, S2:18
 - see also* Renal graft loss; Renal graft rejection; Renal graft survival, USRDS 1996 ADR on
- Outpatient care of HD vascular access complications, 250-256
- Over-the-counter analgesics, *see* Analgesic nephropathy
- P. parasitica* (*Phialophora parasitica*), subcutaneous phaeophomycosis due to, in RT recipients, 137-139
- P (phosphorus), 589-602
- dietary, restriction of, synthesis of renal calcitriol and serum P response to, GH or insulin effects on, 589-595
 - effects of, on development of parathyroid hyperplasia and secondary hyperparathyroidism in CRF, 596-602

- on HD and/or CAPD, *see* P in HD and/or CAPD patients
- serum, *see* Serum P
- P (phosphorus) in HD and/or CAPD patients
 - in insulin-dependent diabetic patients with proximal calciphylaxis, 410
 - see also* P in long-term HD and/or CAPD patients
- P (phosphorus) in long-term HD and/or CAPD patients
 - bone disease and, 920
 - PTH and, 928
 - spontaneous tendon ruptures and, 863
- PAF (platelet-activating factor), role of, in CyA-induced adhesion of leukocytes to vascular endothelium under physiological flow conditions, 27
- PAN (polyacrylonitrile triacetate) membranes modulating TGF- β monocyte production in long-term HD, 395-399
- Pancreas-kidney transplantation (PKT)
 - CyA-associated TMA/HUS in, 561-571
 - early readmission to hospital following, 867-875
- Pancreas-marrow syndrome, Pearson's, mtDNA deletions and, 143
- Papillary necrosis, *see* Renal papillary necrosis, analgesic-induced
- Paracetamol, *see* Acetaminophen
- Paralysis, thyrotoxic periodic, associated with hyperthyroid-related hypokalemia and hypophosphatemia, 270-273
- Paraprotein, serum, and twenty-one year survival with systemic AL-amyloidosis, 279
- 1,84 Parathormone (parathyroid hormone), rHuEPO effects on, 402
- Parathyroid hormone (PTH)
 - and ACEI effects on rHuEPO therapy of ESRD, 538
 - and bone loss as long-term effect of RT, 111
 - effects of IV calcitriol for secondary hyperparathyroidism on, 704-712
 - on HD and/or CAPD, *see* Parathyroid hormone in HD and/or CAPD patients
 - and restless legs syndrome in ESRD, 374
 - rHuEPO effects on 1,84, 402
- Parathyroid hormone (PTH) in HD and/or CAPD patients
 - in insulin-dependent diabetic patients on HD with proximal calciphylaxis, 410
 - see also* Parathyroid hormone in long-term HD and/or CAPD patients
- Parathyroid hormone (PTH) in long-term HD and/or CAPD patients
 - bone disease and, 920
 - enrollment PTH and survival in, 924-930
 - spontaneous tendon ruptures and, 863
- Parathyroid hyperplasia, P effects on development of secondary hyperparathyroidism and, in CRF, 596-602
- Parathyroidectomy (PTX)
 - in long-term HD patients, 919
 - for parathyromatosis with secondary hyperparathyroidism in ESRD, 502-507
 - as risk factor for osteopenia, 515-522
- Parathyromatosis with secondary hyperparathyroidism in ESRD, 502-507
- Partial lipodystrophy, MPGN type III and, 804-810
- Pathology, pathophysiology, and pathogenesis
 - of ADPKD, 791-794
 - of CsA nephrotoxicity, 646-647
 - of EBV-associated PTLT and acute renal graft rejection, compared, 579
 - of FK506 nephrotoxicity, 651
 - of vasculitis, role of elastase antibodies and antineutrophil cytoplasmic antibodies in, 184
 - see also* Pathology, pathophysiology, and pathogenesis of AN and specific conditions
- Pathology, pathophysiology, and pathogenesis of AN, S1:31
- of analgesic-induced RPN, S1:34-38
- Patient characteristics
 - of ARF patients, outcome of CCRT and, S3:76-77
 - of ESRD patients, *see* Patient characteristics of ESRD patients
 - of nephrologists providing primary care to ESRD patients on chronic dialysis, 68
 - of renal or renal-pancreas recipients, CyA-associated TMA/HUS and, 563
 - as risk factors for urolithiasis, 196, 197
 - see also* Age; Education; Race and ethnicity; Sex
- Patient characteristics of ESRD patients
 - of anemic ESRD patients on HD and rHuEPO therapy, 403-404
 - registered in USRDS, S2:40-47
 - with restless legs syndrome, 373
 - see also* Age of ESRD patients on HD and/or CAPD; Race and ethnicity of ESRD patients; Sex of ESRD patients
- Patient eligibility, USRDS 1996 ADR on
 - to hospitalization, 60 day rule and, S2:116
 - to Medicare program, S2:35, S2:153
- Patient evaluation for PKT, 868
- Patient immobilization with CRRT of ARF, S3:93
- Patient selection for anticoagulant therapy in CRRT, S3:10-11
- Patient Standard Analysis File (SAF), S2:27-28
- Patient survival
 - with ARF, *see* Patient survival with ARF
 - on CRRT, *see* Patient survival on CRRT
 - with ESRD, *see* Patient survival with ESRD
 - twenty-one year, with systemic AL-amyloidosis, 278-282
 - see also* Outcome and specific conditions
- Patient survival with ARF, 319
 - of pediatric patients on CRRT, S3:29
- Patient survival on CRRT
 - biocompatibility and, S3:63-64
 - and CRRT as bridge to liver transplantation, S3:65
 - extracorporeal anticoagulation and, S3:64-65
 - with HC-CVVH for MODS with septic shock, S3:54
 - of pediatric ARF patients, S3:29
 - replacement fluid and, S3:65
 - with slow isolated UF for CHF, S3:69-70
 - with spontaneous versus pumped CRRT, S3:62-63
- Patient survival with ESRD
 - on chronic dialysis, impact of initial laboratory data on, 541-548
 - with PKT, 871
 - with TBP, 749
 - see also* Long-term survival of ESRD patients; Patient survival with ESRD, HD and; Patient survival with ESRD, USRDS 1996 ADR on
- Patient survival with ESRD, HD and

- and hypertension, 737-740
- see also Hemodialysis for ESRD, race and survival with
- Patient survival with ESRD, USRDS 1996 ADR on, S2:17
- analysis of, S2:161-162
- with dialysis, S2:162
- international, S2:148-151
- long-term, S2:85-86
- with RT, S2:104-105, S2:162
- PD, see Peritoneal dialysis
- PDGF, see Platelet-derived growth factor; Platelet-derived growth factor receptor- β
- Pearsons's marrow-pancreas syndrome, deletions in mtDNA and, 143
- Pediatric acute renal failure (ARF), CRRT of, S3:28-34
- Pediatric end-stage renal disease (ESRD), USRDS 1996 ADR on
 - causes of death with, S2:101
 - growth and development with, S2:28
- Pentoxifylline for CyA-associated TMA/HUS in renal and renal-pancreas transplantation, 561-571
- Peptides, see Natriuretic peptides; Uroguanylin and specific peptides
- Percutaneous renal artery stent placement for RVH and azotemia, 214-220
- Percutaneous renal biopsy, timing complications of, 47-52
- Percutaneous transluminal renal angioplasty (PTRA) for HTN and azotemia, percutaneous renal artery stent placement compared with, 214-220
- Periarticular calcification in long-term HD patients, 921
- Period prevalence
 - defined, S2:35
 - see also Incidence (and prevalence) of treated ESRD, USRDS 1996 ADR on
- Periodic paralysis, thyrotoxic, associated with hyperthyroid-related hypokalemia and hypophosphatemia, 270-273
- Peripheral blood monocytes of IgA nephropathy patients, increased expression of MMP-9 mRNA in, 32-39
- Peritoneal dialysis (PD)
 - risk factors for, and prevalence of osteopenia in, 515-522
 - see also Continuous ambulatory peritoneal dialysis; Peritoneal dialysis for ESRD; Peritonitis
- Peritoneal dialysis (PD) for ESRD
 - impact of anemia on cardiomyopathy, cardiac disease, and mortality in, 53-61
 - race and survival with, compared with survival on HD and with RT, 72-81
 - in 21st century, 951-957
 - see also Peritoneal dialysis for ESRD, long-term; Peritoneal dialysis for ESRD, USRDS 1996 ADR on
- Peritoneal dialysis (PD) for ESRD, long-term
 - enrollment PTH and survival with, 924-930
 - prealbumin values and survival with, 937-942
 - predictive value of albumin, creatinine, cholesterol, and hematocrit for patients on, 910-917
- Peritoneal dialysis (PD) for ESRD, USRDS 1996 ADR on, S2:49
 - causes of death with, S2:97-99
- Peritoneovenous shunts (PVSs), hemodynamic effects of, in HD patients with ascites, 387-394
- Peritonitis
 - fungal, on chronic PD, 86-91
 - see also Peritonitis on CAPD
- Peritonitis on CAPD, 415-436
 - Candida* peritonitis, prevention of, with oral nystatin, 549-552
 - due to catheter exit site infections, see Exit site infections, catheter, on CAPD, peritonitis due to
 - due to tunnel infections, 415-419
 - long-term outcome and optimal therapy of tuberculous, 747-751
 - massive acute gentamicin intoxication and, 767-771
 - risk factors for, on long-term CAPD, 428-436
 - sclerosing encapsulating, 420-427
 - USRDS 1996 ADR study of, S2:28
- PF4 (platelet factor 4)-heparin complex antibody (Ab) in diagnosis of HIT in HD patients, 82-85
- PGs, see Prostaglandins, inhibition of synthesis of
- pH
 - arterial and urinary, in metabolic alkalosis with ectopic ACTH syndrome, 611
 - arterialized, in acidosis of CRF patients, 351
 - blood, HCO_3 effects on, in hyperkalemic patients on HD, 511
- Phaeohyphomycosis, subcutaneous, in RT, 137-139
- Pharmacokinetics
 - of colchicine, 655
 - of corticosteroids, 637
 - of midodrine, 132-136
 - of OKT3, 652
- Pharmacology of immunosuppressants, see Immunopharmacology of immunosuppressant(s)
- Phenacetin
 - with aspirin, effects of, S1:30
 - in CRF, APAP compared with, S1:10-12
 - RPN and, S1:34
 - see also Analgesic nephropathy; Combination analgesic nephropathy
- Phenotype-genotype correlations in Von-Hippel disease and MEN 2A, 332
- Pheochromocytoma, monogenetic hypertension and, 329-333
- Phialophora parasitica* (*P. parasitica*), subcutaneous phaeohyphomycosis due to, in RT recipients, 137-139
- Phosphate
 - effects of CyA-associated TMA/HUS on, 564, 565
 - hyperthyroid-related hypokalemia and hypophosphatemia, thyrotoxic periodic paralysis associated with, 270-273
 - serum, see Serum phosphate
- Phosphorus, see P
- Physiological flow conditions, CyA effects on leukocyte adhesion to vascular endothelium under, 23-31
- Physiological microalbuminuria, glycated albumin accumulation in ESRD as evidence of, 62-66
- PIH (pregnancy-induced hypertension), therapeutic uses of aspirin in, S1:20-23
- Piroxicam, see Nonrenal toxicity of APAP, ASA, and NSAIDs
- PKD3 gene, ADPKD linked to, but not to PKD1 and PKD2, 759-761
- PKT, see Pancreas-kidney transplantation
- Plasma angiotensin II (AII)
 - AA effects on, 115-123
 - ramipril effects on, 837

- Plasma Cl (chloride) in familial fibrillary GN with giant fibrillar deposits, 671
- Plasma creatinine in familial fibrillary GN with giant fibrillar deposits, 671
- Plasma flow, renal, ramipril effects on, 837
- Plasma K (potassium)
in familial fibrillary GN with giant fibrillar deposits, 671
HCO₃ effects on, in ESRD patients on HD, insulin and albuterol effects compared with, 508-514
- Plasma Na (sodium) in familial fibrillary GN with giant fibrillar deposits, 671
- Plasma renin in metabolic alkalosis with ectopic ACTH syndrome, 611
- Plasma urea, concentrations of brain-to-, postdialytic disequilibrium syndrome and, 2-8
- Plasmacytoma, intramedullary, in RT recipients, immunosuppression and, 904-906
- Platelet-activating factor (PAF), role of, in CyA-induced adhesion of leukocytes to vascular endothelium under physiological flow conditions, 27
- Platelet aggregation, aspirin effects on, S1:20-23
- Platelet count
dialysis dose and, and ARF outcome, S3:83
effects of CyA-associated TMA/HUS on, 564
rHuEPO effects on, 402
- Platelet-derived growth factor (PDGF), transcription of, in chronic renal rejection, 441-450
- Platelet-derived growth factor (PDGF) receptor- β in chronic renal rejection, 444-445
- Platelet factor 4 (PF4)-heparin complex antibody (Ab) in diagnosis of HIT in HD patients, 82-85
- Pleural effusion secondary to CAPD of ESRD, video-assisted talc pleurodesis of, 772-774
- Pleurodesis, video-assisted talc, of pleural effusion secondary to CAPD of ESRD, 772-774
- PMR (polymyalgia rheumatica), microscopic polyarteritis during remission of, renal biopsy of, 289-291
- Point mutations in mitochondrial genes, 142-143
encoding proteins of respiratory chain, 142
in mitochondrial tRNA genes, 142-143
- Point prevalence
defined, S2:35
see also Incidence (and prevalence) of treated ESRD, USRDS 1996 ADR on
- Polyacrylonitrile triacetate (PAN) membranes modulating TGF- β monocyte production in long-term HD, 395-399
- Polyamines, L-arginine as precursor of, 878-887
- Polyarteritis, microscopic, during PMR remission, renal biopsy of, 289-291
- Polyclonal antibodies (Abs)
immunopharmacology of, 654-655
against lipid A and R-core, S3:41
- Polycystic disease, *see* Autosomal dominant polycystic kidney disease
- Polymyalgia rheumatica (PMR), microscopic polyarteritis during remission of, renal biopsy of, 289-291
- Polysaccharide chain, *see* O-polysaccharide chain in sepsis
- Polytetrafluoroethylene graft (PTFE) in HD, complications of, inpatient and outpatient care of, 250-256
- Postdialytic disequilibrium syndrome, *see* Disequilibrium syndrome, postdialytic
- Postdilution in CRRT, defined, S3:6
- Posthemodialysis (HD) fatigue, 732-736
- Posthemodialysis (HD) urea rebound, extreme, screening for, with Smye method, 727-736
- Posttransplant lymphoproliferative disease (PTLD), EBV-associated, severe acute rejection compared with, using Banff schema, 578-584
- Potassium, *see* K
- Practice variations in CCRT of ARF, outcome and, S3:78
- Prealbumin values, and ESRD survival on long-term HD and/or PD, 937-942
- Predialysis body weight of CRF patients, 842
- Predilution in CRRT, defined, S3:6
- Prednisone for renal failure due to HIVAN, 618-621
- Pregnancy
outcome of five-year posttransplant, in CsA-treated patients, 266-269
rapidly reversible ARF due to ureteral obstruction in, 457-460
see also Pregnancy, hypertension in
- Pregnancy, hypertension in
microalbuminuria as predictor of, 220-225
outcome of five-year posttransplant pregnancy in pre-pregnancy hypertensive patients treated with CsA, 267
therapeutic uses of aspirin in, S1:20-23
- Pre-hemodialysis (pre-HD) body temperature, protective effects of cool HD dialysate dependent on, 262-265
- Preliminary trials with intestinal dialysis, 944-945
- Premature discontinuation of dialysis in ESRD with restless legs syndrome, 373-376
- Prematurity in five-year posttransplant pregnancy in CsA-treated patients, 267
- Premorbid renal function in ARF, CRRT and, S3:109
- Prepregnancy diabetes mellitus (DM), and outcome of five-year posttransplant pregnancy in CyA-treated patients, 266-269
- Prescription
of CRRT for pediatric ARF, S3:25-26
of HD and/or CAPD for ESRD, USRDS 1996 ADR on, S2:55-56
- Preservation, kidney, for RT, uses of aspirin in, S1:20-23
- Pretransplantation conditions and interventions, *see* Renal transplantation
- Prevalence
of HCV in idiopathic GN in native and transplanted kidneys, 752-758
of hypertension in chronic renal diseases, diet modification and, 811-821
of osteopenia in HD and PD patients, risk factors and, 515-522
of treated ESRD, USRDS 1996 ADR, *see* Incidence (and prevalence) of treated ESRD, USRDS 1996 ADR on
see also Incidence and specific conditions
- Prevention
of *Candida* peritonitis on CAPD with oral nystatin, 549-552
and prophylactic use of CRRT in patients with normal renal function, S3:114-120
renal protection with future CRRT technologies as, S3:125-127
routine preventive primary care provided by nephrologists to ESRD patients on chronic dialysis, 69

- of urolithiasis, implication of dietary and behavioral risk factors for, 195-201
- Previous renal transplantation (RT), S2:159
- Primary care providers, nephrologists as, for ESRD patients on chronic dialysis, 67-72
- Primary renal disease
 - in chronic renal diseases, hypertension and, 813, 814
 - in CRF, 842
 - in ESRD, *see* Primary renal disease in ESRD
 - in HD patients, fatigue and, 733
 - and HIT on HD, 83, 84
 - in long-term HD patients, 919, 932
 - in nephrosis, 355
 - SEP on CAPD and, 422-423
 - see also specific conditions*
- Primary renal disease in ESRD, 243
 - and fungal peritonitis on CPD, 87
 - hypertension and, 738
 - impact of anemia and, 55, 56
 - in patients on PD, HD, and with RT, race and survival and, 74, 75
 - and rHuEPO administration routes in anemic patients, 401
 - see also* Primary renal disease in ESRD, USRDS 1996 ADR on *and specific conditions*
- Primary renal disease in ESRD, USRDS 1996 ADR on, S2:41-47
 - mortality and, S2:84
 - prevalence and incidence of treated ESRD by, S2:37, S2:41-47
- Product(s) of USRDS, S2:21-33
 - core Standard Analysis Files on CD-ROM as, S2:27-30; *see also specific Standard Analysis Files*
 - data as, *see* Data, USRDS
 - database as, S2:23-24
 - on Internet World Wide Web, S2:25
 - new, S2:21
 - SMR and SHR reports as, S2:25-26; *see also* Standard Hospitalization Ratio, USRDS 1996 ADR on; Standardized Mortality Ratio, USRDS 1996 ADR on
- Profit status of ESRD care facilities, SHR by, S2:123-125
- Progression of IgA nephropathy
 - increased MMP-9 mRNA expression in peripheral blood monocytes and, 32-39
 - SOD activity and, 18-19
- Progression of renal disease
 - of ADPKD, modification in, 799-800
 - of mesangial proliferative GN, SOD activity and, 18-19
 - see also* Progression of IgA nephropathy; Progressive nephropathy *and specific conditions*
- Progressive external ophthalmoplegia, chronic, 143
- Progressive nephropathy, chronic, ACEI effects on 822-831
- Progressive renal failure, rapidly, extracapillary GN and, 695-699
- Project goals, USRDS, S2:21
- Proliferative glomerulonephritis (GN), mesangial, superoxide dismutase activity in, 14-22
- L-Proline, polyamines and, in immune-mediated GN, 878-887
- Prophylactic use of CRRT in patients with normal renal function, S3:114-120
- Prostaglandins (PGs), inhibition of synthesis of
 - by aspirin, S1:20-23
 - by NSAIDs, S1:56-57
 - and RPN, S1:34-38
- Protein(s)
 - Bence-Jones, and twenty-one year survival with systemic AL-amyloidosis, 279
 - cell-surface, anti-T cell and other Abs directed at, in clinical immunosuppressive regimen, 167-168
 - C-reactive, in Wegener's granulomatosis, 188
 - initial total, and survival on chronic dialysis, 542, 543
 - membrane cofactor, role of, in C4R-, leukocyte function-associated antigen-1 α -, and ICAM-1-mediated glomerular immune cell infiltration and activation in IgA nephropathy, 40-46
 - of respiratory chains, point mutations in mitochondrial genes encoding, 142
 - serum, and atherosclerotic lesions in carotid vessels of HD patients, 715
 - small solute clearance effects on intake of, in CAPD patients, 553-560
 - urinary excretion of, *see* Proteinuria; Urinary excretion, protein
 - see also* Dietary protein intake; Normalized protein catabolic rate
- Protein catabolic rate, *see* Normalized protein catabolic rate
- Proteinuria
 - in chronic progressive nephropathy, ACEI effects on, 822-831
 - in GN, *see* Proteinuria in GN
 - in nephrosis, 354-364
 - nephrotic-range, *see* Nephrotic-range proteinuria
 - in NS, rHuEPO effects on, 274-277
 - ramipril effects on protein excretion and BP in normotensive nondiabetic patients with, 832-840
 - renal function and, in Navajo Indians, 343
 - in Wegener's granulomatosis, 188
 - see also* Albuminuria; Microalbuminuria; Urinary excretion, protein
- Proteinuria in GN
 - in familial fibrillary GN with giant fibrillar deposits, 671
 - in idiopathic GN, 753
- Proto-oncogene, *RET*, germline mutation of, associated with pheochromocytoma, 329-332
- Providers of ESRD care, *see* Facilities for ESRD care, USRDS 1996 ADR on
- Proximal calciphylaxis in HD patients with IDDM, 409-414
- Proximal tubular reabsorption, AA effects on, 115-123
- Pseudolymphoma, renal, ARF due to, Sjögren's syndrome with, 762-766
- PTFE (polytetrafluoroethylene graft) in HD, complications of, inpatient and outpatient care of, 250-256
- PTH, *see* Parathyroid hormone
- PTLD (posttransplant lymphoproliferative disease), EBV-associated, severe acute rejection compared with, using Banff schema, 578-584
- PTRA (percutaneous transluminal renal angioplasty) for HTN and azotemia, percutaneous renal artery stent placement compared with, 214-220
- PTX, *see* Parathyroidectomy
- Pulmonary hemorrhages, and WG followed by sarcoidosis, 893-898

- Pumped continuous replacement therapy (CRRT), spontaneous versus, S3:62-63
- Purification, inadequate blood, CRRT and, S3:103
- Purpura
 Henoch-Schönlein, recurrence of, following RT with CyA immunosuppression, 99-104
 thrombotic thrombocytopenic, CyA-associated TMA HUS and, 561-571
- PVSS (peritoneovenous shunts), hemodynamic effects of, in HD patients with ascites, 387-394
- Race code in USRDS 1996 ADR, S2:14, S2:152-153, S2:157
- Race and ethnicity
 of chronic renal disease patients, hypertension and, 813, 814, 818
 of ESRD patients, *see* Race and ethnicity of ESRD patients
 of FSGS-like IgA nephropathy patients, 368
 of HIVAN patients, 204
 of PKT recipients, 870
 of renal AED patients, 494
 renal function and NIDDM in adult Navajo Indians, 339-349
 of renovascular fibromuscular disease patients, 335
 as risk factor for peritonitis on long-term CAPD, 428-436
 socioeconomics and, and withdrawal from CsA therapy by RT recipients, 572-577
 and urolithiasis, 197, 198
- Race and ethnicity of ESRD patients
 and dialysis-refractory hypertension, 258
 on HD, *see* Race and ethnicity of ESRD patients on HD
 insurance status and, and rHuEPO therapy of anemia of ESRD, 239, 242, 243, 245
 and intravenous FeD therapy, 530
 on PD and/or with RT, survival and, 75, 77
 with thyrotoxic periodic paralysis, 270-273
 see also Race and ethnicity of ESRD patients, USRDS 1996 ADR on
- Race and ethnicity of ESRD patients, USRDS 1996 ADR on, S2:15
 expected remaining years of life by, S2:89-90
 modality utilization by, S2:53-55
 mortality by, S2:82-84, S2:95, S2:96
 of patients registered in USRDS, S2:40-43
 of treated patients, S2:37
- Race and ethnicity of ESRD patients on HD
 and HD access complications, 251, 253
 hypertension and, 738
 see also Hemodialysis for ESRD, race and survival with;
 Race and ethnicity of ESRD patients on long-term HD and/or CAPD
- Race and ethnicity of ESRD patients on long-term HD and/or CAPD
 cardiovascular disease and, 932
 or PD, for up to 30 years, 911, 913
 prealbumin level and, 938
 as risk for peritonitis, 428-436
- Race and ethnicity of HD patients
 fatigue and, 733
 risk of mortality and, 742, 744
 see also Race and ethnicity of ESRD patients on HD
- Ragged-red fibers, myoclonic epilepsy with, point mutations in mitochondrial tRNA genes and, 142
- Ramipril, effects of, on blood pressure and protein excretion in normotensive nondiabetic patients with proteinuria, 832-840
- Ramiprilat, effects of, on urinary bladder response to angiotensin I, 603-609
- Rapamycin (sirolimus)
 cellular and molecular mechanisms of, 163-165
 immunopharmacology of, 652
- Rapidly progressive renal failure, extracapillary GN and, 695-699
- Rapidly reversible acute renal failure (ARF) due to ureteral obstruction in pregnancy, 457-460
- RAS, *see* Renal artery stenosis, RVH with
- RBF (renal blood flow), redistribution of, and RPN, S1:34-38
- RCC (Renal Community Council), USRDS, S2:7, S2:22
- R-core (ketodeoxyoctonate) in sepsis, S3:36
 polyclonal antibodies against, S3:41
- Reactive metabolites of APAP, S1:3-4
- Readmissions to hospital, early, after PKT, 867-875
- Recirculation, and extreme posthemodialysis urea rebound, 727-736
- Recombinant human erythropoietin (rHuEPO; rEPO) for anemia
 of ESRD, *see* Recombinant human erythropoietin for anemia of ESRD patients on HD
 of NS, 274-277
- Recombinant human erythropoietin (rHuEPO; rEPO) for anemia of ESRD patients on HD
 ACEI effects on, 535-540
 effects of insurance status on, 235-249
 SC and IV routes of administration of, 400-408
 see also Recombinant human erythropoietin for anemia of ESRD patients on HD, USRDS 1996 ADR on
- Recombinant human erythropoietin (rHuEPO; rEPO) for anemia of ESRD patients on HD, USRDS 1996 ADR on, S2:56
 in DMMS, S2:73-78
- Recombinant immunoblot assays in HCV RNA detection in renal transplant recipients, 437-440
- Recommended procedures for withdrawal of dialysis, 150-151
- Recurrent cyclosporine (CsA) nephropathy in heart transplant recipients, 466-468
- Recurrent IgA (immunoglobulin A) nephropathy following RT with CyA immunosuppression, 99-104
- Recurrent intradialytic hypotension, midodrine for, efficacy and pharmacokinetics of, 132-136
- Refractory hypertension in ESRD, dialysis-, role of volume overload in, 257-261
- Regimens, clinical immunosuppressive, 167-168
- Regional Standard Hospitalization Ratio (SHR), USRDS 1996 ADR on, S2:120-122
- Reimbursements, *see* Insurance status
- Rejection, graft
 PKT, readmissions for, 861-867
 renal graft, *see* Renal graft rejection
- Release of USRDS data, policy on, USRDS 1996 ADR on, S2:30-33

- Remaining years of life of ESRD patients, expected, USRDS 1996 ADR on, S2:89-90, S2:162
- Remission of PMR, renal biopsy of microscopic polyarteritis during, 289-291
- Renal amyloidosis, extracapillary GN and, 695-699
- Renal angioplasty, percutaneous transluminal, for HTN and azotemia, percutaneous renal artery stent placement compared with, 214-220
- Renal artery stenosis (RAS), RVH with, 209-220
and azotemia, PTAA and percutaneous renal artery stent placement for, compared, 214-220
bilateral, 209-213
- Renal artery stent placement, percutaneous, for RVH and azotemia, PTAA compared with, 214-220
- Renal atheroembolic disease (AED), nephrotic-range proteinuria in, 493-501
- Renal biopsy, 289-295
of allograft in CyA-associated TMA/HUS, 566, 567
Banff borderline, significance of, 585-588
of fibrillary GN, 677-678
of IgA nephropathy, 45
of microscopic polyarteritis during PMR remission, 289-291
percutaneous, timing complications of, 47-52
of renal graft, with and without recurrent IgA nephropathy, 101, 102
of SLE with HIV infection, 292-295
see also Histology
- Renal blood flow (RBF), redistribution of, and RPN, S1:34-38
- Renal calcitriol, *see* Calcitriol
- Renal cell carcinoma, and familial fibrillary GN with giant fibrillar deposits, 668-675
- Renal colic due to combination analgesics, clinical features of, S1:40
- Renal Community Council (RCC), USRDS, S2:7, S2:22
- Renal Cu,Zn-SOD (copper,zinc superoxide dismutase), 16
- Renal diseases
mtDNA mutations and, 143-144
see also Molecular therapy of renal diseases and specific types of renal diseases
- Renal excretion
of analgesics, S1:41-42
see also Urinary excretion
- Renal failure
due to HIVAN, prednisone for, 618-621
due to methotrexate, 846-854
rapidly progressive, extracapillary GN and, 695-699
see also Acute renal failure; Chronic renal failure; End-stage renal disease
- Renal function
in adult Navajo Indians, NIDDM and, 339-349
contrast media ARF due to IV urography in patients with impaired, 454-456
CRRT and, *see* Renal function, CRRT and
effects of slow isolated UF for CHF on, S3:70
and hypertension in chronic renal disease, 815-816
survival of, in HIVAN with captopril therapy, 202-208
tubular, in chronic progressive nephropathy, ACEI effects on 822-831
see also specific aspects of renal function; for example: Glomerular filtration rate
- Renal function, CRRT and
and premonitory renal function in ARF, S3:109
prophylactic use of CRRT in patients with normal, S3:114-120
- Renal graft loss
with cadaveric RT, USRDS 1996 ADR on, S2:106-108
see also Renal graft rejection
- Renal graft rejection
acute, *see* Acute rejection, renal graft
chronic, GF mRNA in, 441-450
and five-year posttransplant pregnancy outcome in CyA-treated patients, 267
pretransplantation assessment of risk of, with ELISA of anti-HLA class I antibodies, 92-98
- Renal graft survival, USRDS 1996 ADR on, S2:105-108, S2:120-122
with cadaveric and living related transplantations, S2:106
- Renal hemodynamics, effects of ramipril on, 836, 837
- Renal insufficiency
chronic, capillary electrophoresis using nonradioactive io-hexol to measure GFR in, 173-177
oral sorbents in, intestinal dialysis and, 946-947
- Renal-pancreas transplantation, CyA-associated TMA/HUS in, 561-571
- Renal papillary necrosis (RPN), analgesic-induced
by ASA alone, S1:20-23
by ASA with APAP, S1:30
by combined analgesics, S1:30, S1:49
pathophysiology of, S1:34-38
- Renal plasma flow, ramipril effects on, 837
- Renal protection with future CRRT technologies, S3:125-127
- Renal pseudolymphoma, ARF due to, Sjögren's syndrome with, 762-766
- Renal replacement therapy (RRT)
of familial fibrillary GN with giant fibrillar deposits, 671
see also Continuous ambulatory peritoneal dialysis; Continuous renal replacement therapy; Hemodialysis; Intestinal dialysis, as substitute therapy in ESRD; Peritoneal dialysis; Renal replacement therapy modality(ies) for ESRD, USRDS 1996 ADR on; Renal transplantation and entries beginning with term: Dialysis
- Renal replacement therapy (RRT) modality(ies) for ESRD, USRDS 1996 ADR on, S2:48-57
alternative, S2:19, S2:135-140
analysis of, S2:163
data on modality analyses, S2:49
EPO and, S2:56; *see also* Recombinant human erythropoietin for anemia of ESRD patients on HD, USRDS 1996 ADR on
modality utilization by age, sex, and race, S2:53-55
mortality by, S2:82-84, S2:95, S2:96
options in, 48-49; *see also* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1996 ADR on; Dialysis modalities for ESRD, USRDS 1996 ADR on; Hemodialysis for ESRD, USRDS 1996 ADR on; Renal transplantation for ESRD, USRDS 1996 ADR on
trends in modality utilization, S2:49-53
see also Facilities for ESRD care, USRDS 1996 ADR on; International renal replacement therapy modality(ies) for ESRD, compared, USRDS 1996 ADR on; Treated end-stage renal disease, USRDS 1996 ADR on

- Renal scintigraphy, captopril, in RVH diagnosis, 209-213
- Renal tissue angiotensin II (AII), AA effects on, 115-123
- Renal tissue injury
 due to superoxide dismutase activity in IgA nephropathy and MPGN, 18
 see also specific conditions
- Renal transplantation (RT)
 cadaveric, *see* Cadaveric renal transplantation
 CyA in, *see* Cyclosporine in RT
 for ESRD, race and survival with, compared with survival on HD, PD and, 72-81
 HCV in, *see* Renal transplantation, HCV in
 and immunobiology of antiallograft response, 159-161; *see also* Renal graft rejection
 immunosuppression in, *see* Immunosuppression
 intramedullary plasmacytoma in recipients of, immunosuppression and, 904-906
 long-term bone loss in recipients of, 105-113
 as risk factor for osteopenia, 515-522
 salvage of renal graft with renal vein occlusion secondary to extrinsic compression, 622-623
 subcutaneous phaeohyphomycosis in, 137-139
 see also Pancreas-kidney transplantation and *entries beginning with terms*: Renal graft
- Renal transplantation (RT), HCV in
 HCV RNA detection in, with third-generation assays, 437-440
 prevalence of HCV in native kidneys and, in idiopathic GN, 752-758
- Renal transplantation (RT) for ESRD, USRDS 1996 ADR on, S2:48-49, S2:103-114
 access to, S2:18, S2:110-111
 annual death rate with, S2:159-161
 causes of death with, S2:99
 and HLA matching, S2:108
 international, S2:147-148
 kidney supply for, S2:108-110
 patient survival with, S2:104-105, S2:162
 renal graft survival in, *see* Renal graft survival, USRDS 1996 ADR on
 statistical analysis of, S2:104
- Renal tubules, *see entries beginning with term*: Tubular and *element*: Tubulo-
- Renal vasoconstriction due to IV urography, 454-456
- Renal vein occlusion secondary to extrinsic compression, renal graft salvage with, 622-623
- Renin, plasma, in metabolic alkalosis with ectopic ACTH syndrome, 611
- Renin-angiotensin system
 CsA effects on, 643-644
 urinary bladder, 603-609
- Renovascular fibromuscular disease, predictors of cure of hypertension in, 334-338
- Renovascular hypertension (RVH)
 aspirin effects in, S1:20-23
 CRS in diagnosis of, 209-213
 in RAS, *see* Renal artery stenosis, RVH with
 in renovascular fibromuscular disease, predictors of cure of, 334-338
- Replacement fluid/dialysate anion in CRRT, S3:15-20
 acetate-based fluids, S3:15-16
 citrate anticoagulated hemofiltration or diafiltration, S3:18-19
 HCO₃-based fluids, S3:16-17
 of hepatic and acute renal failure, S3:65
 lactate-based fluids, S3:17-18
- rEPO, *see* Recombinant human erythropoietin for anemia
- Research, investigator initiated, USRDS policy on data release for, S2:30-32
- Residence Standard Analysis File (SAF), described, S2:26
- Resource cost per patient for direct ESRD care, USRDS 1996 ADR on, S2:133-134
- Respiratory chain, point mutations in mitochondrial genes encoding, 142
- Restless legs syndrome (RLS) in ESRD, 372-378
- RET proto-oncogene, germline mutation of, monogenetic hypertension and, 329-332
- Reticulocyte(s), rHuEPO effects on, 402
- Reticulocyte count, and ACEI effects on rHuEPO therapy of ESRD, 538
- Retroviral vectors, gene delivery with, 478-479
- Reuse of dialyzers in DMMS, S2:66-68
- Revascularization, RVH response to, 211
- "Reverse urea hypothesis" of disequilibrium syndrome, 2-6
- Reversible acute renal failure (ARF), rapidly, due to ureteral obstruction in pregnancy, 457-460
- rHuEPO, *see* Recombinant human erythropoietin for anemia
- Ribonucleic acid, *see* RNA
- Ribozymes, molecular therapy with, 484-486
- Risk and risk factors
 associated with phenacetin and APAP, compared, S1:11-12
 behavioral and dietary, for urolithiasis, implications of, for prevention, 195-201
 for cardiovascular disease in long-term ESRD survivors, 934
 for hypertension in chronic renal diseases, 811-821
 of mortality on HD, 741-746
 for peritonitis on long-term CAPD, 428-436
 precipitating thyrotoxic periodic paralysis hypokalemia, 271
 prevalence and, for osteopenia in HD and PD patients, 515-522
 for rejection, pretransplantation assessment of, with ELISA anti-HLA class I antibodies, 92-98
 for renal AED, 494
 see also specific risk factors
- RLS (restless legs syndrome) in ESRD, 372-378
- RNA (ribonucleic acid)
 HCV, in renal transplant recipients, detection of, with third-generation assays, 437-440
 point mutations tRNA genes, 142-143
 see also mRNA expression
- Routine preventive primary care of ESRD patients on chronic dialysis, nephrologists providing, 69
- RPN, *see* Renal papillary necrosis, analgesic-induced
- RRT, *see* Renal replacement therapy
- RS-61443, *see* Mycophenolate mofetil
- RT, *see* Renal transplantation
- Ruptures, spontaneous tendon, in long-term HD and CAPD patients, 861-866
- RVH, *see* Renovascular hypertension

- SACs (Scientific Advisory Committees), USRDS, S2:22
- Safety
- of intravenous FeD, *see* Intravenous iron dextran for anemic ESRD patients on HD, adverse effects of
 - of ramipril, 835
- SAFs, *see* Standard Analysis Files, USRDS
- Sales of analgesics, relationship between AN and, S1:53
- Salicylic acid, *see* Aspirin
- Salt, *see* NaCl
- SAR (severe acute rejection), EBV-associated PTLT compared with, using Banff schema, 578-584
- Sarcoidosis following WG, 893-898
- SC (subcutaneous) administration of rHuEPO to anemic ESRD patients on ESRD, 400-408
- SC (subcutaneous) phaeophycomycosis in RT, 137-139
- Scientific Advisory Committees (SACs), USRDS, S2:22
- Scintigraphy, captopril renal, in RVH diagnosis, 209-213
- Sclerosing encapsulating peritonitis (SEP) on CAPD, 420-427
- SCUF (slow continuous ultrafiltration), defined, S3:3
- Secondary amenorrhea, as risk factor for osteopenia, 515-522
- Secondary hyperparathyroidism
- long-term effects of IV calcitriol on, 704-712
 - P effects on development of parathyroid hyperplasia and, in CRF, 596-602
 - parathyromatosis with, in ESRD, 502-507
 - patient, for anticoagulant therapy on CRRT, S3:10-11
- Seminars on dialysis, withdrawal of dialysis and, 151
- SEP (sclerosing encapsulating peritonitis) on CAPD, 420-427
- Sepsis, *see* Infections; Inflammatory mediators in sepsis; O-polysaccharide chain in sepsis; R-core in sepsis; Sepsis, CRRT and *and specific infections*
- Sepsis, CRRT and
- as CRRT complication, S3:102
 - CRRT effects on hemodynamics, S3:125
 - see also* Multiorgan dysfunction syndrome, septic shock and, CRRT for
- Serum adrenocorticotrophic hormone (ACTH) in metabolic alkalosis with ectopic ACTH syndrome, 611
- Serum albumin
- initial, and survival on chronic dialysis, 542-546
 - and mortality risk on HD, 741-746
 - in nephrosis, 354-364
 - in renal AED patients, 494
 - and UF for ascites, 902
 - see also* Serum albumin in ESRD
- Serum albumin in ESRD
- and impact of anemia on ESRD, 55, 56
 - race and survival and, in ESRD patients on PD, HD, and with RT, 75, 77
- Serum aldosterone in metabolic alkalosis with ectopic ACTH syndrome, 611
- Serum alkaline phosphatase (ALP), and bone loss as long-term effect of RT, 107
- Serum BUN (blood urea nitrogen), and UF for ascites, 902
- Serum Ca (calcium)
- and bone loss as long-term effect of RT, 107
 - initial, and survival on chronic dialysis, 542, 543
 - in metabolic alkalosis with ectopic ACTH syndrome, 611
 - and parathyroid hyperplasia, 601
- Serum cholesterol in nephrosis, 354-364
- Serum Cl (chloride) in metabolic alkalosis with ectopic ACTH syndrome, 611
- Serum cortisol in metabolic alkalosis with ectopic ACTH syndrome, 611
- Serum creatinine (Cr)
- and bone loss as long-term effect of RT, 107, 110
 - in chronic renal disease patients with and without hypertension and, 816
 - dialysis dose and, and ARF outcome, S3:83
 - in FSGS-like IgA nephropathy, 368
 - in HD patients, protective effects of cool dialysate and, 264
 - in idiopathic GN, 753
 - initial, and survival on chronic dialysis, 542, 543
 - and mortality risk on HD, 741-746
 - in MPGN type I, 687
 - and outcome of five-year posttransplant pregnancy in CyA-treated patients, 267
 - in PKT recipients, 869
 - and recurrent IgA nephropathy following RT, 102
 - and UF for ascites, 902
 - in Wegener's granulomatosis, 188
- Serum dehydroepiandrosteredione in metabolic alkalosis with ectopic ACTH syndrome, 611
- Serum folate, rHuEPO effects on, 402
- Serum glucose in metabolic alkalosis with ectopic ACTH syndrome, 611
- Serum Ig (immunoglobulin)-fibronectin complexes, fibrillar, fibrillary GN related to, 676-684
- Serum iron (Fe)
- IV iron dextran effects on, 858
 - rHuEPO effects on, 402
- Serum K (potassium)
- initial, and survival on chronic dialysis, 542-546
 - in metabolic alkalosis with ectopic ACTH syndrome, 611
- Serum Mg (magnesium) in metabolic alkalosis with ectopic ACTH syndrome, 611
- Serum Na (sodium)
- initial, and survival on chronic dialysis, 542-546
 - in metabolic alkalosis with ectopic ACTH syndrome, 611
- Serum 1,25-(OH)₂D₃ (calcitriol), and parathyroid hyperplasia, 601
- Serum P (phosphorus)
- and bone loss as long-term effect of RT, 107
 - and parathyroid hyperplasia, 601
 - synthesis of renal calcitriol and response of, to dietary P restriction, GH or insulin effects on, 589-595
- Serum paraprotein, and twenty-one year survival with systemic AL-amyloidosis, 279
- Serum phosphate
- initial, and survival on chronic dialysis, 542, 543
 - IV calcitriol effects on, 709
- Serum proteins, and atherosclerotic lesions in carotid vessels of HD patients, 715
- Serum transferrin in nephrosis, 354
- Serum urea nitrogen (SUN)
- in HD patients, protective effects of cool dialysate and, 264
 - IHD versus CRRT effects on, S3:23

- in nephrosis, 354
- Service date, first, errors in, S2:153
- Set point for Ca, and long-term effects of IV calcitriol on secondary hyperparathyroidism, 704-712
- Severe acute rejection (SAR), EBV-associated PTLD compared with, using Banff schema, 578-584
- Severity score of ARF, dialysis dose and ARF outcome, S3:81-89
- Sex
 - of ARF patients, *see* Sex of ARF patients on CRRT
 - of chronic renal disease patients, hypertension and, 813-815, 818
 - of FSGS-like IgA nephropathy patients, 368
 - of HD and/or CAPD patients, *see* Sex of HD and/or CAPD patients
 - of HIVAN patients, 204
 - of methotrexate patients, 849
 - of nephrotic patients, 355
 - of percutaneous renal biopsy patients, complications and, 48, 49
 - of PKT recipients, 870
 - of renal AED patients, 494
 - renal function and, in NIDDM Navajo Indians, 342, 343
 - of renovascular fibromuscular disease patients, 335
 - of RT recipients, *see* Sex of RT recipients
 - of RVH patients, 215, 216
 - see also specific conditions*
- Sex of ARF patients on CRRT
 - dialysis dose and outcome of ARF and, S3:83
 - of pediatric ARF patients, S3:29
- Sex of ESRD patients
 - on CPD with fungal peritonitis, 87
 - see also* Sex of ESRD patients, USRDS 1996 ADR on; Sex of ESRD patients on HD and/or CAPD
- Sex of ESRD patients, USRDS 1996 ADR on, S2:15
 - modality utilization by age and, S2:53-55
 - mortality by, S2:84, S2:95, S2:96
 - registered in USRDS, 41-43
 - remaining years of life by, S2:89-90
 - of treated patients, S2:37
- Sex of ESRD patients on HD and/or CAPD
 - anemia and, *see* Sex of ESRD patients on HD and/or CAPD, anemia and
 - and *Candida* peritonitis, 551
 - and dialysis-refractory hypertension, 258
 - and glycated albumin accumulation, 64
 - and HD access complications, 251, 253
 - with HIT, 84
 - hypertension and, 738
 - protective effects of cool dialysate and, 264
 - SEP and, 422-423
 - with TBP, 748
 - see also* Sex of ESRD patients on long-term HD and/or CAPD
- Sex of ESRD patients on HD and/or CAPD, anemia and impact of anemia and, 55, 56
 - intravenous FeD therapy and, 530
 - see also* Sex of ESRD patients on HD and/or CAPD, rHuEPO therapy for anemia and
- Sex of ESRD patients on HD and/or CAPD, rHuEPO therapy for anemia and
 - and ACEI effects on rHuEPO, 537
 - and insurance status effects on rHuEPO therapy, 239, 242, 243, 245
- Sex of ESRD patients on long-term HD and/or CAPD, 919
 - cardiovascular characteristics and, 932
 - and peritonitis on long-term CAPD, 430
 - prealbumin level and, 938
 - spontaneous tendon ruptures and, 863
 - for up to for 30 years, 911, 913
- Sex of HD and/or CAPD patients
 - of CRF patients, and care prior to starting maintenance HD, 842; *see also* Sex of ESRD patients
 - fatigue and, 733
 - and risk of mortality, 744
 - see also* Sex of ESRD patients on HD and/or CAPD
- Sex of RT recipients
 - in continued CsA therapy program, 573
 - long-term bone loss and, 110, 111
 - and recurrent IgA nephropathy following transplantation, 102
 - and/or kidney-pancreas recipients, CyA-associated TMA/HUS and, 564
- SH (symptomatic hypotension) in HD patients, protective effects of cool HD dialysate and, 262-265
- Shock, septic, *see* Multiorgan dysfunction syndrome, septic shock and, CRRT for
- SHR, *see* Standard Hospitalization Ratio, USRDS 1996 ADR on
- Shunts, peritoneovenous, hemodynamic effects of, in HD patients with ascites, 387-394
- Silastic cuffed catheters, HD, thrombolytic and mechanical correction of malfunctioning, 379-386
- Single-nephron glomerular filtration rate (SNGFR), AA effects on, 115-118
- Sirolimus, *see* Rapamycin
- SIRS (systemic inflammatory response syndrome), *see* Inflammatory mediators in sepsis
- 60 day rule, and ESRD patient eligibility to hospitalization, S2:116
- Size
 - of ESRD care facilities, SHR by, S2:122-125
 - of USRDS core, hospital, and Medicare claims SAFs, S2:29
- Sjögren's syndrome with ARF due to renal pseudolymphoma, 762-766
- SLE (systemic lupus erythematosus) with HIV infection, 292-295
- Sleep disorders in ESRD, 372-378
- Slow continuous ultrafiltration (SCUF), defined, S3:3
- Slow isolated ultrafiltration (UF) for CHF, S3:67-76
- Small molecule clearance with future CRRT technology, S3:123
- Small solute clearance, effects of, on dietary protein intake in CAPD patients, 553-560
- Smoking
 - by ESRD patients on PD, HD, and with RT, race and survival and, 75, 77
 - and hypertension cure in renovascular fibromuscular disease, 335
- Smooth muscle cell proliferation, aspirin effects on, S1:20-23

- SMR, *see* Standardized Mortality Ratio, USRDS 1996 ADR on
- Smye method, screening for extreme posthemodialysis urea rebound with, 727-736
- SNGFR (single-nephron glomerular filtration rate), AA effects on, 115-118
- Socioeconomics, and withdrawal from CsA therapy by RT recipients, race and, 572-577; *see also* Race and ethnicity
- SOD, *see* Superoxide dismutase
- Sodium, *see* Na
- Sodium chloride, *see* NaCl
- Sodium chloride homeostasis, *see* Uroguanylin
- Software and software experience needed for utilization of SAFs, S2:30
- Soluble interleukin-1 (IL) receptors blocking IL-1 actions in sepsis, S3:43
- Solute clearance, small, effects of, on dietary protein intake in CAPD patients, 553-560
- Solute control in ARF with CRRT, S3:21-27
ARF outcome and CRRT dose, S3:24-25
and factors influencing therapy delivery, S3:21-22
IHD versus CRRT in, S3:22-24
prescription of CRRT and, S3:25-26
- Sorbents, oral, in renal insufficiency, intestinal dialysis and, 946-947
- Special Studies Review and Implementation Committee (SSRIC), USRDS, S2:7
- Special Studies Standard Analysis File (SAF), USRDS, S2:28
- Spinal osteoporosis, as long-term effect of RT, 105-113
- Spontaneous continuous replacement therapy (CRRT), pumped versus, S3:62-63
- Spontaneous tendon ruptures in long-term HD and/or CAPD patients, 861-866
- SSRIC (Special Studies Review and Implementation Committee), USRDS, S2:7
- ST peptides, bacterial, natriuretic activity of, 299
- Standard Analysis Files (SAFs), USRDS 1996 ADR on core, on CD-ROM as, S2:27-30
equipment needed to use, S2:30
see also specific Standards Analysis Files
- Standard Hospitalization Ratio (SHR), USRDS 1996 ADR on, S2: 119-125
calculating, S2:119-120
by facility size, S2:122-123
by profit status and facility type, S2:123-125
by region, S2:120-122
reports on, S2:25-26
time trends in, S2:125
- Standard population for adjustment in USRDS 1996 ADR, S2:14, S2:152
- Standardization rates for adjustment, analysis of, S2:157-158
- Standardized Mortality Ratio (SMR), USRDS 1996 ADR on, S2:90-92
by ESRD networks, S2:152
facility-specific, S2:90-91
reports on, S2:25-26
- States, ESRD networks and their, S2:7-8, S2:14, S2:152
- Stenosis, *see* Renal artery stenosis, RVH with
- Stent, placement of percutaneous renal artery, for RVH and azotemia, PTRR compared with, 214-220
- Steroids, *see* Corticosteroids and glucocorticoids
- sTNFR (cell-surface tumor necrosis factor receptor) neutralizing TNF in sepsis, 43
- Strokelike episodes in MELAS syndrome, point mutations in mitochondrial tRNA genes and, 143
- Subcutaneous (SC) administration of rHuEPO to anemic ESRD patients on ESRD, 400-408
- Subcutaneous (SC) phaeophomycosis in RT, 137-139
- Subspecialist medical care of ESRD patients on chronic dialysis, nephrologists providing, 67-72
- Substance abuse
by ESRD patients on PD, HD, and with RT, race and survival and, 75, 77
and posthemodialysis fatigue, 734
see also Analgesic abuse
- Substitute decision making on withdrawal of dialysis, advances directives and, 151-152
- Subtraction angiography, digital, of RVH, CRS compared with, 211
- Sucrose-containing Ig (immunoglobulin) therapy, high-dose, in IgA nephropathy, osmotic nephrosis due to, 451-453
- Suction in CRRT, defined, S3:6
- Sulindac, *see* Nonrenal toxicity of APAP, ASA, and NSAIDs
- SUN, *see* Serum urea nitrogen
- Superoxide dismutase (SOD)
activity of, in IgA nephropathy and MPGN, 14-22
see also Cu,Zn-SOD
- Supplemented, very low-protein diet, nephrosis management with, 354-364
- Supply of kidneys for transplantation, USRDS 1996 ADR on, S2:108-110
- Survival, *see* Graft survival; Patient survival
- Symptom(s), *see* Clinical features and presentation
- Symptomatic hypotension (SH) in HD patients, protective effects of cool HD dialysate on, 262-265
- Systemic AL-amyloidosis, twenty-one year survival with, 278-282
- Systemic hypotension, protective effects of cool HD dialysate on, in HD patients, 262-265
- Systemic inflammatory response syndrome, *see* Inflammatory mediators in sepsis
- Systemic lupus erythematosus (SLE) with HIV infection, 292-295
- Systemic necrotizing vasculitis, ANCA in, 183
- Systolic blood pressure, *see* Blood pressure
- T cells, Abs against, directed against cell-surface proteins in immunosuppressive regimens, 167-168
- Table salt, *see* NaCl
- Tacrolimus, *see* FK506
- Talc pleurodesis, video-assisted, of pleural effusion secondary to CAPD for ESRD, 772-774
- Targeting diseases for molecular therapy, 476-477
- TBP (tuberculous peritonitis) in ESRD patients on CAPD, therapy and long-term outcome of, 747-751
- TBW (total body water), effects of, on azotemia control, S3:22
- Technical complications of CRRT, S3:100-101
- Temperature, body, *see* Hypothermia

- Tendon ruptures, spontaneous, in long-term HD and CAPD patients, 861-866
- Tense ascites secondary to decompensated liver cirrhosis in ESRD, UF for, 899-903
- TG(s), *see* Triglyceride(s)
- TGF- β , *see* Transforming growth factor- β
- Therapy
- analgesic, *see* Analgesic nephropathy
 - anticoagulant, *see* Anticoagulants on CRRT; Heparin
 - antihypertensive, *see* Antihypertensives
 - anti-inflammatory mediator, in sepsis, S3:37, S3:40-44
 - captopril and antiretroviral HIVAN, renal survival and, 202-208
 - corticosteroid, *see* Corticosteroids and glucocorticoids
 - dietary, *see* Dietary management
 - effects of albuterol and insulin, on plasma K in ESRD patients on HD, HCO₃ potentiating, 508-514
 - FeD, *see* Intravenous iron dextran for anemic ESRD patients on HD
 - α -IFN, FSGS with ARF due to, 888-892
 - of IgA nephropathy, 36, 42, 45
 - immunosuppressive, *see* Immunosuppression and specific immunosuppressive drugs
 - inpatient and outpatient care of HD access complications, 250-256
 - IV calcitriol, long-term effects of, on secondary hyperparathyroidism, 704-712
 - K, of ectopic ACTH syndrome with metabolic alkalosis, 610-613
 - L-lysine, Fanconi's syndrome and tubulointerstitial nephritis associated with, 614-617
 - methotrexate, renal failure with, 846-854
 - midodrine, for recurrent intradialytic hypotension, efficacy and pharmacokinetics of, 132-136
 - molecular, *see* Molecular therapy of renal diseases
 - peritonitis, *see* Therapy of peritonitis
 - preventive, *see* Prevention
 - PTX as, *see* Parathyroidectomy
 - of renal failure due to HIVAN, 618-621
 - renal replacement, *see* Renal replacement therapy
 - rHuEPO, *see* Recombinant human erythropoietin for anemia
 - urokinase, for silastic cuffed HD catheter problems, 379-386
 - see also* Acute renal failure, management of and specific conditions
- Therapy of peritonitis
- due to acute massive gentamicin intoxication on CAPD, 767-771
 - of fungal peritonitis on CPD, 88-89
 - and long-term outcome of TBP in ESRD patients on CAPD, 747-751
- Third-generation assays, HCV RNA detection in renal transplant recipients with, 437-440
- Thrombocytopenia, heparin-induced, in HD patients, 82-85
- Thrombosis
- as CRRT complication, S3:101-102
 - silastic cuffed HD catheter, mechanical and thrombolytic correction of, 379-385
- Thrombotic microangiopathy/hemolytic uremic syndrome (TMA/HUS), CyA-associated, in renal and renal-pancreas transplantation, 561-571
- Thrombotic thrombocytopenic purpura (TTP) in CyA-associated TMA/HUS, 561-571
- Thromboxane (TxB), aspirin effects on secretion of, S1:20-23
- Thyrototoxic periodic paralysis associated with hyperthyroid-related hypokalemia and hypophosphatemia, 270-273
- Time
- bleeding, of percutaneous renal biopsy patients, complications and, 48, 49
 - and covariates of mortality risk on HD, 741-746
 - on CRRT for pediatric ARF, S3:29
 - spent by nephrologists in dispensation of primary care, 68, 69
 - see also* Time on dialysis; Time trends
- Time on dialysis
- on chronic dialysis to patient death, initial laboratory data and, 546
 - and dialysis-refractory hypertension, 258
 - on HD, *see* Time on HD and/or CAPD
 - and recurrent IgA nephropathy following RT, 102
 - of renal transplant recipients with HCV, 438
 - and rHuEPO for anemia of ESRD, 245
- Time on HD and/or CAPD
- and ACEI effects on rHuEPO therapy of anemia, 537
 - Candida* peritonitis and, 551
 - fatigue and, 734
 - osteopenia and, 518-519
 - spontaneous tendon ruptures and, 863
 - USRDS 1996 ADR on, S2:63
- Time trends
- in resource cost per ESRD patient, S2:133-134
 - in SHR, S2:125
- Timing complications of percutaneous renal biopsy, 47-52
- TIN, *see* Tubulointerstitial nephritis
- TINU (tubulointerstitial nephritis and uveitis) syndrome with ANCA, 124-127
- TMA/HUS (thrombotic microangiopathy/hemolytic uremic syndrome), CyA-associated, in renal and renal-pancreas transplantation, 561-571
- TNF, *see* Tumor necrosis factor in sepsis
- TNF α (tumor necrosis factor α), high-flux CT and PAN membranes modulating monocyte production of, in long-term HD, 395-399
- Tobacco, *see* Smoking
- Total admissions for ESRD, crude rates of hospitalization based on, S2:116-119
- Total bilirubin in CyA-associated TMA/HUS on, 564, 565
- Total body iron (Fe), IV iron dextran effects on, 858
- Total body water (TBW), effects of, on azotemia control, S3:22
- Total Ca (calcium) in long-term HD and/or CAPD patients with bone disease, 920
- Total cholesterol
- and cardiovascular disease in long-term ESRD survivors, 935
 - initial, and survival on chronic dialysis, 542, 543
- Total CO₂ (carbon dioxide)
- assays in chronic HD ESRD patients with metabolic acidosis, 700-703
 - in long-term HD patients with bone disease, 920
- Total federal spending for ESRD

- errata in 1992 estimate of, in USRDS 1995 ADR on, S2:134
- limitations of research on, USRDS 1996 ADR on, S2:134-135
- see also* Medicare expenditures for ESRD, USRDS 1996 ADR on
- Total protein, initial, and survival on chronic dialysis, 542, 543
- Toxicity, *see* Adverse effects and specific substances
- Transcription, *see* mRNA expression; Transcriptional factors
- Transcriptional factors, nuclear, of steroids, 638
- Transfer RNA (tRNA) genes, point mutations in mitochondrial, 142-143
- Transferrin
- in ESRD, *see* Transferrin in ESRD
- IV iron dextran effects on, 858
- serum, in nephrosis, 354
- Transferrin in ESRD
- and ACEI effects on rHuEPO therapy of ESRD patients, 538
- and restless legs syndrome, 374, 375
- Transforming growth factor- β (TGF- β)
- high-flux CT and PAN membranes modulating monocyte production of, in long-term HD, 395-399
- TGF- β hypothesis of CyA mechanisms of action, 643
- Transfusions, blood, for anemia of ESRD, 537
- transcription of, in chronic renal rejection, 441-450
- Transluminal renal angioplasty, percutaneous, for HTN and azotemia, percutaneous renal artery stent placement compared with, 214-220
- Transplant Standard Analysis File (SAF), S2:28
- Transplantation, *see* Heart transplantation; Liver transplantation; Renal transplantation
- Treated end-stage renal disease (ESRD), USRDS 1996 ADR on
- by age, race, and sex, S2:37
- mortality with, S2:79-85
- number of, S2:13
- see also* Incidence (and prevalence) of treated ESRD, USRDS 1996 ADR on; Medicare end-stage renal disease program; Renal replacement therapy modality-(ies) for ESRD, USRDS 1996 ADR on
- Treatment plan, withdrawal of dialysis and, 151, 152
- Triglyceride(s) (TGs)
- initial, and survival on chronic dialysis, 542, 543
- in nephrosis, 354
- Triglyceridemia, and atherosclerotic lesions in carotid vessels of HD patients, 715
- tRNA (transfer RNA) genes, point mutations in mitochondrial, 142-143
- Truncated IgA (immunoglobulin A) heavy chain deposition disease (HCDD), crescentic nodular GS secondary to, 283-288
- TTP (thrombotic thrombocytopenic purpura) in CyA-associated TMA/HUS, 561-571
- Tuberculous peritonitis (TBP) in ESRD patients on CAPD, therapy and long-term outcome of, 747-751
- Tubular acidosis, type IV, and familial fibrillary GN with giant fibrillar deposits, 668-675
- Tubular function in chronic progressive nephropathy, ACEI effects on 822-831
- Tubular necrosis, acute, factors affecting recovery of renal function with, 316
- Tubular reabsorption, proximal, AA effects on, 115-123
- Tubular transport, ion and water, NSAIDs and interruption of, S1:59
- Tubular wall cell proliferation, ADPKD and, 791-792
- Tubulointerstitial nephritis (TIN)
- Fanconi's syndrome and, associated with L-lysine ingestion, 614-617
- FSGS and, due to α -IFN therapy, 888-892
- and uveitis syndrome with ANCA, 124-127
- Tumor necrosis factor (TNF) in sepsis, S3:37-39
- inhibiting synthesis of, S3:42-43
- monoclonal Abs against, S3:43
- sTNFR neutralizing, S3:43
- Tumor necrosis factor α (TNF α), high-flux CT and PAN membranes modulating monocyte production of, in long-term HD, 395-399
- Tunnel infections, catheter, peritonitis on CAPD due to, 415-419
- Twenty-one year survival with systemic AL-amyloidosis, 278-282
- TxB (thromboxane), aspirin effects on secretion of, S1:20-23
- Type 1 diabetes mellitus (insulin-dependent diabetes mellitus; IDDM), proximal calciphylaxis in HD patients with, 409-414
- Type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus), renal function and, in adult Navajo Indians, 339-349
- Type 2 multiple endocrine neoplasia (MEN 2), monogenetic hypertension and, 329-332
- Type I membranoproliferative glomerulonephritis (MPGN), ICAM-1, ICAM-3, and leukocyte integrins in leukocyte accumulation in, 685-694
- Type III membranoproliferative glomerulonephritis (MPGN), discordant findings between complement profiles and histopathology of, 804-810
- Type IV tubular acidosis, and familial fibrillary GN with giant fibrillar deposits, 668-675
- UF, *see* Ultrafiltration
- Ultrafiltrate in CRRT, defined, S3:6
- Ultrafiltration (UF)
- of tense ascites secondary to decompensated liver cirrhosis in ESRD, 899-903
- see also* Ultrafiltration in CRRT
- Ultrafiltration (UF) in CRRT
- CRRT defined, S3:6
- with future CRRT technology, S3:124
- slow continuous, defined, S3:3
- slow isolated, for CHF, S3:67-76
- UF control system, defined, S3:6
- Unilateral renal artery stenosis, RVH and, 211
- United States Renal Data System (USRDS)
- age of ESRD patients registered in, S2:40, S2:40-43
- committees of, S2:6-7, 22-23
- contacts of, S2:24
- data of, *see* Data, USRDS
- organizational structure of, S2:21-22

- products of, *see* Product(s) of USRDS
- project goals of, S2:21
- who's who in, S2:5-8
- see also* United States Renal Data System, 1993 ADR of; United States Renal Data System, 1995 ADR of; United States Renal Data System, 1996 ADR of
- United States Renal Data System (USRDS), 1993 ADR of, undercount in, S2:36, S2:152, S2:154
- United States Renal Data System (USRDS), 1995 ADR of differences between analytical methods used in 1996 ADR and, S2:152-153
- errata in, on estimate of 1992 total federal spending for ESRD, S2:134
- United States Renal Data System (USRDS), 1996 ADR of executive summary of, S2:12-20
- introduction to, S2:1-3
- list of acronyms used in, S2:9-11
- on vascular access for HD of ESRD, S2:69-73
- see also* Analytical methods used in USRDS 1996 ADR; Cost and cost-effectiveness of ESRD care, USRDS 1996 ADR on; Facilities for ESRD care, USRDS 1996 ADR on; Hospitalization for ESRD, USRDS 1996 ADR on; Incidence (and prevalence) of treated ESRD, USRDS 1996 ADR on; Morbidity due to ESRD, USRDS 1996 ADR on; Mortality of ESRD patients, USRDS 1996 ADR on; Patient survival with ESRD, USRDS 1996 ADR on; Pediatric end-stage renal disease, USRDS 1996 ADR on; Renal replacement therapy modality(ies) for ESRD, USRDS 1996 ADR on
- Urea
- L-arginine metabolized to, by arginase, 878-887
- blood, in acidosis of CRF patients, 351
- midodrine effects on, 133
- "reverse urea hypothesis" of postdialytic disequilibrium syndrome, 2-6
- see also* BUN; Kt/V; Serum urea nitrogen; Urea rebound
- Urea rebound, extreme posthemodialysis, Smye method in screening for, 727-736
- Uremia, *see* Chronic renal failure; End-stage renal disease
- Ureteral obstruction in pregnancy, rapidly reversible ARF due to, 457-460
- Urinary bladder, ramiprilat and enalaprilat effects on response of, to angiotensin I, 603-609
- Urinary cortisol in metabolic alkalosis with ectopic ACTH syndrome, 611
- Urinary excretion
- albumin, *see* Urinary excretion, albumin
- of analgesics, S1:41-42
- Cl, in familial fibrillary GN, 671
- creatinine, ramipril effects on, 837
- K, *see* Urinary excretion, K
- Na, *see* Urinary excretion, Na
- protein, *see* Urinary excretion, protein
- see also* entries ending with suffixes: -uria, -uric
- Urinary excretion, albumin
- in chronic progressive nephropathy treated with antihypertensives and/or ACE inhibitors, 828
- of glycosylated albumin, 65
- ramipril effects on, 837
- see also* Albuminuria; Microalbuminuria
- Urinary excretion, K
- in chronic progressive nephropathy, ACEI effects on, 822-831
- in chronic renal disease with and without hypertension, 816, 818
- in familial fibrillary GN, 671
- Urinary excretion, Na
- in chronic progressive nephropathy, ACEI effects on, 822-831
- in chronic renal disease with and without hypertension, 816
- in familial fibrillary GN, 671
- ramipril effects on, 837
- Urinary excretion, protein
- in IgA nephropathy, *see* Urinary excretion, protein, in IgA nephropathy
- in MPGN type I, 687
- in nephrosis, 356
- ramipril effects on BP and, in normotensive nondiabetic patients with proteinuria, 832-840; *see also* Albuminuria; Microalbuminuria; Proteinuria
- and twenty-one year survival with systemic AL-amyloidosis, 279
- Urinary excretion, protein, in IgA nephropathy, 44, 45
- in FSGS-like IgA nephropathy, 368
- Urinary light chains, and twenty-one year survival with systemic AL-amyloidosis, 279
- Urinary pH in metabolic alkalosis with ectopic ACTH syndrome, 611
- Urinary tract infections (UTIs) due to combination analgesics, clinical features of, S1:40
- Urine volume and output
- AA effects on, 118
- following start of HD for ARF, recovery of renal function and, 316
- Urography, IV, in renally impaired patients, ARF due to, 454-456
- Uroguanylin, 296-304
- background of, 296-297
- discovery of, 297-298
- as intestinal natriuretic hormone, 299-300
- mechanism of action of, 300-301
- myocardial, 300
- natriuretic activity of, 299
- other properties of, 301-303
- tissues producing, 298-299
- Urokinase for silastic cuffed HD catheter problems, 379-386
- Urolithiasis (calculi), dietary and behavioral risk factors for, implications of, for prevention, 195-201
- USRDS, *see* United States Renal Data System
- UTIs (urinary tract infections), due to combination analgesics, clinical features of, S1:40
- Uveitis, tubulointerstitial nephritis and, with ANCA, 124-127
- Vascular access, *see* Arteriovenous fistulas in HD; Catheters; Vascular access, CRRT; Vascular access, HD, for ESRD; Vascular access recirculation
- Vascular access, CRRT
- anticoagulants and, S3:9
- malfunction of, S3:100

- Vascular access, HD
in maintenance HD of CRF patients, 841-845
see also Vascular access, HD, for ESRD
- Vascular access, HD, for ESRD
in 21st century, 954
USRDS 1996 ADR on, S2:69-73
- Vascular access recirculation, and extreme posthemodialysis urea rebound, 727-736
- Vascular adhesion molecule-1 (VCAM-1), role of, in CyA-induced adhesion of leukocytes to vascular endothelium under physiological flow conditions, 23-31
- Vascular diseases, collagen, ANCA in, 183
- Vascular endothelium, CyA effects on leukocyte adhesion to, under physiological flow conditions, 23-31
- Vasculature, CsA interactions with, 644
- Vasculitis, Abs in
elastase and antineutrophil cytoplasmic Abs in, 178-185
see also Wegener's granulomatosis
- Vasoactive agents in ARF management, 321-323
- Vasoconstriction, renal, due to IV urography, 454-456
- VCAM-1 (vascular adhesion molecule-1), role of, in CyA-induced adhesion of leukocytes to vascular endothelium under physiological flow conditions, 23-31
- Venovenous (VV) bypass, CVVHDF with, S3:5
- Venovenous (VV) circuit in CRRT, defined, S3:6
- Venovenous (VV) hemodiafiltration, *see* Continuous venovenous hemodiafiltration
- Venovenous hemodialysis, *see* Continuous venovenous hemodialysis
- Venovenous hemofiltration, *see* Continuous venovenous hemofiltration
- Ventricular dilatation, left, in ESRD, impact of anemia on, 57
- Ventricular hypertrophy, *see* Left ventricular hypertrophy
- Vertebral fractures, as long-term effects of RT, 110
- Very low-protein diet, supplemented, nephrosis management with, 354-364
- VHL (Von Hippel-Lindau) gene, monogenetic hypertension and germline mutation of, 329-332
- Video-assisted talc pleurodesis of pleural effusion secondary to CAPD of ESRD, 772-774
- Vitamin B₁₂, rHuEPO and, 402
- Vitamin D, and bone disease in ESRD patients on long-term HD and/or CAPD, 918-923
- Volume overload, role of, in dialysis-refractory hypertension in ESRD, 257-261
- Von Hippel-Lindau (VHL) gene, monogenetic hypertension and germline mutation of, 329-332
- VV, *see* entries beginning with term: Venovenous
- Water
brain, effects of urea-containing dialytic bath on, 6
homeostasis of, *see* Uroguanylin
NSAIDs and, *see* Water, NSAIDs and
total body, effects of, on azotemia control, S3:22
treatment of, for HD of ESRD, USRDS 1996 ADR on, S2:68
- Water, NSAIDs and
interruption of tubular transport of, S1:59
NSAID-induced water retention, S1:57
- WBC (white blood cell) count in renal AED patients, 494
- Wearable device, HD, 21st-century, 954-955
- Weekly sessions of HD for ESRD, USRDS 1996 ADR on, S2:64
- Wegener's granulomatosis (WG)
sarcoidosis following, 893-898
see also Wegener's granulomatosis, Abs in
- Wegener's granulomatosis (WG), Abs in, 178-194
disease activity and AECAs in, 186-194
elastase antibodies and antineutrophil cytoplasmic antibodies in, 178-185
- Weight gain, interdialytic, by HD patients with ascites, PVS effects on, 389, 391, 393
- Weight-reducing diet in prevention of urolithiasis, 195-201
- Western blot analysis of fibrillary GN, 680-681
- WG, *see* Wegener's granulomatosis
- White Americans, *see* Race and ethnicity
- White blood cell (WBC) count in renal AED patients, 494
- Who's who in USRDS, S2:5-8
- Withdrawal
from CsA therapy by RT recipients, insurance status, race and, 572-577
from dialysis, *see* Discontinuation of dialysis by ESRD patients
see also Withdrawal of dialysis, ethical issues related to
- Withdrawal of dialysis, ethical issues related to, 147-153
advance directives and substitute decision making in, 151-152
case studies of, 147-148, 150
clinical factors in, 148
informed choice issue, 148-150
justice issues, 149-150, 152
recommended procedures for withdrawal, 150-151
- Zinc, copper superoxide dismutase, *see* Cu,Zn-SOD